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Renal transplantation  
Kidney transplantation is the best treatment for patients with end stage renal failure, in 
terms of quality of life and life expectancy. Due to many reasons, such as increasing age of 
the general population and growing incidence of obesity and diabetes, the number of 
patients with end stage renal disease is increasing world-wide, and consequently, the 
demand for donor kidneys remains increasing. In 2010, in the Netherlands >800 kidney 
transplantations have been performed, half of them with donor kidneys from living donors. 
Within the Netherlands the waiting list for renal transplantation is >900 patients, with a 
waiting time for post-mortal kidneys of over 4 years (http://www.renine.nl and 
http://www.nierstichting.nl). Over the last decades the use of several potent new immune 
suppressive drugs after renal transplantation has led to a sharp decline in the incidence of 
acute rejection. Therefore, the focus of transplantation research moved towards long term 
graft survival, which remains sub-optimal because of progressive damage culminating in 
chronic transplant dysfunction, which has barely improved over the last 30 years (1).  
 
Chronic transplant dysfunction 
Chronic transplant dysfunction (CTD) is associated with decline in kidney function over 
time and is related to progressive tissue remodeling in the transplanted kidney. CTD is the 
second leading risk for graft loss (after death) and has an incidence of >70% already 2 years 
after transplantation based on biopsies without clear functional loss (2,3). The pathogenesis 
of CTD is multifactorial. It is believed that long term graft survival reflects the dual impact 
of immunologic and non-immunologic injury (4). Non-immunological risk factors include 
hypertension, hyperlipidemia, hyperfiltration, calcineurin inhibitor toxicity (side effect of 
immunosuppressive drug), urological complications,, smoking, and viral or bacterial 
infections (5). A close correlation has been found between the presence of proteinuria and 
worse allograft survival (6). Fibrosis/sclerosis is a major morphological characteristic 
occurring in most intrarenal microstructures, including the glomeruli, arteries and tubulo-
interstitium, leading to glomerulosclerosis, transplant vasculopathy with neointima 
formation, and interstitial fibrosis, respectively (7). 
 
Histopathological hallmarks of CTD  
Focal segmental glomerulosclerosis (FSGS) - The sclerotic lesions of FSGS are 
characterized by diffuse effacement of podocyte foot processes, detachment and loss of 
podocytes from the glomerular basement membrane, obliterated capillaries, mesangial 
proliferation and matrix expansion (8,9). FSGS is the result of structural and functional 
abnormalities of podocytes, the glomerular epithelial cells that are involved in glomerular 
ultrafiltration (10). Thus, malfunctioning of podocytes results in proteinuria as well as 
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flattening of these cells with segmental sclerosis in FSGS. FSGS might be induced by 
various pathogenetic mechanisms including mutations in proteins that are specific to 
podocytes, steroid toxicities, bacterial and viral infections and glomerular hypertension 
(12). De novo FSGS has been reported after renal transplantation and is associated with 
transplant dysfunction and early graft loss (11-14). 
 
Transplant Vasculopathy - Upon renal transplantation, the host immune system primarily 
responds to the renal vasculature of the allograft. In the arteries this results in progressive 
intimal thickening of the arteries, referred as transplant vasculopathy or arteriopathy, which 
contributes to renal allograft failure. The pathological features of transplant vasculopathy 
include the accumulation of migrated vascular smooth muscle cells (VSMCs) as well as 
immune cells such as macrophages and T-cells and extracellular matrix components within 
the neointimal lesions (15). In response to allo-transplantation, activation of VSMCs 
occurs, which in turn leads to the phenotypic modulation of VSMCs from a ‘contractile and 
quiescent’ into a ‘synthetic and proliferative’ phenotype. This phenotypic change is 
characterized by the production of extracellular matrix components and the loss of VSMC 
marker genes (16). Both macrophages and activated T cells are able to initiate and induce 
the proliferation or apoptosis of intimal cells, and can alter the synthesis of extracellular 
matrix components in the newly-formed intima (17,18). However, the precise mechanism 
underlying the pathogenesis of TV remains elusive. 
 
Tubulo-interstitial damage - Interstitial fibrosis/tubular atrophy (IF/TA) is a main 
characteristic of chronic transplant dysfunction, and is often associated with progression to 
late graft loss (1). Interstitial fibrosis is characterized by excessive deposition of 
extracellular matrix in the tubular interstitium by myofibroblasts characterized by the 
expression of alpha-smooth muscle actin (α-SMA) (19). Tubular atrophy refers to flattening 
and loss of tubular epithelium and increased luminal size of the tubules, and is furthermore 
characterized by thickening of the tubular basement membranes (20,21). IF/TA is an 
irreversible histopathological entity that can be induced already early after transplantation 
and which is chronic, progressive and non-specific (22). Myofibroblasts are crucial cells 
which are involved in interstitial fibrosis due to their excessive production of extracellular 
matrix. In the kidney, myofibroblasts are derived from multiple cell types, including 
activated resident interstitial fibroblasts, bone marrow-derived cells, perivascular 
fibroblasts and pericytes, endothelial and tubular epithelial cells (19,23,24). Epithelial to 
mesenchymal transition (EMT) of tubular epithelium is also playing an important role in 
chronic allograft related interstitial fibrosis (25). Calcineurin inhibitors may result in 
interstitial fibrosis, and in particular cyclosporine A has been associated with the 
development of interstitial fibrosis (26). Many studies showed the role of infiltrating renal 
macrophages as mediators of interstitial fibrosis (27), indicating a role of influxed 




Taken together, in CTD endothelial and epithelial activation is followed by the recruitment 
of inflammatory cells, mainly macrophages, which in turn activate mesenchymal cells such 
as vascular smooth muscle cells, mesangial cells and interstitial fibroblasts leading to renal 
tissue remodeling. In general, a large number of mediators such as cytokines, chemokines, 
growth factors and adhesion molecules are involved in tissue remodeling. Many of these 
mediators will only evoke cellular signaling in the presence of a proteoglycan co-receptor 
by the formation of a ternary signaling complex composed of mediator, high affinity 
receptor and low-affinity proteoglycan co-receptor. Indeed, proteoglycans have been highly 
implicated in tissue remodeling such as development, adhesion, migration, growth, wound 
healing and repair processes, proliferation and fibrosis (28,29).This implies that targeting 
proteoglycan function might provide a strategy to combat CTD-associated tissue 
remodeling. Therefore in the next paragraphs we further focus on proteoglycans in general 
and renal proteoglycans more specific.  
 
Proteoglycans and glycosaminoglycans  
Proteoglycans (PGs) are constituted by various core proteins to which linear, anionic 
polysaccharide, glycosaminoglycan (GAG) side chains are covalently conjugated (30). 
GAGs consist of repeating hexosamine and hexuronic acid disaccharide units (except 
keratan sulfate that comprise of repeating hexosamine and galactose disaccharides), with 
variable –N and/or –O sulfation. PGs are ubiquitously expressed and can be found 
throughout the extracellular matrix (ECM) including basement membranes and on virtually 
all cell surfaces (31). Based on their ability to interact with various proteins (see below), 
PGs mediate biological processes such as cell-cell and cell-matrix interactions, growth 
factor signaling cascades, chemokine and cytokine activation, tissue morphogenesis during 
development, cell migration and proliferation, and wound healing (28,29). 
Based on the presence of different types of GAGs, PGs are mainly classified as heparan 
sulfate PGs (HSPGs), chondroitin sulfate PGs, dermatan sulfate PGs and keratan sulfate 
PGs. Hyaluronic acid (HA), unlike the other GAGs, is synthesized as a free GAG chain and 
is not linked to a core protein. HA is synthesized at the cytoplasmic surface of the plasma 
membrane rather than the endoplasmic reticulum and Golgi (32). Heparin is a highly 
modified HS produced by mast cells. During its biosynthesis heparin becomes attached to 
the serglycin protein core but is released as free heparin GAG chain (33). Since most of the 
studies in this thesis deal with HSPGs, the various HSPG families, HS biosynthesis and 







Heparan sulfate proteoglycans 
Depending on their core protein, the major HSPGs are classified as syndecans and 
glypicans (cell –surface HSPGs), and perlecan, agrin and collagen type XVIII (extracellular 
matrix HSPGs). The cell surface HSPGs consists of two major families: Firstly, the family 
of syndecans (members 1-4) belongs to the transmembrane cell surface HSPGs, consisting 
of ecto, transmembrane and cytoplasmic domains. Virtually all cell types, with the 
exception of erythrocytes, express at least one syndecan. Syndecans have pivotal roles 
during development, wound healing, inflammation, angiogenesis and tumor progression 
(28,34). Secondly, glypicans (members 1-6) are linked with a glycosyl-phosphatidylinositol 
anchor to the cell membrane. Glypicans display cell-type and development-stage-specific 
expression and are involved in various biological processes such as cell proliferation, 
differentiation and morphogenesis (35).  
Agrin, perlecan and collagen type XVIII are the major extracellular HSPGs, which are 
abundantly present in basement membranes. Agrin, known to be expressed in the 
specialized basement membranes of the neuromuscular junction plays an important role in 
the development of synaptic apparatus (36,37). Apart from the neuromuscular junction, 
agrin is also widely expressed in the basement membranes of the kidney, lung and 
microvasculature (38-41). Perlecan plays a key role in the vasculature and angiogenesis 
(42). The HS residues on perlecan are able to interact with fibroblast growth factor-2 
(FGF2), and were shown to participate in mitogenesis and angiogenesis in vitro, CHO cells 
and in vivo rabbit ear model respectively. Perlecan-HS bound FGF2 is presented to its high 
affinity receptor located on the cell surface (43,44). Collagen type XVIII, another basement 
membrane HSPG, has structural properties of both a collagen and a proteoglycan (45). 
Upon proteolytic cleavage of the C-terminus of collagen type XVIII, a domain called 
endostatin is released, which displays strong antiangiogenic effects (46). Generally collagen 
type XVIII is present in the basement membranes of the lung, retina, kidney and blood 
vessels (47,48) often in conjunction with perlecan (49). 
 
Heparan sulfate biosynthesis and structural heterogeneity 
of Heparan sulfates  
Proteoglycan synthesis starts by cellular uptake of building blocks (i.e. monosaccharides 
and sulphate) for GAG synthesis through specialized transporter complexes. By nucleotide 
metabolism in the cytoplasm, sugars and sulphates are then activated to form UDP-sugars 
and 3’-phosphoadenosine 5’-phosphosulphate (PAPs) respectively. The formed UDP-
sugars and PAPs are translocated into the endoplasmic reticulum and Golgi by specific 
transporters (50,51). HS biosynthesis initiates by the assembly of a so-called linkage 
tetrasaccharide on specific serine residues (GlcA-Gal-Gal-Xyl-Ser) of the protein core 





Figure 1. Schematic representation of Heparan sulfate biosynthesis that includes chain initiation, polymerization and 
modification. Each monosaccharide unit is represented by a geometric symbol and named accordingly. NA, NA/NS, NS domains 
are shown with specific binding domains for the ligands, such as FGF-1/FGF2 and antithrombin (from 30). Figure reproduced with 
permission of the publisher from Annual Review of Biochemistry 2002;71:435-471. 
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forming heparosan, composed of repeating α-linked N-acetyl-glucosamine (GlcNAc) and β-
linked glucuronic acid (GlcA). Subsequently, a series of modifications might occur in the  
chain that involves partial N-deacetylation of GlcNAc units, followed by N-sulfation of the 
unsubstituted amino groups to form GlcNS residues, 5-epimerization of GlcA to form 
iduronic acid (IdoA), O-sulfation of IdoA at C-2 and O-sulfation of GlcNSO3- at C-6 and 
C-3 (52,53). The various biosynthetic enzymes that are involved in the chain modification 
procedure act non-uniformly along the chain, and form specific domains. In particular, N-
acetylated (NA) domains that are rich in GlcA and GlcNAc derivatives, N-sulfated (NS) 
domains rich in IdoA and GlcNS derivatives with a high density of O-sulfates, and in 
between domains that contain alternating NA and NS units of glucosamine (NA/NS 
domains) with variable degree of O-sulfation (54) as shown in the figure 1 (30). 
Extracellularly, HS chains can be modified by heparanase (55), an enzyme that specifically 
cleaves HS chains to deliver free HS oligosaccharide fragments (eventually with HS-bound 
proteins). SULF1 and SULF2 are extracellularly acting HS endo-6-O-sulfatases that can 
remove 6-O sulfates at specific positions along the HS chain. Latter enzymes may thus 
regulate protein binding to HSs that is critically dependent on 6-O sulfate units (56,57). 
 
Heparan sulfate – protein interaction 
Due to their vast structural heterogeneity HS are able to bind and interact with a myriad of 
proteins, such as growth factors, chemokines, cytokines and extra cellular matrix 
components. Table 1 shows different proteins that might interact with HSs and modulate 
various processes. The interaction of a certain protein with HS depends on a number of 
critical requirements, namely i) degree of sulfation and formation of patches with high 
charge density; ii) the length of the HS chain and the spacing of the N-sulfated domains; iii) 
3-dimensional confirmation and flexibility of the HS chain. Studies in mice that were 
knocked out for different enzymes in HS biosynthesis unexpectedly revealed that many HS-
protein interactions appear to depend more on the overall organization of HS domains than 
on their fine structure. Nowadays it is generally accepted that polymer modification in HS 
biosynthesis is primarily regulated with regard to domain distribution and degree of 
sulfation. The resultant clusters of negative charge will determine interactions with proteins 
that may be relative nonselective with sharing/overlap of saccharide target sequences 
between different protein ligands. More selective interactions would require either 
sequences containing rare components (like 3-O-sulfates and/or unsubstituted GlcNH3+ 
units) or precise spacing of the N-sulfated domains (58). 
 
From the list of HS-binding proteins it can be anticipated that HSPGs are involved in 
adhesion and migration, cell growth and survival, angiogenesis, fibrosis and inflammation. 
HSPGs fulfil these functions via a number of different mechanisms. i) HSPGs bind and 
concentrate/store protein ligands on cell surfaces and in extracellular matrices; ii) HSPGs 
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function as high abundant low affinity receptors that modulate the quality of chemokine, 
cytokine and growth factor responses (such as amplitude and kinetics of 
actication/inactivation); iii) HSPGs stabilize chemokine/morphogen gradients, thereby 
guiding directed cell migration; iv) HSPGs stabilize extracellular matrices by cross-linking 
to matrix components; v) HSPGs regulate internalization of receptor complexes; vi) HSPG 
ectodomain shedding or HS degradation by heparanase may release HS-bound ligands from 
the cell surface or from the matrix (59). This implies that HSPGs orchestrate tissue 
plasticity and remodelling and as such might be crucial in tissue remodelling associated 
with CTD in transplanted kidneys. In the next paragraphs we will further highlight renal 
involvement of PGs. 
 
Table 1. Examples of glycosaminoglycan binding proteins and their biological activity 
Class Examples Physiological/pathophysiological 
effects of binding 
Enzymes Glycosaminoglycan biosynthetic enzymes, 
thrombin and coagulation factors (proteases), 
complement proteins(esterases, extracellular 
superoxide dismutase, topoisomerase 
Multiple 
Enzyme inhibitors Antithrombin III, Heparin cofactor II, secretory 





P-selectins, L-selectin, neural cell adhesion 
molecule (N-CAM), Platelet endothelial cell 
adhesion molecule (PECAM-1), Heparin 
interaction protein (HIP), Monocyte adhesion 
molecule(MAC-1) 
Cell adhesion and migration 
Etracellular matrix 
proteins 
Laminin, Fibronectin, collagens, 
thrombospondin, tenascin, vitronectin 
Matrix organisation 
Chemokines CCL-2 (MCP1), CCL-5 (RANTES), CXCL12, 
platelet factor 4 
Chemotaxis 
Growth factors Fibroblast growth factors (FGF), heparin 




Vascular endothelial growth factor (VEGF), 
Hepatocyte growth factor, Transforming growth 
factor- β (TGF- β) 
Morphogen Hedgehogs, Bone morphogenic protein (BMP) Development 
Tyrosine kinase growth 
receptors 
Fibroblast growth factors receptors, vascular 




Apolipoprotein E and B, Lipoprotein Lipase, 
Hepatic lipase, annexins 
Lipid metabolism 
Table 1 shows the list of the glycosaminoglycan binding proteins that modulate different biological processes through this 
interaction 
Renal involvement of proteoglycans  
Proteoglycans in normal kidney 
Kidney development - In normal renal tissue a number of PGs are expressed. With a focus 
on HSPGs, in basement membranes three HSPGs are abundantly present, namely agrin, 
perlecan and collagen type XVIII (60). The expression of cell surface HSPG (Syndecans 1-
4, Glypicans 1-6, CD44V3 variant) is less well described. Syndecan-1 seems to be the 
major epithelial HSPG during development and in renal cell lines, but is barely expressed in 
adult kidney (61). At the mRNA level it has been shown that cell surface syndecan-4 is 
abundantly expressed (62). It also has been shown that in the developing kidney various 
growth factors are involved in the activation of their specific cell surface receptors in 
growth and branching morphogenesis of the isolated ureteric bud (63), and also these 
processes are regulated by sulfated proteoglycans (64). Syndecan-1 expression showed both 
spatial and temporal correlation with kidney morphogenesis, thus suggesting the important 
role for this cellular proteoglycan in development (65). Mice deficient in the HS2st showed 
developmental anomalities that include skeletal malformation and kidney agenesis (66,67). 
Thus, proteoglycans are likely to play major roles in the development of the kidney. 
 
Proteoglycans in glycocalyx - The glycocalyx is a thick carbohydrate-rich layer lining the 
vascular endothelium and considered to be attached to the endothelium through several 
“backbone” molecules that include proteoglycans and also glycoproteins. A dynamic 
equilibrium exists between soluble components of the glycocalyx and the flowing blood, 
continuously affecting composition and thickness of the glycocalyx (68,69). Under healthy 
physiological conditions the glycocalyx acts as an anti-thrombotic, anti-proliferative, anti-
adhesive and anti-inflammatory sheath (69). However, in inflammatory state the glycocalyx 
can be shed into the circulation leaving denuded endothelial cells with activated apical 
membranes. Studies in healthy mouse cremaster muscle venules show that upon breakdown 
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of heparan sulfate side chains by heparitinase an increased leukocyte adhesion to the 
endothelium occurs in a dose-dependent manner (70). HSPG expression may alter in the 
glycocalyx as the endothelial expression of proteoglycans as well as the fine composition of 
the HS side chains depend on various stimuli. As an example, syndecan-1 has a tightly 
regulated expression pattern which alters with activation of endothelial cell or stimulation 
with various chemokines (71). Heterogeneity of the GAG chain gives rise to an array of 
binding sites on GAGs for various plasma-derived molecules. The roles of proteoglycans in 
the glycocalyx of glomerular endothelial cells strongly suggest a role in charge-dependent 
permeability (72), but this concept has been challenged recently, as outlined below. 
 
Proteoglycans in glomerular ultrafiltration - The filtration barrier of the glomerular 
capillary wall is made up of three specialized layers which determine its permselective 
properties, namely the fenestrated endothelium, the glomerular basement membrane (GBM) 
and the glomerular epithelial cells or podocytes (73). Within the kidney, HSPG research has 
focussed for 30 years on the role of HSPGs in glomerular filtration. It is assumed that the 
highly anionic HSPGs in the glomerular basement membrane contribute to electrostatic 
repulsion of albumin and thereby keep the formed primary urine free of protein (74). 
Studies in mice have shed new light on this classical dogma. Collagen type XVIII knockout 
mice (col18a1-/-) have no lethal phenotype and display mild mesangial expansion and 
slightly elevated serum creatinine levels compared to controls (75). Agrin and perlecan 
knockout mice showed neuromuscular defects and have an embryonic or perinatal lethal 
phenotype respectively (76,77). Mice lacking the GAG attachment sites in the N-terminal 
domain I of perlecan (Hspg2∆3/∆3) showed normal glomerular ultrastructure and GBM 
charge, and no evidence of kidney disease (78). Podocyte-specific agrin knockout mice 
(conditional knockout) revealed normal glomerular filtration barrier even when these mice 
were challenged with bovine serum albumin overload (79). Also the podocyte-specific 
EXT-1 knockout mice showed fully normal glomerular ultrafiltraton (80). The generation 
of these conditional HSPG-deficient mice has questioned the role of HSPG in charge 
selective permeability, and made this concept very controversial.  
 
Proteoglycans in the diseased kidney 
Inflammation - Tissue injury results in inflammatory responses that primarily involve the 
recruitment of leukocytes to the site of injury. Immune cells, such as macrophages, release 
TNF-alpha and interleukin-1 immediately after injury and further activate nearby 
endothelial cells. During the process of inflammation and leukocyte extravasation, HSPGs 
play several important roles (81). GAG chains are mainly involved in three major steps 
during the migration of leukocytes into the site of inflammation: L-selectin-mediated cell 
rolling, chemokine-mediated activation and transmigration between the endothelial cells, 
and stabilization of chemokine gradients in extracellular matrix to facilitate directed 
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migration of the leukocytes (80,82,84). Recent studies of endothelium specific N-
deacetylase/sulfotransferase-1 knockout mice revealed that decreasing HS sulfation by 
~60% significantly reduced neutrophil infiltration. Alterations in N-
deacetylase/sulfotransferase-1 expression in leukocytes did not affect neutrophil 
recruitment or T-cell mediated responses, indicating that endothelial HS dominates in the 
system (82). It also has been demonstrated in vitro that culturing microvascular brain 
endothelial cells in medium containing chlorate (inhibiting GAG sulfation) or treatment 
with heparitinase (HS degradation) resulted in reduced transendothelial migration of 
monocytes (83). In contrast, the role of leukocyte HSPGs in leukocyte extravasation was 
evidenced by syndecan-1 knockout mice, which show increased leukocyte-endothelial 
adhesion (84). This effect was shown to be mostly due to the lack of syndecan-1 on 
leukocytes (85). Rops et al. showed increased leukocyte recruitment in syndecan-1 
knockout mice following induction of experimental anti-glomerular basement membrane 
nephritis (86). Celie et al. showed that L-selectin binding HSPGs are detected at the 
abluminal side of peritubular capillaries in both experimental and human renal 
inflammatory conditions and these basement membrane HSPGs contribute to the influx of 
inflammatory cells (87,88). In vivo, collagen type XVIII/endostatin knockout mice with 
anti-GBM disease developed more severe glomerular and tubulointerstitial injury than 
wild-type mice. The Collagen XVIII/endostatin knockout mice showed altered matrix 
remodeling, induced inflammatory responses, and vascular endothelial cell damage 
suggesting that collagen type XVIII/endostatin plays major role in maintaining the integrity 
of the extracellular matrix and capillaries in the kidney, protecting against progressive 
glomerulonephritis (89). Another type of proteoglycans named Small Leucine-Rich 
proteoglycans (SLRPs; such as decorin, biglycan, fibromodulin and lumican) are very much 
involved in the regulation of inflammatory kidney disorders. The basic concept comprises 
activation of inflammatory routes via Toll-like receptor activation by fragments of these 
small PGs upon matrix degradation by MMPs. The roles of SLRPs in the normal and 
diseased kidney were reviewed in detail recently by Schaefer et al (90). 
Fibrosis - Fibrosis is the result of continuous wound healing upon severe/chronic injury, in 
which there is progression rather than resolution of scarring. Myofibroblasts are the cells 
that play a crucial role in the pathogenesis of fibrosis. Myofibroblasts are terminally 
differentiated cells, responsible for the synthesis and accumulation of interstitial ECM 
components during wound healing and at sites of scarring and fibrosis (91). GAGs can bind 
a variety of ligands depending on their composition and FGF-2 is known to be one of the 
GAG binding proteins involved in fibrosis (92). It was demonstrated in renal interstitial 
fibroblasts, that HSPGs are essential for the control of the proliferative response to FGF-2 
(93-95). Hepatocyte Growth Factor (HGF) is a clinically important pleiotropic factor with 
therapeutic potential for the treatment of interstitial fibrosis and chronic renal failure. It has 
been suggested that HGF plays an important role in the regulation of proteoglycan synthesis 
in rat renal interstitial fibroblasts (NRK-49F cells) (96). 
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In addition, VSMCs have been shown to express FGF-2, which act as a autocrine/paracrine 
mitogen. Its effect on VSMCs in vivo is only present in case of vascular injury, since 
quiescent medial VSMCs are unresponsive to FGF-2 due to the lack of FGF-2 binding 
domains in their HSs (97). Recently, it has been shown that syndecan 4, a cell surface 
proteoglycan, ameliorates neointimal formation after vascular injury by regulating VSMC 
proliferation and vascular progenitor cell mobilization (98). The well-known heparan 
binding growth factor HB-EGF is mitogenic for several cell types. It has been shown that 
HB-EGF is synthesized and expressed by mesangial cells and in an autocrine fashion 
stimulates mesangial cell proliferation and collagen synthesis in vitro (99). Our own data 
(chapter3) show the involvement of mesangial HSPGs in FGF2-driven mesangial 
proliferation. These data indicate that HSPGs are involved in renal mesenchymal cell 
proliferation and matrix expansion.  
Regeneration - We recently observed upregulation of syndecan-1 expression in tubular 
epithelial cells in functioning human renal allografts. Interestingly, the level of syndecan-1 
expression was positively correlated with graft function and survival as well as with 
binding of HB-EGF. Using the HK-2 proximal tubular epithelial cell line, we were able to 
demonstrate a functional role for syndecan 1 in TEC proliferation. In line with this, in vitro 
knockdown of syndecan-1 in HK2 cells reduced cell proliferation. Moreover, after renal 
ischemia/reperfusion, tubular repair was hampered in syndecan-1 KO mice (Kidney Int 
2012: in press; chapter 6 of this thesis). Previously it has been shown that growth factors 
such as HGF and HB-EGF and follistatin are involved in renal repair and regeneration 
(100-105). For these growth factors, HSPGs serve as co-receptors and mediate the cell 
signaling cascades. Thus proteoglycans are most likely involved in renal regeneration and 
repair.  
 
Heparinoids as therapeutic modalities to reduce tissue 
remodeling 
According the abovementioned previous findings HSPGs play major roles in tissue 
remodeling in renal CTD. This fuels the hypothesis that exogenously administered 
heparinoids as decoy molecules for growth factors, selectins and chemokines can interfere 
with the endogenous HS-mediated growth factor signaling cascades and the process of 
inflammatory cell recruitment that characterizes the development of CTD. Such an 
approach would potentially be a useful adjunct to the current treatment strategies in CTD 
that are mainly based on immunosuppressive regimens, that have substantial side effects 
such as increased susceptibility to infections, chronic calcineurin inhibitor toxicity (106), 
and increased risk for metabolic syndrome and diabetes. So far, adjunct treatment in renal 
transplant recipients addressed the control of hypertension, proteinuria and metabolic 
abnormalities. No therapy directly targeting renal remodeling is available. As mentioned 
before heparin/HS GAGs have great structural heterogeneity and are involved in various 
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cellular processes. Most of the biological activities of these polysaccharides are associated 
with complexation with proteins involved in tissue remodeling and inflammation. Therefore 
these glycans could be interesting therapeutic decoy molecules to retard CTD. 
 
Heparin is a molecule specifically well known for its anticoagulant activity and which has a 
very broad spectrum of actions that include anti-inflammatory and anti-tumor properties. 
The anti-inflammatory and anti-angiogenic properties of heparin are thought to be largely 
associated with the influence on pathophysiological functions of HS chains of HSPGs 
(107,108). Treatment with exogenous heparin and low-molecular-weight heparins have 
been shown to exert beneficial outcomes in inflammation(109-111). However, prolonged 
heparin therapy leads to significant complications that includes bleeding, heparin-induced 
osteoporosis and heparin-induced thrombocytopenia (112-114). Thus, prolonged 
administration of heparin to transplanted patients might results in impaired coagulative 
function and other undesirable side effects. To date, many efforts have been made to design 
heparin derivatives with specific, predictable binding properties. Non-anticoagulant 
heparins are used in several experimental renal disease models and demonstrated that these 
heparin-like glycomimetica are able to reduce the inflammation after renal 
ischemia/reperfusion. It was demonstrated that N-desulfated heparin, which has a strongly 
reduced anti-coagulant activity compared to normal heparin, is able to reduce the renal 
damage significantly in a rat renal I/R model(115). These results were supported by 
findings which show that treatment with non-anticoagulant hypersulfated heparin and low 
molecular weight heparin reduced inflammation after renal ischemia/reperfusion, and renal 
allograft rejection, and CTD in the Fisher to Lewis rat model of renal transplantation 
(109,116). Recently it has been demonstrated that intervention with a LMWH, sulodexide, 
was not renoprotective in patients with type 2 diabetes, renal impairment, and 
macroalbuminuria (117). Although sulodexide has similar structure as unfractionated 
heparin, it has a lower degree of sulfation and shorter polysaccharide length compared to 
normal unfractionated heparin and RO-heparin (118). Together, exogenously administered 
heparin-like glycomimetica might be potential therapeutics to retard development of CTD 
upon renal transplantation.  
  
Aim of the Thesis 
The aim of this thesis focuses on the role of proteoglycans in renal CTD. The general 
introduction (chapter 1) of this thesis briefly outlines kidney transplantation, the 
histopathological lesions of CTD, potential involvement of proteoglycans in CTD-related 
tissue remodeling and potential beneficial therapeutic effects of heparinoids. Most of the 
experiments in this thesis are performed in a rat kidney transplantation model for CTD. 
This rat model was previously used and well described in which kidney transplantation 
occurs from Dark Agouti donor to Wistar Furth recipient (119). However, whether and how 
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proteoglycans mediate tissue remodeling in CTD was unanswered. Therefore in chapter 2 
we characterize differential heparan sulfate proteoglycans (collagen type XVIII, perlecan 
and agrin) and chondroitin sulfate proteoglycan (Versican) expression in transplant 
vasculopathy, glomerulosclerosis and interstitial fibrosis in rat renal allografts with chronic 
transplant dysfunction. Later we continued to unravel the functional importance of the 
upregulated proteoglycans in CTD, so in chapter 3, we investigate the glomerular and neo-
intimal induction of perlecan and FGF2 in allografted kidneys. In addition, we characterize 
the heparan sulfate (HS) polysaccharide side chains by anti-HS mAbs and their binding 
capacity for FGF2. Finally, we evaluate the functional role of HSPG by in vitro cell culture 
assays to demonstrate the HSPG dependency of FGF2-driven mesangial proliferation. 
According to the results obtained in chapter 2 and 3, proteoglycans most likely involved in 
tissue remodelling in CTD. Therefore in chapter 4, we test the therapeutic effects of 
exogenously administered heparin and two non-anticoagulant heparin derivatives (N-
acetyl-heparin and Reduced/oxidized-heparin) to ameliorate CTD in the experimental 
transplantation model. As the molecular mechanisms behind the neointima formation is still 
unclear in the arteries of the kidneys effected with CTD. So in chapter 5 we specifically 
focus on the vascular component of CTD, namely transplant vasculopathy in the rat CTD 
model. In addition, we investigate genes indicative of (de)differentiation of medial SMCs in 
rat renal allografts with transplant vasculopathy by micro dissection of neointimal and 
medial layers using laser dissection microscopy and gene expression was analyzed with a 
low density array, and expressions of the corresponding proteins in renal allograft tissue 
sections and their function in an in vitro SMC functional assay. 
Lastly in chapter 6, we test the hypothesis that syndecan-1 is involved in tubular survival 
and repair upon renal transplantation. To this purpose we study the expression of syndecan-
1 in human renal allograft biopsies, including protocol biopsies and biopsies taken at 
indication, and correlated syndecan-1 expression to allograft function and survival, and to 
the binding of relevant growth factors. To show the functional role of syndecan-1, we study 
the effect of syndecan-1 knockdown (in vitro) on TEC proliferation. In addition, we 
perform bilateral renal IRI in syndecan-1 versus wildtype mice and studied functional and 
histological outcome.  
In chapter 7 the experimental data presented in chapters 2-6 are discussed in their context 
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Background: Chronic transplant dysfunction explains the majority of late renal allograft 
loss and is accompanied by extensive tissue remodeling leading to transplant vasculopathy, 
glomerulosclerosis and interstitial fibrosis. Matrix proteoglycans mediate cell-cell and cell-
matrix interactions and play key roles in tissue remodeling. The aim of this study was to 
characterize differential heparan sulfate proteoglycan and chondroitin sulfate proteoglycan 
expression in transplant vasculopathy, glomerulosclerosis and interstitial fibrosis in renal 
allografts with chronic transplant dysfunction. 
Methods: Renal allografts were transplanted in the Dark Agouti (DA)-to-Wistar Furth 
(WF) rat strain combination. DA-to-DA isografts and non-transplanted DA kidneys served 
as controls. Allograft and isograft recipients were sacrificed 81 and 66 days (mean) after 
transplantation, respectively. Heparan sulfate proteoglycan (collXVIII, perlecan and agrin) 
and chondroitin sulfate proteoglycan (versican) expression, as well as CD31 and LYVE-1 
(vascular and lymphatic endothelium, respectively) expression were (semi-)quantitatively 
analyzed using immunofluorescence.  
Findings: Arteries with transplant vasculopathy and sclerotic glomeruli in allografts 
displayed pronounced neo-expression of collXVIII and perlecan. In contrast, in interstitial 
fibrosis expression of the chondroitin sulfate proteoglycan versican dominated. In the 
cortical tubular basement membranes in both iso- and allografts, induction of collXVIII was 
detected. Allografts presented with extensive lymphangiogenesis (p<0.01 compared to 
isografts and non-transplanted controls) which was associated with induced perlecan 
expression underneath the lymphatic endothelium (p<0.05 and p<0.01 compared to 
isografts and non-transplanted controls, respectively). The magnitude of lymphangiogenesis 
correlated with severity of interstitial fibrosis (R2=0.7634, p=0.0002) and reduced graft 
function (proteinuria: R2=0.4350, p=0.0002; plasma creatinine: R2=0.4350, p=0.0347).  
Interpretation: Our results reveal that changes in the extent of expression and the type of 
proteoglycans being expressed are tightly associated with tissue remodeling after renal 
transplantation. Therefore, proteoglycans might be potential targets for clinical intervention 





Chronic transplant dysfunction (CTD) explains the majority of long-term loss of 
transplanted kidneys [1,2]. Although considerable improvement has been made in overall 
graft survival due to improved prevention and treatment of acute rejection, the rate of long-
term renal graft loss has remained unchanged over more than a decade. CTD is the overall 
outcome of tissue remodeling processes in multiple intrarenal structures (i.e. the intrarenal 
arteries, the glomeruli and the interstitium leading to transplant vasculopathy (TV), focal 
glomerulosclerosis (FGS) and interstitial fibrosis (IF), respectively [2-4] and is the resultant 
of various underlying causes [5]. TV is presumed to result from activation of the vascular 
endothelium, leading to the activation and migration of vascular smooth muscle cells 
(SMCs) and the development of an occlusive neointima in the lumen of the arteries [6]. The 
neointima consists of smooth muscle cells, extracellular matrix and inflammatory cells [7]. 
FGS presumedly results from defects in the filtration barrier, which is formed by podocytes, 
the glomerular basement membrane (BM) and endothelial cells [8]. IF results from the 
accumulation of extracellular matrix synthesized by infiltrating and proliferating interstitial 
myofibroblasts. To date, due to the lack of knowledge on the pathogenesis of tissue 
remodeling leading to CTD, no effective therapies are available to prevent or treat CTD. 
The identification of molecules involved in pathological tissue remodeling after renal 
transplantation might provide novel targets for intervention. 
Proteoglycans are glycoconjugates that play an important role in tissue remodeling. They 
consist of a core protein with one or more carbohydrate side chains (i.e. 
glycosaminoglycans, GAGs) attached. Depending on the composition of these GAGs, 
different types of proteoglycans can be distinguished: heparan sulfate (HS), chondroitin 
sulfate (CS), dermatan sulfate (DS), and keratan sulfate proteoglycans. The extracellular 
matrix HS proteoglycans collagen type XVIII (collXVIII), perlecan and agrin are 
components of BMs of various tissues [9-11]. The CS/DS proteoglycan versican is a major 
extracellular matrix component which is not expressed in BMs. Depending on the sulfation 
patterns of the carbohydrate side chains, HS and CS/DS proteoglycans are capable of 
binding and presenting a variety of proteins like chemokines and growth factors and are 
involved in various cell-cell and cell-matrix interactions [12].  
Using a rat renal transplant model for chronic transplant dysfunction [13-15], we sought to 
determine the spatial expression of HS (collXVIII, perlecan, agrin) and CS/DS (versican) 
proteoglycans and its association with lymphangiogenesis. We used specific (semi-)-
quantitative immunofluorescent (double)labeling to identify the spatial expression of 
proteoglycans and lymphatics in non-transplanted kidney, isografts and allografts. We 
established a clear spatial relationship between the presence of HS and CS/DS 
proteoglycans in allografts and the development of CTD. Allografts were characterized by 
marked tubulointerstitial lymphangiogenesis coinciding with enhanced perlecan expression. 
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Both the magnitude of lymphangiogenesis and perlecan expression correlated with IF 




Inbred female (175-210 gram) and male (200-225 gram) Dark Agouti (DA) rats were 
obtained from Harlan (Horst, the Netherlands) and inbred male Wistar Furth (WF) rats 
(240-295 gram) from Charles River Laboratories Inc. (l’Arbresle, Cedex, France).  
 
Ethics statement 
All animals received care in compliance with the Principles of Laboratory Animal Care 
(NIH Publication No.86-23, revised 1985), the University of Groningen guidelines for 
animal husbandry (University of Groningen, the Netherlands), and the Dutch Law on 
Experimental Animal Care. 
 
Kidney transplantation and experimental groups 
Female DA kidneys were orthotopically transplanted into male recipients as described 
previously [14]. Cold ischemic time ranged from 16 to 38 min. Warm ischemic time ranged 
from 19 to 32 min. Recipients received cyclosporine A (5 mg/kg bodyweight) 
(Sandimmune, Novartis, the Netherlands) subcutaneously on the first 10 days after 
transplantation. The contralateral native kidney was removed 8 to 14 days after 
transplantation. Total follow-up was 12 wks or shorter in case animals had to be sacrificed 
due to graft failure. The following experimental groups were included: control (non-
transplanted) DA kidneys (n=5), DA-to-DA isografts (n=5), and DA-to-WF allografts 
(n=11). Clinical variables of recipients within these groups have been described in detail 
elsewhere [14;15]. Briefly, isograft recipients were sacrificed at day 81 [70-84] (mean 
[range]) and allograft recipients at day 66 [40-84] after transplantation. The allograft 
recipients showed significantly increased plasma creatinine levels measured at time of 
sacrifice compared with isograft recipients (119 [93-139] µmol/L vs. 42 [34-50] µmol/L, 
respectively, p<0.005 Mann-Whitney test). In addition, allograft recipients developed 
severe proteinuria compared with isograft recipients (110 [9-262] vs. 18 [9-43] mg/day, 
respectively, p<0.05 Mann-Whitney test). 
 
Immunofluorescence 
Four-micron frozen sections fixed in acetone or 4% formaldehyde were blocked for 
endogenous peroxidase activity with 0.03% H2O2 if appropriate. For some stainings the 
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sections were blocked with normal goat, rabbit or mouse serum. Sections were incubated 
for 1 hr with the following primary antibodies: rabbit anti-mouse collagen XVIII 
(NC11,kindly provided by Dr. T. Sasaki, Shrines Hospital for Children, Portland, OR, USA 
), mouse anti-rat perlecan (10B2, kindly provided by Dr. Couchman, Biomedicine Institute, 
University of Copenhagen, Denmark), sheep anti-rat agrin (Gr14) [16], mouse anti-heparan 
sulfate stub region (F69-3G10, Tokyo, Japan), mouse anti-HS (JM-403) [17,18], mouse 
anti-rat CD31 (TLD-3A12, BD Pharmingen, the Netherlands), and rabbit anti-LYVE-1 
(Millipore, USA). Binding of primary antibodies was detected by incubating the sections 
for 30 min with secondary antibodies diluted in PBS with normal rat serum: rabbit anti-
mouse HRP (DAKO, Belgium), goat anti-rabbit FITC (SouthernBiotech, USA), and rabbit 
anti-sheep HRP (DAKO). HRP activity was visualized using the TSATM 
Tetramethylrhodamine System (PerkinElmer LAS Inc., USA). Nuclei were stained with 
DAPI. 
 
L-selectin binding assay with enzymatic pre-treatments  
L-selectin-IgM chimeric protein, consisting of the extracellular domain of human L-selectin 
linked to an IgM Fc-tail [19] was allowed to bind for 1hr. L-selectin binding was detected 
by incubation with rabbit anti-human IgM HRP (DAKO) for 30 min, followed by the use of 
the TSATM Tetramethylrhodamine System. Heparitinase I (EC4.2.2.8), and chondroitinase 
ABC (EC4.2.2.4) (both from Seikagaku, Tokyo, Japan) were used to digest the side chains 
of the heparan sulfate and chondroitin sulfate proteoglycans, respectively. To this end, prior 
to some L-selectin binding assays, enzymatic pretreatments were performed with 
heparitinase I (0.05 U/ml) and/or chondroitinase ABC (1 U/ml) in acetate buffer (50 mM 
C2H3O2Na, 5 mM CaCl2•2H2O, 5 mM MgCl2•6H2O, [pH 7.0 for heparitinase I, pH 8.0 for 
chondroitinase ABC]) for 1 hr at 37°C. 
 
Fluorescence microscopy 
Fluorescence microscopy was performed using a Leica DMLB microscope (Leica 
Microsystems, Rijswijk, the Netherlands) equipped with a Leica DC300F camera and 
LeicaQWin 2.8 software. Confocal imaging was performed with a Leica TCS SP2 confocal 
laser scanning microscope equipped with the Leica Confocal Software package (version 
2.61). 
 
Quantification of protein expression in stained tissue 
sections 
Semiquantitative scoring of proteoglycan expression was performed independently by two 
observers (HR and KK) and the mean value of both observers was used. In the rare cases 
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discrepancies were identified between the values of both observers, the respective sections 
were re-evaluated in the presence of a third observer (JvdB) until consensus was reached. 
Both intensity of the staining as well as the stained surface area of the structures in the 
specific renal compartments (i.e. intima, media, neointima, Bowman’s capsule, glomerular 
BM, mesangial matrix, interstitial matrix and tubular BMs) were scored separately in a 
semi-quantitative manner on a scale ranging from 0-4. For staining intensity the following 
grading was used (relative to the strongest staining observed in a specific renal 
compartment of interest): 0= no staining, 1=weak staining, 2=moderate staining, 3=strong 
staining, 4= most intense staining observed. For surface area stained the following grading 
system was used (relative to the total area of the specific renal compartment of interest): 0= 
no staining, 1= 0-25% area positive, 2= 26-50% area positive, 3= 51-75% area positive, 4= 
76-100% area positive. Quantification of perlecan, CD31 and LYVE-1 in the outer medulla 
was performed in four overview photomicrographs of randomly selected fields 
(magnification 320x). The total area stained was quantified using ImageJ 1.41 (Rasband, 
W.S., ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA) which was 
downloaded from http://rsb.info.nih.gov/ij/download.html). 
 
Statistics 
Differences between non-transplanted control kidneys, isografts and allografts in total area 
stained for perlecan, CD31 and LYVE-1 were tested with a Mann-Whitney test. Spearman 
correlation analysis was performed to correlate the magnitude of lymphangiogenesis to 
interstitial fibrosis and renal function parameters. p<0.05 was considered statistically 
significant. Statistics were performed using GraphPad Prism 5.00 for Windows (GraphPad 
Software Inc., USA).  
 
Results 
Chronic tissue remodeling in renal grafts 
The rat renal allografts showed severe CTD with transplant vasculopathy (TV), focal 
glomerulosclerosis (FGS) and interstitial fibrosis (IF) (Figure 1), as reported previously 
[14,15]. The isografts developed some interstitial remodeling characterized by tubular 
atrophy and IF, but to a much lesser extent than observed in the allografts (not shown) 






Figure 1. Allografts present severe development of transplant vasculopathy (A), focal glomerulosclerosis (B) and interstitial 
fibrosis (C). (A) Intrarenal artery with a neointima (Verhoeff staining [elastic laminae: black; collagen: red; smooth muscle cells: 
yellow]). (B) Glomerulus with a sclerotic lesion (periodic acid-Schiff staining [glycogen in connective tissue: purple-magenta]). 
(C) Part of the tubulointerstitium with a fibrotic area (Masson’s trichrome staining [collagen: blue]). Stainings were performed on 
2 µm formalin-fixed paraffin sections. Abbreviations: IEL: internal elastic lamina; IF: interstitial fibrosis; M: media; NI: neointima. 
Magnification 400x. 
 
Heparan sulfate proteoglycan expression in non-
transplanted control kidneys 
In non-transplanted DA control kidneys, the HS proteoglycans collXVIII, perlecan, and 
agrin, as well as the CS/DS proteoglycan versican were strongly expressed in the intima of 
the arteries (Figure 2A-D). More specifically, the HS proteoglycans were located in the 
subendothelial BM whereas versican was located in the apical endothelial cell membrane 
(Figure 2D, insert). The BM of vascular SMCs in the media were characterized by a strong 
expression of collXVIII and a patchy expression of perlecan (Figure 2A and B). The arterial 
expression of proteoglycans was similar in arteries in isografts and arteries without TV in 
allografts (not shown). 
 
In the glomerular BM of non-transplanted control kidneys, expression of collXVIII was 
moderate whereas perlecan was virtually absent (Figure 2E and F). In contrast to collXVIII 
and perlecan, agrin was abundantly present (Figure 2G). All three HS proteoglycans were 
strongly expressed in the Bowman’s capsule but only minimally in the mesangial matrix 
(Figure 2E-G). A patchy glomerular versican expression pattern was observed suggesting 
non-glomerular BM staining (Figure 2H).  
 
Double labeling for versican and the mesangial cell marker CD90 (Thy-1) [20] did not 
reveal co-localization indicating non-mesangial versican origin (not shown). Double 
labeling for versican and CD31 revealed minor co-localization of versican and glomerular 
ECs (not shown). Since the limited endothelial versican expression could not account for 
the majority of glomerular versican expression, these data suggest podocyte origin of 
glomerular versican. These observations are in line with previous data showing that 





Figure 2. Proteoglycan expression in arteries, glomeruli and tubulo-interstitium of non-transplanted control kidneys. All 
proteoglycans were strongly expressed in the intima of arteries (A-D). HS proteoglycans were located in the subendothelial BM 
while versican was located in the endothelial cell membrane (insert D, confocal image, magnification 3780x). The BMs of vascular 
SMCs in the media showed a strong expression of collXVIII and a patchy expression of perlecan (A and B). In the glomeruli (E-
H), the glomerular BM moderately expressed collXVIII (E) while perlecan was virtually absent (F) whereas agrin was abundantly 
present (G). All HS proteoglycans were expressed in Bowman’s capsule but only minimally in the mesangial matrix (E-G). Dotted 
staining pattern for versican suggested expression by podocytes (H). In the tubulo-interstitium (I-L), tubular BMs minimally 
expressed collXVIII and perlecan in the cortex (I.1 and J). Compared with the cortex, collXVIII expression was increased in 
medullary tubular BMs (I.2). Perlecan was moderately to strongly expressed in peritubular capillaries (J). Agrin was uniformly 
expressed in tubular BMs (K). Versican was not present in tubular BMs but strongly expressed in the tubulointerstitial matrix (L). 
Magnifications: A-G, H & J: 640x; I: 320x. 
 
In the tubular BM, expression of collXVIII was only minimal in the cortical regions (Figure 
2I.1) but more pronounced in the medullary regions (Figure 2I.2). Agrin was strongly 
expressed in all tubular BMs in a uniform fashion (Figure 2K). The tubular BMs were 
virtually devoid of perlecan expression but we observed moderate to strong expression of 
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perlecan in the peritubular capillaries (Figure 2J) as well as in larger vessels (Figure 2B). 
Although versican was not present in the tubular BM, it was strongly expressed in the 
interstitial matrix (Figure 2L), where all three HS proteoglycans were absent. 
Table 1 summarizes the semi-quantitative scoring of proteoglycan expression (both 
intensity and surface area) in the intrarenal arteries, glomeruli and interstitium. Below we 
describe the significant changes in expression of HS proteoglycans and versican in renal 
isografts, and allografts with CTD. 
 
Differential proteoglycan expression in isografts compared 
with control kidneys  
Table 1. Proteoglycan expression in the specific renal compartments in non-transplanted control kidneys, isografts, and 
allografts. 
 
  Artery  Glomerulus  Tubulointerstitium 
  Intima Media NI  BC GBM MM  Matrix TBM 
           cortex med 
 
            
CollXVIII             
control  3 (3) 2 (4)   3 (4) 2 (4) 1 (4)  0 ½ (4) 1½ (4) 
isograft  3 (3) 2 (4)   3 (4) 2 (4) 1 (4)  ½ (1) 2 (4) 2 (4) 
allograft  3 (3) 2 (4) 3 (4)  3 (4) 1-3 (4) 1-3 (4)  ½ (1) 2 (4) 2 (4) 
 
 
           
Perlecan             
control  3 (2) 1-3 (4)   1-3 (3) ½ (1) ½ (1)  0 ½ (1) ½ (1) 
isograft  3 (2) 1-3 (4)   1-3 (3) 2-3 (2) 1-3 (2)  1 (1) 1 (2) 1 (2) 
allograft  3 (2) 1-3 (4) 3 (4)  1-3 (3) 3 (4) 1-3 (4)  1 (1) 1 (2) 1 (2) 
 
 
           
Agrin             
control  3 (4) ½ (1)   1-3 (3) 3 (4) 1 (2)  0 2½ (4) 3 (4) 
isograft  3 (4) ½ (1)   1-2 (3) 3 (4) 1 (2)  0 2-3 (4) 2-3 (4) 
allograft  3 (4) 1-2 (1) 1-3 (2)  1-3 (3) 3½ (4) 1 (2)  0 2-3 (4) 2-3 (4) 
 
 
           
Versican             
control  2 (4) 1 (3)   0 0 0  3 (4) 0 0 
isograft  2 (4) 1-2 (3)   0 0 0  2-3 (4) 0 0 
allograft  2 (4) 1-2 (3) 2 (1)  0 0 0  2-3 (4) 0 0 
             
 
Semi-quantitative scores (ranging from 0-4) of proteoglycan expression presented as the staining intensity and, between 
parentheses, the surface area stained (as described in detail in the Methods section). Scores given are the group means of the 
different grafts analyzed. Numbers of grafts analyzed are: non-transplanted control, n=5; isografts, n=5; allografts, n=11. The 
framed values indicate differentially expressed proteoglycans in the various groups as discussed in more detail in the Results 
section. Abbreviations: NI, neointima; BC, Bowman’s capsule; GBM, glomerular basement membrane; MM, mesangial matrix; 




The expression profile of proteoglycans in renal isografts was mostly similar to the 
expression profile in control kidneys except for changes in the glomerular and tubular BMs 
(Table 1). In the glomerular BM, perlecan expression was increased compared with control 
kidneys, but to a far lesser extent than observed in allografts (described below). In the 
tubular BM of isografts, an increased cortical expression of collXVIII and slight induction 
of perlecan was observed. The expression of agrin in the tubular BM remained strong alike 
control kidneys, although after transplantation the expression was slightly interrupted. In 
regions with IF (only limited present compared with allografts), an increased expression of 
versican was observed.  
 
Differential proteoglycan expression in neointima and FGS 
versus IF in allografts 
In arteries with TV in allografts, strong expression of collXVIII and perlecan was observed 
in the newly-formed neointima (Figure 3A and B). The expression of agrin and versican in 
the neointima was less prominent than collXVIII and perlecan, and varied in intensity 
within a single neointima. Agrin and versican expression in the media was slightly 
upregulated compared with non-transplanted control kidneys (Figure 3C and D).  
In sclerotic lesions of FGS, we also observed a strong expression of collXVIII and perlecan 
(Figure 3E and F). Within a single glomerulus differential expression of collXVIII 
expression was detected and contained both areas with decreased or strongly increased 
expression compared with control kidneys and isografts (Figure 3E). Agrin was not 
differently expressed in these lesions (Figure 3G) compared with glomerular BM staining 
in control kidneys. Compared with control kidneys and isografts, no altered expression of 
versican was observed in the glomeruli of allografts (Figure 3H). In the glomerular BM, 
and probably also podocytes of allografts, an impressive induction of perlecan expression 
was detected compared with its expression in control kidneys and isografts (Figure 3F).  
In contrast to the neointima and glomerulosclerotic lesions, collXVIII and perlecan were 
minimally expressed in IF with complete absence of agrin (Figure 3I-K). However, 
collXVIII/agrin and perlecan were clearly expressed in the tubular BM and peritubular 
capillaries, respectively (Figure 3I-K) as described in more detail below. In contrast to the 
HS proteoglycans, we observed a massive expression of versican in IF (Figure 3L). These 
data indicate that in neointimal and glomerular lesions HS proteoglycans dominate, 
whereas in regions with IF CS/DS proteoglycans are more prominent. 
 
Increased expression of collXVIII in cortical tubular 
basement membranes in allografts 
The expression profile of proteoglycans in the cortical tubular BM was similar in allografts 
and isografts (Table 1). In the allografts, increased expression of collXVIII and a slight 
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induction of perlecan was detected (Figure 3I and J). Increased collXVIII expression was 
observed in both cortical (Figure 3 I.1) and medullary (Figure 3 I.2) tubular BMs. Agrin 
remained strongly expressed; however, in a less homogeneous pattern compared with 
control kidneys (Figures 2K and 3K). 
 
 
Figure 3. Proteoglycan expression in transplant vasculopathy (TV), focal glomerulo¬sclerosis (FGS) and tubulointerstitial 
fibrosis (IF) in allografts. In the neointima in TV, collXVIII and perlecan were strongly expressed (A and B). Expression of agrin 
and versican was less prominent in the neointima but their expression was slightly upregulated in the media (compared with non-
transplanted control tissue) (C and D). Dotted lines indicate the internal elastic lamina. In the glomeruli (E-H), expression of 
collXVIII in the glomerular BM was variable with strong expression in glomerulosclerotic lesions (E). Perlecan was strongly 
induced in the glomerular BM (F). Agrin expression remained similar to its expression in glomerular BMs in non-transplanted 
control tissue (G). Versican staining was comparable with non-transplanted control tissue (H). In the tubulointerstitium (I-L), 
collXVIII (I) and perlecan (J) were minimally present in IF in which agrin expression was absent (K). CollXVIII was clearly 
expressed by tubular BMs in cortical (I.1) and medullary (I.2) regions at similar levels. Versican was strongly expressed in IF (L). 
In the cortical tubular BM, collXVIII was strongly expressed with a strong, but slightly interrupted, expression of agrin (I and K). 
Perlecan was only weakly expressed in the tubular BM but strongly expressed in peritubular capillaries (J). Magnification 640x. 
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Proteoglycan core proteins expressed in allografts contain 
functional glycosaminoglycan side chains 
 
 
Figure 4. Proteoglycan core proteins expressed in transplant vasculopathy, glomerulosclerosis and interstitial fibrosis in 
allografts contain functional glycosaminoglycan side chains. Neointimal cells in TV (A), glomerular BMs in non-sclerotic areas 
(B) and tubular BMs in IF (C) express heparan sulfate domains with N-unsubstituted glucosamine residues as recognized by 
antibody JM-403. Following heparitinase treatment presence of heparan sulfate stub regions was identified in medial and 
neointimal cells in TV (D), in glomerular BMs (E) and in tubular BMs (F) using antibody F69-3G10. Dotted line in panel A and D 
represents the internal elastic lamina. Abbreviations: M: media; NI: neointima. L-selectin-IgM chimeric protein binding in the 
tubulointerstitial in no pre-treated sections (G), sections pre-treated with heparitinase I [hep I] (H), sections pre-treated with 
chondroitinase ABC [chonABC] (I) and sections pre-treated with both heparitinase I and chondroitinase ABC (J). Insets show high 
power magnifications of the framed areas. Arrow: tubular BMs, asterisk: interstitium.  
 
In order to determine whether the proteoglycans (differentially) expressed in allografts 
contain HS glycosaminoglycan side chains, stainings with the antibodies JM-403 and 3G10 
were performed. JM-403 recognizes heparan sulfate domains with N-unsubstituted 
glucosamine residues [17,18]. As shown in Figure 4 A-C, neointimal cells in TV (A), 
glomerular BMs in non-sclerotic areas of glomeruli (B) and tubular BMs in IF (C) indeed 
expressed heparan sulfate domains with N-unsubstituted glucosamine residues, thereby 
confirming the presence of HS side chains. As JM-403 only recognizes a specific subset of 
HS side chains, not all HS glycosaminoglycans present will be detected using JM-403. 
Therefore, we additionally performed stainings using antibody F69-3G10. F69-3G10 
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recognizes HS stubs that remain attached to the proteoglycan core protein following 
heparitinase treatment. As shown in Figure 4 D-F, F69-3G10 staining revealed presence of 
HS stubs in medial and neointimal cells in TV (D), in glomerular BMs (E) as well as 
tubular BMs (F), also confirming presence of HS glycosaminoglycans on the proteoglycan 
core proteins.  
 
Finally, to demonstrate that the glycosaminoglycan side chains are capable of binding L-
selectin (as an example of a natural ligand), L-selectin binding assays were performed. As 
shown in Figure 4G, L-selectin binding in the tubulointerstitium was detected on the 
tubular BMs as well as in the interstitium. To determine whether L-selectin preferentially 
binds to HS or CS/DS proteoglycans, sections were pre-incubated with heparitinase I and/or 
chondroitinase ABC. Following heparitinase I pre-treatment, only interstitial L-selectin 
binding was preserved indicating preferential binding of L-selectin to HS proteoglycans in 
tubular BMs (Figure 4H). Following chondroitinase ABC pre-treatment, only L-selectin 
binding to tubular BMs was preserved indicating preferential binding of L-selectin to 
CS/DS proteoglycans in the interstitium (Figure 4I). Sections pre-treated with both 
heparitinase I and chondrointinase ABC were completely devoid of L-selectin binding 
(Figure 4J).  
 
Abundant lymphangiogenesis is related to increased 
expression of perlecan 
In the interstitium of allografts we observed a significant increase in expression of perlecan 
in a capillary-like pattern (Figure 5A-C). Since perlecan has been related to angiogenesis 
[23-26], we analyzed whether the increased perlecan expression was associated with the 
formation of new peritubular capillaries. However, quantification of interstitial CD31 
staining revealed that allografts do not contain an increased number of peritubular 
capillaries (Figure 5D-F). Instead, we observed a non-significant decrease in area stained 
positively for CD31 per given surface area in both allografts and isografts, which might be 
associated with enlargement of the renal graft after transplantation due to removal of the 
contralateral kidney [15]. When staining for the lymphatic marker LYVE-1 [27], we 
observed a marked increase in the number of lymph vessels in the allografts (Figure 4G-I) 
indicative of lymphangiogenesis. In isografts, we also observed an increase in LYVE-1 
staining but to a significant lesser extent than observed in allografts (Figure 5I). Double 
labeling for perlecan and LYVE-1 revealed that the newly-formed lymph vessels all 
express perlecan in their BM (Figure 5J-L). In addition, allografts also displayed abundant 
presence of capillary-like structures that were strongly positive for perlecan but LYVE-1 
negative, indicating an overall upregulation of perlecan in pre-existing peritubular 
capillaries as well (Figure 5J-L). The observed increase in perlecan expression in isografts 
and allografts positively correlated with the severity of IF (Spearman r=0.5580, p=0.0475) 
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as well as serum creatinine levels (Spearman r=0.7770, p=0.0004 [8 wk] and Spearman 
r=0.8182, p=0.0011 [12 wk]) and proteinuria (Spearman r=0.6714, p=0.0061 [8 wk] and 




Figure 5. Lymphangiogenesis in the tubulo-interstitium is associated with perlecan expression. Expression of perlecan in 
allografts was significantly increased compared with non-transplanted control kidneys and isografts (A-C). After transplantation 
(of both iso- and allografts), the area with CD31 expression slightly decreased (D-F) (NS: not significant). In allografts, LYVE-1 
expression was significantly increased compared with non-transplanted control kidneys and isografts (G-I). Double staining for 
perlecan and LYVE-1 revealed that perlecan is expressed in association with lymphatic endothelium in the newly-formed 
lymphatics (J-L). Arrowheads indicate peritubular capillaries strongly positive for perlecan but negative for LYVE-1. C, F and I 
represent the quantification of surface area stained for perlecan, CD31 and LYVE-1, respectively. Magnification A, B, D, E, G, H: 




Lymphangiogenesis in renal grafts correlate with IF and 
impaired graft function. 
In order to analyze whether the magnitude of tubulointerstitial lymphangiogenesis 
correlates with the severity of IF and graft function, Spearman correlation analyses were 
performed in which data from both the isografts and allografts were included. As shown in 
Figure 6A, the magnitude of lymphangiogenesis showed a significant positive correlation 
with the severity of IF. When analyzing proteinuria and plasma creatinine levels (measured 
at 8 wks after transplantation), also these functional variables turned out to be positively 
correlated with the magnitude of lymphangiogenesis at sacrifice (Figures 6B & C, 
respectively). Similarly, plasma creatinine levels at sacrifice positively correlated with 
lymphangiogenesis (Spearman r=0.8571, p=0.0137). Increased plasma creatinine levels 
translated into reduced creatinine clearance, which was inversely correlated with the 
magnitude of lymphangiogenesis (Figure 6D). 
 
 
Figure 6. Lymphangiogenesis in the tubulo-interstitium correlates with severity of interstitial fibrosis (A), proteinuria (B), 
plasma creatinine levels (C) and creatinine clearance (D). Interstitial fibrosis, proteinuria (8 wks post transplantation), plasma 
creatinine levels (8 wks post transplantation) and creatinine clearance (8 wks post transplantation) were determined as recently 




This study is the first to demonstrate the extensive involvement of proteoglycans in tissue 
remodeling in experimental CTD, demonstrating marked changes in proteoglycan 
expression in the intrarenal arteries, glomeruli and interstitium. The following key 
observations were made. First, whereas heparan sulfate (HS) proteoglycans dominate in 
neointimal lesions in transplant vasculopathy (TV) and in focal glomerulosclerosis (FGS), 
the chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycan versican dominates in 
interstitial fibrosis (IF). Second, glomerular remodeling is associated with an impressive 
induction of perlecan expression in the glomerular BM. Third, the HS proteoglycan content 
becomes increased in cortical tubular BMs, especially due to increased collXVIII 
expression. Finally, allografts are characterized by marked tubulointerstitial 
lymphangiogenesis which correlates with IF development and impaired graft function. 
Some earlier work demonstrated increased HS polysaccharides in fibrotic and sclerotic 
lesions in vessels, interstitium and mesangium of chronic renal transplant dysfunction [28], 
along with increased glycosaminoglycan-mediated chemokine binding [29,30]. However, 
proteoglycan core-proteins were not identified in those studies. In non-transplant renal 
diseases, tubular upregulation of collagen XVIII/endostatin was reported in a number of 
experimental models [31-33]. Mesangial expression of perlecan and agrin was reported in 
human diffuse mesangial sclerosis [34], in diabetic nephropathy [35,36], and some other 
human glomerulopathies with mesangial expansion [37]. Concerning proteoglycan 
expression in the neointima, both perlecan and versican have been shown to be present in 
neointimal lesions formed after experimental or human stenting or denudation or related to 
atherosclerosis [38-40]. The neointima in arteries of human cardiac allograft contain 
versican [41]. The striking similarities in proteoglycan expression in transplantation 
unrelated kidney diseases and chronic renal allograft dysfunction suggest comparable 
matrix remodeling programmes. This might indicate that anti-fibrotic treatments in various 
kidney diseases might also reduce chronic transplant dysfunction. 
We showed differential expression of HS proteoglycans in neointimal lesions and FGS on 
one hand, and CS/DS proteoglycans in IF on the other, suggesting the existence of spatial 
(i.e. compartment-specific) proteoglycan responses during the development of CTD with 
potentially variable biological effects. Expression of the CS/DS proteoglycan versican in IF 
is likely involved in leukocyte recruitment and infiltration by its L-selectin-binding capacity 
[30,42]. The abundant versican expression in IF supports our previous finding 
demonstrating that L-selectin in the interstitium binds to CS/DS side chains and not HS side 
chains [43] which was supported by preliminary data obtained in our experimental 
transplant model in rats revealing virtual absence of L-selectin binding following 
chondroitinase treatment (not shown). Moreover, the high L-selectin-binding capacity of 
CS/DS proteoglycans in IF fits well with our observation that most leukocyte infiltration 
was observed in interstitial regions and to a far lesser extent in neointimal lesions and FGS. 
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The marked expression of versican in IF is probably produced by interstitial myofibroblasts 
[44,45]. Tubulointerstitial versican might contribute to the activation and proliferation of 
intra- and extrarenal myofibroblasts and may also mediate their recruitment. In line with 
this, we recently demonstrated that ~53% of interstitial myofibroblasts in IF are derived 
from extrarenal sources [14] and may originate from a population of recirculating 
fibrocytes. Fibrocytes are mesenchymal progenitor cells exhibiting morphological 
characteristics of hematopoietic stem cells, monocytes and fibroblasts and have the capacity 
to differentiate into α-SMA-expressing myofibroblasts which is promoted by TGF-ß [46]. 
Although HS proteoglycans have been shown to modulate hematopoietic progenitor cell 
homing [47] this needs to be experimentally proven for CS/DS proteoglycans. 
In contrast to interstitial myofibroblasts in IF, neointimal SMCs in experimental renal 
allografts are solely derived from an intrarenal source, probably the arterial media [14]. In 
the current study, we observed a strong expression of perlecan in the neointima. Perlecan 
expression in arteries has been associated with inhibition of SMC proliferation and reduced 
intimal hyperplasia [25,39,48-50] which favours for a role of perlecan in neointima 
stabilization. However, data reported by others indicate that arterial HS proteoglycans can 
actually activate SMC proliferation by modulating the function of basic fibroblast growth 
factor (bFGF/FGF2) [51]. Although clear expression of collXVIII was observed in the 
neointima, its potential role in neointima formation is as yet unknown.  
After transplantation, we observed a strong induction of perlecan in the glomerular and 
peritubular capillary BMs. Peritubular capillaries play an essential role in graft rejection 
[52]. Upon capillary inflammation, endothelial cells become activated and changes occur in 
the BM, like splitting and multi-layering [53,54]. The response in peritubular capillaries is 
similar to that observed in glomerular capillaries, and the thickened BM might be the 
resultant of processes associated with endothelial cell death and regeneration [53,54]. 
Capillary BM changes are related to our previous data indicating endothelial chimerism 
(i.e. presence of recipient-derived endothelial cells) in glomerular and peritubular 
capillaries in CTD [14]. Both endothelial chimerism and perlecan expression in capillaries 
could be essential in capillary endothelial regeneration [23]. Perlecan in capillary BM might 
thus play a role in maintaining the capillary endothelial integrity but also contribute to the 
inflammatory response [30]. 
We observed a major increase of collXVIII expression in the tubular BM after renal 
transplantation in both iso- and allografts. The integrity of the tubular BM and its changes 
are involved in inflammation, phenotypic changes of tubular epithelial cells, and the 
development of IF and tubular atrophy [29,55-57]. Tubular epithelial cells can contribute to 
IF via epithelial-to-mesenchymal transition (EMT) in which epithelial cells 
transdifferentiate into interstitial myofibroblasts [58-60]. CollXVIII and (weakly expressed) 
perlecan in the tubular BM could play a role in the EMT process by binding of chemokines 
and growth factors resulting in a concentration gradient in the tubular BM [61]. This 
gradient might then direct migration of tubular epithelial cells into the interstitium during 
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EMT. In line with this, preliminary data indeed suggest increased binding capacity of HS 
proteoglycans for HB-EGF in the tubular BM in allografts (not shown). 
The more interrupted and less uniform expression of agrin in tubular BMs after 
transplantation supports the assumption that agrin normally plays a role in anchoring 
tubular epithelial cells and focal loss of agrin could therefore be related to migration of 
transdifferentiated tubular cells in EMT or tubular atrophy [62,63]. In addition to tubular 
atrophy and EMT, proteoglycan expression in the tubular BM could be involved in binding 
of L-selectin, thereby facilitating inflammatory responses in tubules [30,64]. The potential 
causal role of BM HS proteoglycans in tubular atrophy or EMT are under current 
investigation in HS proteoglycan mutant mice. 
We showed a marked induction of lymphangiogenesis in allografts, which was 
accompanied by the expression of perlecan at the abluminal side of lymphatic endothelium. 
Recovery of renal lymph drainage is shown to occur as early as 24 hours after renal 
transplantation [65], suggesting that lymph drainage and the process of lymphangiogenesis 
after renal transplantation is of potential functional relevance. However, it is still a matter 
of debate whether lymphangiogenesis and potential development of lymphoid structures in 
renal grafts is beneficial or detrimental to clinical outcome. Lymph vessels could be 
beneficial by mediating the drainage of extravasated fluid and the export of leukocytes [66-
68]. On the other hand, lymph vessels and additional development of lymphoid structures 
could also perpetuate the inflammatory response [66,67,69-71]. We observed a clear 
correlation between the magnitude of lymphangiogenesis and severity of IF, suggesting that 
new lymph vessel formation may enhance the fibrotic process by stimulating the 
inflammatory process. This is supported by recent findings in diabetic nephropathy 
indicating that lymphangiogenesis is associated with inflammatory cell infiltration and 
progression of IF [72]. In our study, increased lymphangiogenesis correlated with reduced 
graft function suggesting that therapies that target de novo lymphatic formation might 
contribute to improved graft function. The existence of a causal relation between 
lymphangiogenesis and loss of graft function, however, needs to be established in future 
studies. The expression of perlecan in close proximity of lymphatic endothelial cells 
suggests a functional role for perlecan in lymphangiogenesis. This is supported by results 
from studies performed in a mouse model for regenerating skin which suggest that perlecan 
is involved in lymphatic endothelial cell migration, lymphatic organization and maturation 
[73]. In addition, also versican, which was abundantly present in the interstitium, might 
play a role in lymphangiogenesis [74]. 
 
In conclusion, we identified increased spatial expression of HS and CS/DS proteoglycans in 
the intrarenal arteries, glomeruli and tubulointerstitium undergoing extensive tissue 
remodeling associated with CTD in renal allografts. Compartment-specific expression of 
proteoglycans in CTD might translate into compartment-specific responses to therapy. In 
line with this concept, we recently reported a differential response in renal allograft 
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remodeling to aldosterone receptor blockade using spironolactone in which spironolactone 
ameliorated TV and FGS but not IF [15]. The potential role of proteoglycans in the 
spironolactone-induced effects are currently under investigation. 
Although our results are descriptive in nature, the observed differential expression of 
proteoglycans in renal allografts most likely also have functional consequences as the 
proteoglycan core proteins were shown the have GAGs that were able to bind L-selectin. 
Preliminary data furthermore suggest altered endogenous expression of natural 
proteoglycan ligands (such as FGF-2, HB-EGF and L-selectin). As a resultant, the 
bioavailability of these ligands, which are key in driving tissue remodeling and 
inflammation, is most likely modulated due to altered proteoglycan expression as well as 
glycosaminoglycan side chain modifications. 
Based on our results we propose that proteoglycans could be targets for intervention to 
ameliorate CTD. As an example, antibodies recognizing, and thereby blocking, specific 
HS-motifs/domains may inhibit leukocyte extravasation resulting in reduced inflammation. 
Also generated small inactive chemokine fragments might be used to block the HS 
proteoglycan-binding sites of their in vivo active counterparts thereby making the HS 
proteoglycans less bioactive. Alternatively, we suggest the possibility to produce small HS-
mimetics which may target more specifically a particular component of HS/heparin 
bioactivity [75]. Therefore, focus should now be on the identification of the precise 
functional role of proteoglycans in chronic tissue remodeling after renal transplantation 
followed by exploration of the feasibility to use proteoglycans as targets for therapeutic 
intervention to ameliorate the development of CTD. 
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Depending on the glycan structure, proteoglycans can act as co-receptors for growth factors 
thereby contributing to cell survival, proliferation and fibrosis. Chronic transplant 
dysfunction is characterized by extensive fibrotic tissue remodeling including 
glomerulosclerosis and neointima formation in arteries. We hypothesize that proteoglycans 
and their growth factor ligands orchestrate tissue remodeling in chronic transplant 
dysfunction. Therefore, in a rat renal transplantation model, we studied proteoglycan and 
growth factor expression in glomeruli, arterial mediae and neointimae by qRT-PCR and 
immunofluorescence. To this end, laser microdissection of glomeruli, arterial mediae and 
neointimae followed by low density qRT-PCR was performed. Uniform upregulation of 
collagen I, IV, and TGF-β1 in the allografted kidneys was observed. However, spatial 
differences in proteoglycan expression and ligand binding properties were detected. In 
glomeruli and neointimae of allografts we found induction of the matrix heparan sulfate 
proteoglycan perlecan along with massive accumulation of FGF2. Profiling the heparan 
sulfate polysaccharide side chains of renal heparan sulfate proteoglycans revealed 
conversion from a non-FGF2-binding heparan sulfate phenotype in control and isografted 
kidneys towards a FGF2-binding phenotype in allografts. The functional significance of 
these findings was evidenced by in vitro experiments with rat mesangial cells showing that 
FGF2-induced proliferation is dependent on sulfation and can be inhibited by exogenously 
added heparan sulfate. These data indicate that heparan sulfate proteoglycans such as 
perlecan serve as docking platforms for FGF2 in various renal compartments in chronic 
transplant dysfunction. We speculate that heparin-like glycomimetica could be a promising 





Renal chronic transplant dysfunction (CTD) is the leading cause of long-term loss of 
transplanted kidneys (1,2). CTD is the result of tissue remodeling in the intrarenal arteries, 
glomeruli and tubulointerstitium leading to transplant vasculopathy, focal 
glomerulosclerosis (FGS), interstitial fibrosis and tubular atrophy (2-4). These lesions are 
characterized by accumulation of extracellular matrix, activation of mesangial cells, 
interstitial myofibroblasts and tubular epithelial cells, and chronic inflammation. To date, 
due to the lack of knowledge on the pathogenetic mechanisms leading to the development 
of these lesions, no effective therapies are available to prevent or treat renal CTD. 
Progressive loss can only be retarded by anti-hypertensive and anti-proteinuric treatment in 
combination with lipid lowering drugs. 
Recently, we showed accumulation of the heparan sulfate proteoglycans (HSPGs) collagen 
type XVIII and perlecan during tissue remodeling in CTD in rats (5). However, whether 
and how these proteoglycans mediate tissue remodeling in CTD is as yet unknown. In 
native kidney diseases and ischemia-reperfusion injury we have already shown that HSPGs 
are involved in leukocyte influx and proteinuria-mediated renal injury (6-8). 
The carbohydrate side chains (i.e. the glycosaminoglycans) are attached to proteoglycan 
core proteins and can bind a variety of ligands depending on their highly variable 
composition, mainly variations in N- and O-sulfation patterns (9). Along with chondroitin 
sulfate- and dermatan sulfate proteoglycans, HSPGs form the large majority of the 
proteoglycan family. Potential ligands are chemokines (9) and growth factors such as basic 
fibroblast growth factor (bFGF/FGF2; 10,11). Proteoglycans are highly involved in 
morphogenesis and tissue remodeling processes (12-17). 
Studies in non-transplantation models of renal and vascular disease have shown potential 
roles of FGF2 in FGS and neointima formation (18-22). These data led us to hypothesize 
that interaction of FGF2 with proteoglycans also affects tissue remodeling processes in 
CTD. To test this hypothesis we used an experimental rat CTD model, from which we 
microdissected glomeruli, the arterial media as well as the neointima followed by low 
density qRT-PCR analysis for matrix and cell surface proteoglycans and FGF2. In addition, 
we profiled the heparan sulfate (HS) polysaccharide side chains by anti-HS mAbs and their 
binding capacity for FGF2. Finally, we investigated the HSPG involvement of FGF2-driven 
mesangial proliferation. Our data indeed indicate spatial proteoglycan involvement in CTD, 




Materials and Methods  
Rats  
Inbred female (175-210 gram) Dark Agouti (DA) rats were obtained from Harlan (Horst, 
The Netherlands) and inbred male Wistar Furth (WF) rats (240-295 gram) from Charles 
River Laboratories Inc. (l’Arbresle, Cedex, France). All animals received care in 
compliance with the Principles of Laboratory Animal Care (NIH Publication No.86-23, 
revised 1985), the University of Groningen guidelines for animal husbandry and the Dutch 
Law on Experimental Animal Care.  
 
Kidney transplantation and experimental groups  
Female DA kidney allografts were orthotopically transplanted into male Wistar Furth 
recipients as described previously (5,23). Cold ischemic time ranged from 16 to 38 minutes. 
Warm ischemic time ranged from 19 to 32 minutes. Recipients received cyclosporine A (5 
mg/kg bodyweight) (Sandimmune, Novartis, Arnhem, the Netherlands) subcutaneously for 
10 days posttransplantation. The native kidney was removed after 8 to 14 days. Total 
follow-up was 12 weeks or shorter in case animals had to be sacrificed due to renal failure. 
Allografts used in this study had developed severe CTD (n=5). Further characteristics of the 
model are described elsewhere (5,18). Non-transplanted DA kidneys (n=5) and DA to DA 
isografted kidneys (n=5) served as controls. 
 
Laser Microdissection and Gene Expression Analysis 
Laser microdissection, RNA isolation and qRT-PCR were performed essentially according 
to Asgeirsdottir et al. (39). Briefly, frozen kidneys were sectioned at 9 µm and mounted on 
UV pretreated slides (PALM Micro Laser Technology, Bernried, Germany). Sections were 
quickly fixed in acetone and air-dried for 3 min. Sections were subsequently stained with 
Mayer’s hematoxylin (Merck, Darmstadt, Germany) for 1 min and rinsed in diethyl 
pyrocarbonate (DEPC) treated tap water for 20 s. Slides were then used for microdissection 
using the Leica Microdissection microscope (Leica Microsystems, Houston, Texas). 
Glomeruli and various layers (including media and neointima) of larger arteries were 
separately dissected from 9 serial sections per kidney. An average of 194 [range 71-308 ] 
glomeruli and 63 [range 25-117] arteries were dissected from each kidney. 
Total RNA was isolated from microdissected structures by using the RNeasy Micro Kit 
(Qiagen, Hilden, Germany). Reverse transcription was carried out using Superscript III 
reverse transcriptase (Invitrogen, Breda, the Netherlands) and random hexamer primers 
(Promega, Leiden, the Netherlands). Gene expression was analyzed with a custom made 
microfluidic card-based low density array (Applied Biosystems, Nieuwerkerk a/d IJssel, the 
Netherlands) using the ABI Prism 7900HT Sequence Detection System (Applied 
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Biosystems, Nieuwerkerk a/d IJssel, the Netherlands). Composition of the low density array 
is indicated in Table 1. Relative mRNA levels were calculated as 2−∆CT, in which ∆CT is 
CTgene of interest – CTβ-actin. CT-values that were beyond detection level were set manually to 
50. 
 
Table 1. Composition of low-density array 
Gene name General 
name 
Gene 
symbol Assay ID 
Matrix molecules    
collagen, type I, alpha 1 Collagen I Col1a1 Rn01463848_m1 
collagen, type IV, alpha 1 Collagen IV Col4a1 Rn01482925_m1 
    
Proteoglycans    
perlecan Perlecan LOC313641 Rn01515780_g1 
agrin Agrin Agrn Rn00598349_m1 
versican Versican Vcan Rn01493755_m1 
biglycan Biglycan Bgn Rn00567229_m1 
syndecan 1 Syndecan 1 Sdc1 Rn00564662_m1 
syndecan 4 Syndecan 4 Sdc4 Rn00561900_m1 
    
Growth factors     
fibroblast growth factor 2 FGF2 Fgf2 Rn00570809_m1 
transforming growth factor, beta 1 Tgf-b1 Tgfb1 Rn01475963_m1 
    
Reference genes    
beta actin Beta-actin Actb Rn00667869_m1 
beta 2 microglobulin B2m B2m Rn00560865_m1 
Eukaryotic 18S rRNA 18S 18s Hs99999901_s1 
    
 
Immunofluorescence on rat kidney sections  
Four µm frozen sections were fixed in acetone or 4% formaldehyde and were blocked for 
endogenous peroxidase activity with 0.03% H2O2 if appropriate. Sections were blocked 
with normal goat or rabbit serum. Sections were incubated for 1h with the following 
primary antibodies: mouse anti-human FGF2 (Peprotech, London, UK), mouse anti-HS 
mAb JM-403, which recognizes low sulfated heparan sulfate domains with N-unsubstituted 
glucosamine residues (25), mouse anti-HS stub mAb 3G10 (epitope becomes expressed 
after heparitinase I digestion of HS; Seikagaku, Tokyo, Japan; ref. 26) and mouse anti-rat 
perlecan (clone10B2 kindly provided by Prof. dr. J.R. Couchman, Copenhagen, Denmark). 
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Binding of primary antibodies was detected by incubating the sections for 30 min with 
secondary antibodies diluted in PBS with 5% normal rat serum: goat anti-mouse IgG1 HRP 
(Southern Biotech, Birmingham, AL, USA), rabbit anti-mouse IgM HRP (DAKO, 
Heverlee, Belgium,), or goat anti-mouse IgG1 Alexa488 (Invitrogen-Molecular Probes, 
Breda, the Netherlands). HRP-activity was visualized using the TSATM 
Tetramethylrhodamine System (PerkinElmer LAS Inc.). All fluorescence microscopy was 
performed using a Leica DMLB microscope (Leica Microsystems, Rijswijk, the 
Netherlands) equipped with a Leica DC300F camera and Leica QWin 2.8 software.  
 
Ligand binding assays on rat kidney sections  
To detect capacity of renal proteoglycans to bind FGF2, formalin-fixed rat renal sections 
were incubated with recombinant human FGF2 (Peprotech) for 60 min. After washing, the 
staining was continued according to the FGF2 staining protocol described above. Formalin 
fixation essentially avoids recognition of endogenous renal FGF2 by anti-FGF2 antibodies. 
To confirm that the observed binding pattern was mediated by HS proteoglycans, the 
sections were pretreated with 0.05 U/ml heparitinase I (Flavobacterium heparinum, EC 
4.2.2.8; Seikagaku, Tokyo, Japan) for 1h at 37°C in a humidified chamber. 
  
FGF2 stimulation assay on rat mesangial cells  
Rat mesangial cells (Thy 1.1 and α-smooth muscle actin positive, passage 11-15) were 
cultured in 24 well plates in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 25 mM HEPES, 4.5 mg/ml glucose, pyridoxine, 1 mM pyruvate, 50 ng/ml insulin, and 
10% fetal bovine serum. Before stimulation with FGF2 cells were grown until confluency, 
serum deprived (0.5% serum) for 24 h and subsequently incubated with different 
concentrations (0.031 – 8 ng/ml) of FGF2 for 24 h. Proliferation was measured by adding 
0.5 µCi/ml 3H-thymidine (Amersham, Buckinghamshire, UK) for 24 h to the cultures. 
After 24 h, 5% trichloric acid precipitable material was dissolved in 0.1% SDS, Optiphase 
“HiSafe 3” was added and radioactivity was counted in a 1214 Rackbeta liquid scintillation 
counter. To study whether FGF2-induced proliferation of mesangial cells was reduced in 
the presence of exogenous HS, mesangial cells were stimulated with 0.5 ng/ml FGF2 for 24 
hours in the presence of various concentrations (0, 8, 32 and 128 µg/ml) exogenous HS 
from bovine kidney [HSBK] (Seikagaku, Tokyo, Japan). Proliferation was measured as 
described above. To study whether proteoglycan sulfation was reduced by chlorate, 
mesangial cells were cultured for 24 hrs in the presence of various concentrations (5-25 
mM) Na-chlorate (Sigma) and 35S-sulfate (2 µCi/ml; Amersham, Buckinghamshire, UK). 
Incorporation of 35S-sulfate into proteoglycans was quantified similarly as described above 
for 3H-thymidine incorporation. Finally, to analyze whether chlorate impairs FGF2-induced  
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proliferation of mesangial cells, cells were stimulated with FGF2 (0.5 ng/ml) for fixed 
times (0, 0.5, 1, 2, 4 and 24 hrs) in the presence or absence of 25 mM Na-chlorate and in 
the presence of 0.5 µCi/ml 3H-thymidine. Total culture time was 24 hrs. Proliferation was 
determined as described above. 
 
Statistics  
mRNA expression levels were analyzed using a one-way ANOVA with Turkey’s post-hoc 
test. P values of <0.05 were considered statistically significant (SPSS® software package). 
Mesangial cell culture data were expressed as mean ± standard error of the mean (SEM) 
and analyzed by one-way ANOVA. If overall p<0.05, Bonferroni’s Multiple Comparison 
Test was performed (GraphPad Prism 5.0, GraphPad Software, Inc.). 
 
Results  





Figure 1. Chronic transplant dysfunction in renal allografts. A: Representative photomicrographs showing development of 
glomerulosclerosis in allografted kidneys, in contrast to isografted and control kidneys (upper row; PAS staining). Neointima 
formation was observed in allografts but not in isografts and controls (lower row, Verhoeff staining). Magnification: 400x. B: qRT-
PCR analysis performed on RNA isolated from microdissected glomeruli from non-transplanted control tissue, isografts and 
allografts (n=5/group). Expression levels of ColIVα1, ColIα1 and TGF-β1 are expressed relative to the expression level of β-actin. 
** p<0.01 vs. isografts and non-transplanted control tissue. Abbreviations: IEL: internal elastic lamina, M: media, A: adventitia, 
NI: neointima 
 
Progressive renal function loss was evidenced in the allografted kidneys by a 50% loss in 
creatinine clearance and a 15-fold rise in urinary protein excretion at 8 weeks after 
transplantation, both of which were not observed in isografted kidneys, as we showed 
before in this model (5,23). The rat renal allografts showed development of severe CTD 
with FGS and arterial neointima formation (Figure 1A). In isografts, development of FGS 
was minimal and no neointima formation was observed (5,23). The development of FGS 
coincided with significantly increased expression of the pro-fibrotic factors Col Iα1, Col 
IVα1 and TGF-β1 as determined by qRT-PCR on microdissected glomeruli (Figure 1B). 
These molecular responses were also observed in RNA isolated from microdissected 
arterial medial and neointimal tissue as well as in whole kidney material (not shown). These 
data confirm development of CTD in our rat transplantation model. 
 
Induction of glomerular and neointimal perlecan 
expression in CTD 
Proteoglycans can modulate growth factor responses by virtue of their glycosaminoglycan 
side chains. Therefore, we profiled the matrix HS proteoglycans agrin and perlecan, the 
matrix chondroitin sulfate- and dermatan sulfate proteoglycans versican and biglycan, and 
the major epithelial cell surface proteoglycans syndecan-1 and -4 by qRT-PCR. PCR 
analysis showed the expression of the basement membrane HSPG perlecan to be 
upregulated mainly in the glomeruli (Figure 2A), and mediae and neointimae (Figure 2B) 
of the allografts. This spatial upregulation of perlecan by qRT-PCR in glomeruli, mediae 
and neointimae was however not observed when performing qRT-PCR analysis on whole 
kidney RNA isolates (Figure 2C), which clearly stresses the power, and need, of using 
microdissection of specific structures to demonstrate differential proteoglycan expression in 
specific renal compartments. Using immunofluorescence, expression of perlecan was 
virtually absent in the glomerular basement membranes of non-transplanted control 
kidneys. In the glomerular basement membranes of isografts, perlecan expression was 
increased compared with control kidneys, but to a far lesser extent than the increase 
observed in allografts (Figure 2D, left column). In glomeruli with FGS in allografts a strong 
expression of perlecan was observed in the glomerular basement membranes and mesangial 
areas (Figure 2D, left column). In control tissue, isografts and allografts the Bowmans 
capsule was positive for perlecan. Immunofluorescence also showed perlecan expression in 
the newly-formed neointimae present in allografts (Figure 2D, right column). No significant 
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differences in expression levels were found for syndecan-1 and -4, agrin, and biglycan, 
although these proteoglycans were expressed in the neointimae based on qRT-PCR data 
(Figure 3A-E).  
 
 
Figure 2. Upregulation of perlecan in glomeruli and neointimae of renal allografts with CTD. A-C. Perlecan expression 
measured by qRT-PCR in glomeruli (n=5/group) (A), arteries (n=4-5/group) (B), and whole kidney tissue (n=3/group) (C). D: 
Immunofluorescence demonstrating perlecan accumulation in glomeruli (left column) and neointimae (right column) of allografts 
with CTD. In isografted kidneys a minor increase of perlecan was seen in glomeruli and arterial media compared to control tissue. 
Dotted line represents the internal elastic lamina. Magnification: 640x except for the lower right panel (artery of allograft) which 
was taken at 320x. Expression levels of perlecan are expressed relative to the expression level of β-actin. ** p<0.01 vs. isografts 





Figure 3. Proteoglycan mRNA expression profiles in microdissected glomeruli (A.1-E.1), arteries (A.2-E.2) and total 
kidney lysates (A.3-E.3) of non-transplanted control tissue, isografts and allografts with CTD.  
Expression of syndecan-1 (A), syndecan-4 (B), agrin (C), biglycan (D) and versican (E) was analyzed using qRT-PCR (n=3-
5/group). Expression levels of the respective genes are expressed relative to the expression level of β-actin. Transcripts for the 




Versican expression was significantly upregulated in the media of the allografted kidneys 
(Figure 3E.2), which is in line with a pro-migratory phenotype of the vascular smooth 
muscle cells. This proteoglycan profiling led us to conclude that glomerular and neointimal 
perlecan is upregulated in renal allografts at both the mRNA and protein level. 
 
Heparan sulfate profiling 
Since HS proteoglycans are involved in morphogenesis and tissue remodeling mainly by 
their HS glycosaminoglycan side chains, we profiled HS polysaccharide structures in renal 
sections. To this end we visualized HS epitopes by anti-HS mAbs JM-403 and 3G10, and 
by a ligand binding assay using the HS-binding growth factor FGF2. Characteristics of the 
corresponding HS-epitopes are detailed in Table 2. 
 
Table 2. Basic characteristics of the HS epitopes recognized by the anti-HS mAbs and FGF2 
 
 
Anti-HS mAb JM-403 demonstrated a clear staining of the glomerular basement 
membranes in control (Figure 4A.1) and isografted (Figure 4A.2) kidneys. Mesangial 
staining was weak for mAb JM-403. In allografts however, glomerular JM-403 HS staining 
is partly or completely lost in sclerotic areas (Figure 4A.3), likely due to increased HS 
sulfation. The 3G10 HS epitope, which becomes available after heparitinase cleavage of 
HS, is absent in the glomerular basement membranes of control kidneys (Figure 4B.1), 
becomes weakly expressed in the isografted kidneys (Figure 4B.2), and is strongly 
upregulated in glomerular basement membranes and sclerotic areas in the allografts (Figure 
4B.3). The 3G10 staining nicely paralleled perlecan stainings (see Figure 2D), suggesting 
this HS epitope to be expressed by perlecan. FGF-2 binding is completely HS-dependent as 
evidenced by control experiments on heparitinase pretreated sections, where all binding of 
FGF-2 was lost (not shown). In glomeruli of control kidneys (Figure 4C.1) and isografts 
(Figure 4C.2) FGF-2 binding to HS was absent or only weakly present. In allografts, 
Anti-HS mAb or HS-binding 
protein Basic characteristics of the HS epitope 
Anti-HS mAb JM-403 GlcUA-rich sequences with N-unsubstituted GlcN 
units in low sulfated HS (24) 
Anti-HS mAb 3G10 Desaturated Uronate residues after digestion with heparitinase (GlcNAc/NS α1-4 GlcA linkage; ref.25) 
FGF2 2-O sulfation in heparin and heparan sulfates (26) 
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increased binding of FGF-2 was observed (Figure 4C.3). These data indicate changes in 
glomerular HS composition in CTD as evidenced by an increased FGF2 binding capacity, 
which occurred most likely due to increased sulfation.  
 
 
Figure 4. Modification of glomerular HS structure in allografts with CTD. Glomerular expression of HS was evaluated by 
two anti-HS mAbs (JM-403 [A] and 3G10 [B]) as well as by the binding of FGF2 (C) In allografts, glomerular JM-403 staining is 
partly lost in sclerotic areas (arrows). On the, contrary HS expression as evidenced by 3G10 (B.3) and FGF2 binding capacity 
(C.3) was increased in glomeruli in allografts. Dotted line represents Bowmans capsule. Arrows indicate sclerotic area. 
Magnification: 640x. 
 
In the arterial media of control and isografted kidneys moderate staining for anti-HS mAbs 
JM-403 (Figure 5A.1,2) and 3G10 (Figure 5B.1,2) was observed, however binding capacity 
for FGF2 was absent (Figure 5C.1,2). Compared to the mediae of control and isografted 
kidneys, in allografts JM-403 staining was lost in the media (Figure 5A.3), whereas 3G10 
staining was increased (Figure 5B.3). Moreover, FGF2 binding capacity was increased in 
the allograft media (Figure 5C.3). In the neointimae strong binding of anti-HS mAbs JM-




Collectively, these data show changes in glomerular and arterial HS composition in 
allografts with CTD, with loss of JM-403 staining and increased FGF2 binding capacity, 
which can be explained by increased HS sulfation. 
 
 
Figure 5. Modification of arterial HS structure in allografts with CTD. Medial and neointimal expression of HS was 
evaluated by two anti-HS mAbs (JM-403 [A] and 3G10 [B]) as well as by the binding of FGF2 (C). In the media of allografted 
kidneys, JM-403 staining was largely lost, whereas in the neointima this epitope was clearly expressed (A.3). Both the media and 
neointima of the allografts expressed the 3G10 HS epitope (B.3). The media but not neointima bound FGF2 (C.3). Magnification: 
640x except for B.3 which was taken at 320x. 
 
Endogenous expression of FGF-2 in allografts with CTD 
After showing an upregulation of glomerular and neointimal perlecan expression 
accompanied by increased binding capacity for FGF2 in renal allografts, we next evaluated 
endogenous expression levels of FGF2. In control kidneys, we only observed weak 
segmental FGF2 expression in the glomeruli (Figure 6A.1), the tubulointerstitium (Figure 
6A.1) and arteries (Figure 6B.1) being devoid of any FGF2 expression. In isografts, a slight 
upregulation of FGF2 expression in glomeruli was observed (Figure 6A.2), with the arteries 
remaining devoid of any FGF2 expression (Figure 6B.2). However, in the allografts, FGF2 
was strongly and homogeneously accumulated throughout the glomeruli, and present 
mainly in the glomerular capillary wall and mesangium (Figure 6A.3). PCR analysis 
Chapter 3 
70 
showed no significant differences in glomerular FGF2 expression, although a tendency 
towards higher expression was observed in the allografts (Figure 6C). We suggest that this 
discrepancy may be explained by plasma-derived FGF2 being trapped in the glomeruli by 
perlecan endowed with HS chains able to bind FGF2 (as shown in Figure 4) during 
ultrafiltration. This would cause local accumulation of FGF2 protein in the absence of an 
increase in mRNA expression. In addition, in the neointimae of allografts increased FGF2 





Figure 6. Glomerular and arterial expression of FGF2 in allografts with CTD. Endogenous expression of FGF2 was 
evaluated by immunofluorescence (A-B) and qRT-PCR (C-D). In allografts with CTD, a strong expression of FGF2 was 
exclusively found in glomeruli (A.3) and neointimae (B.3). In glomeruli of isografts a slight increase in FGF2 expression was 
found (A.2). The dotted line represents the internal elastic lamina. qRT-PCR analysis revealed an increase in FGF2 expression in 
the glomeruli in allografts, which did however reach the level of statistical significance when compared with isografts and non-
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transplanted control tissue (C). Neointimal expression of FGF2 was clearly present (D) although again not being significantly 
different from isografts and non-transplanted control tissue (n=4-5/group). Magnification of the photomicrographs: 640x. 
 
Involvement of proteoglycans in FGF2-driven proliferation 
of mesangial cells 
As described above, we showed an upregulation of the HS proteoglycan perlecan in the 
glomeruli of allografts, which coincided with increased FGF2 binding capacity and FGF2 
expression. We next hypothesized that the upregulation of perlecan and FGF2 may be 
involved in mesangial expansion and formation of FGS. To explore a possible mechanistic 
relation between mesangial HSPGs and FGF2 in more detail, we conducted a number of in 
vitro experiments. Primary rat mesangial cells were cultured until confluency, serum 
starved for 24 h followed by 24 h stimulation with FGF2. Figure 7A shows a dose-
dependent increase in proliferation of mesangial cells in response to FGF2.  
 
Figure 7. FGF2-induced proliferation of mesangial cells depends on sulfated proteoglycans. A: Rat mesangial cells were 
stimulated with various concentrations of FGF2 for 24 h. Proliferation was measured by 3H-thymidine incorporation. Data are 
expressed as the stimulation index, i.e. fold increase in proliferation + FGF2 / proliferation – FGF2 (n=4; *p<0.05, **p<0.01 vs. no 
FGF2 added). B: Exogenous HS from bovine kidney (HSBK) hampers FGF2-induced mesangial cell proliferation in a dose-
dependent manner (n=2). C: Proteoglycan sulfation of mesangial cells is reduced by chlorate in a dose-dependent manner 
(**p<0.01, ***p<0.001 vs. no chlorate added). D: Chlorate impairs FGF2-induced proliferation of mesangial cells which is 




Based on these data we used the FGF2 concentration of 0.5 ng/ml in the subsequent in vitro 
experiments. The FGF2-induced proliferative response was blunted by the addition of 
exogenous competitive bovine kidney-derived HS (Figure 7B). This was due to reduced 
binding of FGF2 to the cells as demonstrated by reduced binding of 125I-labeled FGF2 to 
the mesangial cells (not shown).  
 
These data suggest that due to competition between mesangial and exogenous HS for 
binding of FGF2, less FGF2 was bound to the endogenous HS proteoglycans, resulting in 
decreased proliferation of the mesangial cells. To show that proliferation of the mesangial 
cells was dependent on active FGF2 binding by endogenous HS, cells were cultured in the 
presence of chlorate. Chlorate inhibited the sulfation of the side chains of the proteoglycans 
in a dose-dependent manner (Figure 7C) which should lead to loss of binding sites for 
growth factors including FGF2. Indeed, chlorate prevented the FGF2-induced proliferative 
response of mesangial cells, which appeared to be dependent on the duration of FGF2 
stimulation (Figure 7D). These results indicate that the proliferation of mesangial cells is 
dependent on FGF2 binding to endogenous HS proteoglycans. The interaction between 
FGF2 and HS proteoglycans on mesangial cells may therefore play a key role in the 
development of FGS. 
 
Discussion  
In this study we provide evidence that HSPGs such as perlecan serve as functional docking 
platforms for FGF2 and contribute to glomerular and arterial tissue remodeling in 
experimental CTD. The concept of extracellular regulation of growth factors by 
proteoglycans has been studied predominantly in tissue remodeling related to embryonic 
development (12,13), ontogenesis (14,15) and angiogenesis (16,17). Our data indicate that 
HSPGs modulate growth factors in the renal transplant setting as well. This is an important 
finding that opens the possibility to target proteoglycans by therapeutic intervention to 
ameliorate the development of CTD. 
Development of CTD in renal allografts is the result of tissue remodeling affecting all 
functional-structural compartments of the kidney including the tubulointerstitium (tubular 
atrophy and interstitial fibrosis), glomeruli (focal glomerulosclerosis), and larger arteries 
(neointima formation) (2-4). We recently demonstrated compositional changes of the 
HSPGs collXVIII, perlecan and agrin in tissue remodeling in experimental CTD by 
immunofluorescence (5). We now investigated functional aspects of proteoglycans in 
experimental CTD as well as in renal cell culture assays. Depending on their highly 
variable composition, HS carbohydrate side chains can bind a variety of ligands including 
FGF2 (10), which is known to be involved in renal tissue remodeling. In experimental 
allografts with CTD, a massive increase in matrix HSPG-mediated binding capacity for 
FGF2 was observed. Enhanced binding capacity for this growth factor was the result of 
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increased HSPG expression, and modified HS sulfation [most likely increased 2-O sulfation 
leading to loss of JM-403 staining (24,25) and increased FGF2 binding (26)]. This finding 
suggests that upon allo-transplantation the kidney mobilizes matrix HSPGs to become 
docking molecules for heparin-binding growth factors such as FGF2. This was also 
reported by Morita et al. (27) showing increased FGF2 binding in fibrotic areas of native 
kidney diseases. 
The laser microdissection approach on isolated glomeruli, arterial mediae and neointimae 
revealed spatial differences in HSPG expression, which were not seen, and would have 
been missed, in whole kidney homogenates. We observed increased glomerular and 
neointimal perlecan expression in allografted kidneys. This regional HSPG regulation 
opposes the uniform induction of pro-fibrotic pathways (Coll I, Coll IV, TGF-β1) seen in 
glomeruli, mediae and whole kidney tissue, which probably reflects a more generalized 
response upon allo-transplantation. Like perlecan, FGF2 showed a restricted glomerular 
and neointimal expression pattern as well. The marked FGF2 and perlecan expression 
observed in glomeruli of allografted kidneys suggests a role in the proliferative response of 
mesangial cells. In other settings perlecan/FGF2 has been shown to induce proliferation in a 
number of cell types including chondrocytes, neural stem cells, retinal pigmental epithelial 
cells and vascular smooth muscle cells (17, 28-30). In the kidney FGF2 has been shown to 
be proliferative for fibroblasts and mesangial cells (29,30). In vitro studies showed that the 
expression of cell surface HSPG was a prerequisite for the proliferation of renal fibroblasts 
in response to FGF2 (31). We therefore studied the functional role of the FGF2-
proteoglycan interaction in mesangial cell proliferation in vitro. FGF2 was shown to induce 
mesangial cell proliferation in a dose- and sulfation-dependent manner indeed favoring for 
a role of the FGF2-proteoglycan interaction in mesangial cell proliferation. Although FGF2 
binding on allograft sections was shown to be heparitinase-sensitive (indicating that FGF2 
interacts with HSPGs), the exact identity of the FGF2-binding HSPG(s) is as yet unknown. 
Since both collXVIII and perlecan are upregulated in FGS (5 and this study) we propose 
that FGF2 binds to (one of) these proteoglycans. The exact mechanism by which HSPGs 
enhance FGF2-induced mesangial cell proliferation is unknown. We propose that binding 
of FGF2 to mesangial (matrix) HSPGs facilitates the interaction between FGF2 and its 
surface receptor on mesangial cells, as has been demonstrated for other cell types (28-33). 
This is supported by our observation that removing the FGF2 binding capacity of 
proteoglycans on mesangial cells by chlorate treatment resulted in a significant delay, but 
not complete abrogation of FGF2-induced proliferation. 
Based on our data, HSPGs could be interesting therapeutic targets to limit CTD, especially 
focusing on the potential of inhibiting growth factor signaling. To study the possibility that 
exogenous glycosaminoglycans may hamper growth factor responses, heparin(oids) have 
been shown to reduce progressive renal failure in experimental renal diseases, including 
renal transplantation (34-36). Increasing research interest is focusing on the possibility to 
produce small HS-mimetics, which may more specifically target a particular component of 
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HS/heparin bioactivity (37). The use of HSPGs as targets, for example using antibodies that 
recognize and thereby block specific HS-motifs/domains, may also have clinical potential. 
This strategy has been exemplified in vitro by the demonstration that 6-O-sulfate specific 
anti-HS antibodies produced in a phage-display library can inhibit leukocyte rolling and 
firm adhesion to glomerular endothelial cells, whereas anti-HS antibodies with different 
specificities do not (38). Mutant growth factors, which are made incapable of 
glycosaminoglycan binding, could be used to specifically inhibit cell survival/proliferation. 
In addition, small inactive growth factor fragments could be generated that block the 
HSPG-binding sites of their in vivo active counterparts. Together, there are various options 
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The pathogenesis of chronic transplant dysfunction (CTD) is multifactorial and is 
histologically characterized by interstitial fibrosis and tubular atrophy, transplant 
vasculopathy and focal segmental glomerulosclerosis, and is also associated by an 
inflammatory component. To date, no effective therapies are available to treat renal CTD. 
Via their heparan sulfate polysaccharide side chains, heparan sulfate proteoglycans are 
crucial players in tissue homeostasis. We hypothesized that heparan sulfate proteoglycans 
could be promising therapeutic targets to limit CTD, by their involvement in inflammation 
and chemokine/growth factor signaling cascades. To test this hypothesis, in a rat model for 
renal CTD, by daily subcutaneous injections we intervened with vehicle, unfractionated 
heparin, and the non-anticoagulant heparinoids N-acetyl heparin and periodate-oxidized, 
borohydrate-reduced (RO-) heparin for 9 weeks. Both these non-anticoagulant heparinoids 
have been described to exert similar anti-inflammatory and anti-proliferative properties as 
heparin. Compared to the vehicle group, RO-heparin ameliorates the cortical tubulo-
interstitial accumulation of CD45+ inflammatory cells (week 9: 0.8% surface area in RO-
heparin group versus 1.8% surface area in vehicle group; p<0.02). Additionally, a tendency 
for lower proteinuria was present.Regular heparin adversely increased neointima formation 
in arteries <200 µm (week 9: heparin vs vehicle group: p=0.006), whereas both non-
anticoagulant heparinoids did not provoke this arterogenic response and did not differ from 
vehicle group. Heparin(oid) treatment did not affect body weight, graft survival, blood 
pressure, and renal function, and neither reduced glomerular and interstitial tissue 
remodeling, although glomerulosclerosis score was non-significantly reduced in the RO-
heparin group. These data demonstrate that specifically modified heparinoids can reduce 
inflammation in experimental CTD, and suggest that carefully selected non-anticoagulant 





Chronic transplant dysfunction (CTD) is characterized by decline in kidney function over 
time and is related to progressive tissue remodeling in the transplanted kidney. CTD is the 
second leading risk for graft loss (after death) and has a histological incidence of >70% 
already 2 years after transplantation. The pathogenesis of CTD is multifactorial and is 
clinically associated by progressive hypertension, proteinuria and increased values of 
triglycerides (1-3). At present, besides immunosuppressive therapy, progressive loss of 
transplant function is only symptomatically treated by anti-hypertensive and anti-
proteinuric treatment in combination with lipid lowering drugs. Histologically, CTD is 
characterized by chronic lesions such as interstitial fibrosis and tubular atrophy (IF/TA), 
transplant vasculopathy (TV) and focal segmental glomerulosclerosis (FSGS) (1,4,5). To 
date, due to lack of knowledge on tissue remodeling and development of these lesions, no 
effective therapies are available to treat renal CTD.  
Recently, we showed increased expression of heparan sulfate proteoglycans (HSPGs) 
during tissue remodeling in experimental CTD (6). We also showed that renal HSPGs 
modulate FGF2 signaling in mesangial cells in culture (chapter 3 of this thesis). In native 
kidney diseases and ischemia-reperfusion injury we demonstrated that HSPGs are critically 
involved in leukocyte influx and proteinuria-mediated renal injury (7-9). However, the 
precise mechanism behind the involvement of proteoglycans in CTD-associated progressive 
renal failure is still not unraveled.  
In general, via their heparan sulfate (HS) glycosaminoglycan side chains, HSPGs act as co-
receptors for a number of growth factors resulting in the formation of active signaling 
complexes that lower the concentration of growth factor necessary to initiate signaling 
through its receptor and extend the duration of the response (10,11). Moreover, after injury 
HSPGs can also act as ligands for adhesion molecules such as L- and P-selectin, MAC-1 
and VLA-4, and also as docking molecules for complement factors and chemokines. By 
doing so HSPGs play pivotal roles in cellular activation, and leukocyte adhesion, activation 
and extravasation (12). Thus, HSPGs are crucial players in inflammation, cell survival and 
proliferation, fibrosis, regeneration and repair. Based on these functions, HSPGs are 
potential targets for intervention in order to reduce leucocyte recruitment and fibrotic 
processes. Heparin is well known for its anti-coagulant activity and used in the prevention 
and treatment of thromboembolic complications. In addition heparin has anti-inflammatory, 
anti-proliferative and anti-oxidative properties.  
Non-anticoagulant heparins and various other heparin derivatives (low-molecular weight 
heparins, synthetic heparin mimetics and anti-HS antibodies) are regarded as agonists or 
antagonists of HS function (13-16). Non-anticoagulant heparins are obtained from regular 
heparin by removing and/or changing residues that are essential for high affinity binding to 
antithrombin (17,18).  
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Beneficial effects of exogenously administered (non-anticoagulant) heparinoids is thought 
to be associated with altered molecular processes involving HS chains of cell surface and 
extracellular matrix HSPGs on one hand, and growth factors and their receptors, 
chemokines and adhesion molecules on the other hand. Thus, these (non-anticoagulant) 
heparinoids most likely intervene in several processes that include blocking selectins, 
preventing chemokine presentation, interruption of chemokine gradient formation, and 
down modulation of growth factor signaling cascades. 
Previously, it has been shown that treatment with LMWH reviparin reduces signs of 
progressive renal failure in experimental renal transplantation (19,20). Human renal 
allograft recipients, receiving unfractionated heparin therapy early after transplantation 
showed increased risk of hemorrhagic complications (21). Moreover, heparin therapy can 
have side effects that include heparin-induced thrombocytopenia type II, a potentially 
harmful threat to patient and graft survival (22). In experimental renal ischemia-reperfusion 
injury (a non-transplant renal disease), it has been demonstrated that treatment with a 
synthetic and non-anticoagulant heparin showed reduced inflammation and neutrophil 
accumulation(23,24).  
Based on our previous data and other heparinoids intervention studies, we hypothesize that 
HSPGs could be promising therapeutic targets to limit CTD, especially focusing on the 
potential to inhibit inflammation and growth factor signaling cascades. To test this 
hypothesis, in a well established rat model for renal chronic transplant dysfunction (25), we 
intervened with vehicle, with unfractionated heparin, and with two different non-
anticoagulant heparinoids (N-desulfated/reacetylated (NAc-) heparin and periodate-
oxidized/borohydride-reduced (RO-)heparin). Both these non-anticoagulant heparinoids 
exert similar anti-inflammatory and anti-metastatic properties as heparin. In addition 
biostability, activity and specificity of these heparinoids were properly controlled and also 
showed beneficial effects in several experimental model (18,26,27). Lastly, these 
heparinoids can be produced in larger quantities within affordable costs and limited time. 
Our studies demonstrate significant beneficial effects of RO-heparin on the development of 
triglyceride levels and renal influx of inflammatory cells along with a tendency to lower 
proteinuria in an experimental CTD model. 
 
Material & methods 
Animals 
In this study 52 ten weeks old female inbred Dark Agouti (DA) rats (donors) and 52 ten 
weeks old male inbred Wistar Furth (WF) rats (recipients) were used. DA and WF rats were 
obtained from Harlan Nederland (Zeist, The Netherlands) and Charles River Laboratories 
(I’Arbresle, Cedex, France) respectively. Animals were kept in a temperature controlled 
room, with a 12:12-h light:dark cycle and fed standard rodent chow and water ad libitum. 
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The local animal ethics committee of the University of Groningen approved all the 
procedures used in the study and the Principles of Laboratory Animal Care (National 
Institute of Health publication no. 86-23) were followed. 
 
Kidney transplantation 
Kidney allotransplantation was performed from female DA donors to male WF recipients 
according to standard procedures as described previously (25). Cold and warm ischemia 
times were 15±3 (mean±SD) and 25 minutes, respectively. After transplantation the 
recipients were placed in an incubator at 28ºC for approximately 6 hours and caged 
individually. After transplantation all recipients subcutaneously received Cyclosporine A (5 
mg/kg BW/day) for 10 days. The native kidney was removed after 12 to 14 days after 
transplantation. Total follow up was 65±4 days (mean±SD). Fourteen rats were excluded 
from the study because of technical surgery failure (n=3) or acute rejection (n=11) which 
became evident by inspection of the graft during nephrectomy procedure. Thus 38 
transplanted rats were included in the study. 
 
Experimental groups 
In this experiment, an intervention was done with regular, unfractionated heparin (Hep; 
n=9) and two non-anticoagulant heparinoids derived from regular unfractionated heparin: 
N-desulfated, N-reacetylated heparin (NAc-Hep; n=10) and periodate-oxidized, 
borohydride-reduced heparin (RO-Hep; n=9). Production and characterization of these 
heparinoids have been described before (28). The control transplanted group (Con; n=10) 
received daily vehicle (physiological saline) injections. One day before transplantation, 
treatment with the respective formulations was started. The above mentioned groups daily 
received heparin(oids) between 9.00 and 12.00 AM dissolved in physiological salt, injected 
subcutaneously at 2 mg/kg BW/day until sacrifice. The treatment dose was chosen 
according to previous studies (19,20) and is in the physiological range normally used for 
the treatment of thrombotic complications. 
 
Clinical variables 
Animals were weighed every day and observed for signs of decreasing animal welfare 
reflecting their clinical condition. Upon weight loss of >15% compared to highest measured 
body weight, animals were sacrificed and regarded as drop outs. Blood pressure was 
measured non-invasively with tail cuff method (CODA; Kent Scientific, Torrington, CT). 
Two weeks before transplantation the rats were trained to undergo blood pressure 
measurements. Rats were placed individually in metabolic cages to obtain 24h urines, food 
and water intake measurements. Blood pressure, 24h urine sampling and non-fasting blood 
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sampling by orbital puncture were taken before transplantation (baseline), four and eight 
weeks after transplantation. Urine was analyzed for urea, creatinine and total protein. Blood 
was analyzed for urea, creatinine and triglycerides. Analyses were performed on a multi-
test analyzer system (Roche Modular; F.Hoffmann-La Roche Ltd, Basel, Switzerland) at 
the central clinical laboratory of the University Medical Center Groningen. Creatinine 
clearance was calculated from 24h urinary volume, plasma and urinary creatinine.  
 
Quantification of glomerulosclerosis and neo-intima 
formation 
Kidneys were perfused with saline prior to sacrification. Half of the kidney was fixed in 4% 
formaldehyde and processed for paraffin embedding and other half was cryopreserved. 
Paraffin sections (4µm) were stained with periodic acid-Schiff (PAS) and Verhoeff’s stain 
to evaluate focal glomerulosclerosis (FGS) and transplant vasculopathy, respectively. The 
sections were semi-quantitatively scored for focal glomerulosclerosis in a blinded fashion 
by determining the level of mesangial expansion and focal adhesion in each quadrant in a 
glomerulus and expressed on a scale from 0 to 4. If the glomerulus was unaffected, it was 
scored as 0; if one quadrant of the glomerulus was affected, it was scored as 1, two affected 
quadrants as 2, three affected quadrants as 3 and 4 affected quadrants as 4. In total, 50 
glomeruli per kidney were analyzed, and the total FGS score was calculated by multiplying 
the score by the percentage of glomeruli with the same FGS score. The sum of these scores 
gives the total FGS score with a maximum of 400.  
To investigate the transplant vasculopathy, neo-intima formation was determined using a 
Verhoeff staining. Neo-intima formation was scored at 200x magnification (Olympus BX 
50 (Olympus Europa, Hamburg, Germany) by determining the percentage of luminal 
occlusion. All the identifiable elastin positive intra renal vessels were evaluated in a blinded 
fashion. Lumen of vessels was the mean lengths of two straight lines drawn from the 
internal elastic lamina (IEL) and passing through the center of vessel. The areas enclosed 
by lumen, internal elastic lamina and external lamina were measured. The area between the 
lumen and internal elastic lamina was described as neointimal area. The percentage of neo-




Renal tissue was processed for immunohistochemistry. Details on fixation, antigen 
retrieval, antibodies and conjugates are given in Table 1. After the staining procedure, 
quantification was done in cortical tissue by using the MacBiophotonics ImageJ program 




Table 1. Immunohistochemical procedures for various fibrotic, inflammatory and lymphatic cell types 
 













Goat anti-mouse IgG2a-PO 
(Southern Biotech, 
Birmingham, USA); 1:100. 
Tetramethylrhodamine 
System (PerkinElmer LAS 
Inc) 
30 photomicrographs 
randomly selected at 
200 x magnification. 
Digital image 
analysis by ImageJ 
Leukocytes Cryosections, 
Acetone fixed 
CD45 Mouse anti-rat 
CD45 antibody 
(clone OX-
1)(ref.29) 1:2  
Goat anti-mouse IgG 
PO(Southern Biotech, 
Birmingham, USA); 1:100, 
Tetramethylrhodamine 
System (PerkinElmer LAS 
Inc) 
30 photomicrographs 
randomly selected at 
200 x magnification. 
Digital image 
analysis by ImageJ 
Macrophages Cryosections, 
Acetone fixed 











randomly selected at 
200 x magnification. 
Digital image 









Goat anti-rabbit Ig PO 
(DAKO); 1:100, 
tetramethylrhodamine 
System (PerkinElmer LAS 
Inc) 
30 photomicrographs 
randomly selected at 
200 x magnification. 
Digital image 















Goat anti mouse Ig PO 
(Southern Biotech, 




randomly selected at 





Data are expressed as % positive stained surface areas. Lymph vessels were counted 
manually and expressed as number/ high power field. 
 
Statistics 
Differences among the groups were tested with a Mann-Whitney U test, p<0.05 was 
considered statistically significant. The graphs and statistics were done by GraphPad Prism 
5.00 for Windows (GraphPad Software Inc., La Jolla, CA, USA). 
 
Results 
Development of CTD-related renal failure 
This study included 38 male WF rats that were transplanted with a female DA kidney. 
During follow-up from 2-9 weeks, pre-term graft loss occurred in 3 rats in the vehicle 
treated group (n=10), 5 rats in the normal unfractionated heparin (n=9), 5 rats in the N-
acetyl heparin (n=10) and 2 rats in the RO-heparin group (n=9). Renal graft loss was 
evidenced by clinical signs such as pilo-erected fur, severe body weight loss, disoriented 
behaviour and high blood creatinine values. Graft loss among the various heparinoid groups 
was statistically not significantly different. The rats that had to be sacrificed before the end 
of the experiment (before 9 weeks after transplantation) were excluded from all histological 
and biochemical analyses described later. Accordingly, the following groups with 
mentioned group size were studied: Allografts treated with Vehicle (n=7), with 
unfractionated heparin (n=4), with N-acetyl heparin (n=5) and with RO-heparin (n=7). In 
the plasmas of the rats taken at 8 weeks after renal transplantation, four hours after 
heparin(oid) injection, we measured the activated partial thromboplastin time. In the saline 
treated transplanted rats this was 75 sec (median value). In the heparin(oid) groups this time 
was 173 sec in regular heparin group (saline versus regular heparin: p<0.05), 73 sec in the 
RO-heparin group, and 69 sec in the N-acetyl heparin group (both non-anticoagulant 
heparinoids being not different from saline treated rats). These data show that both 
chemically modified heparin preparations indeed were non-anticoagulant, and clearly 
different from regular heparin, and not from the saline-treated rats. 
 
No effects of (non-)anticoagulant heparin(oids) on body 
weight, blood pressure, food and water intake, and urine 
output  
Treatment with heparin and non-anticoagulant heparins had no effect on body weight of the 
WF recipient rats. In accordance with our previous transplantation data, during the follow-
up, the mean arterial pressure increased gradually in recipient WF rats until the end of the 
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experiment without statistical significances among the groups. Similarly, food and water 
intake and urine output in all the groups were not affected by the treatment (Table 2).  
 
Effects of (non-)anticoagulant heparin(oids) on renal 
function, proteinuria and plasma triglycerides  
Vehicle treated groups developed CTD-related renal failure according to previous findings 
(30), as evidenced by rise in plasma urea and creatinine, rise in urinary protein excretion 
and blood pressure, and rise in plasma triglycerides (Table 2). The plasma creatinine and 
urea levels increased in all the groups over time. Although plasma creatinine and urea 
levels in the RO-heparin group at 8 weeks seems to be higher compared to all other groups, 
these values were not significantly different. In addition, at 8 weeks, unfractionated heparin 
and RO-heparin treated groups have significantly lower plasma triglycerides compared to 
vehicle and N-acetyl heparin treated groups (week 8: 0,4±0,26 mmol/l in RO-heparin group 
versus 0,8±0,2 mmol/l in vehicle group; p< 0.02). RO-heparin treated group showed less 
urinary protein excretion after 8 weeks follow-up compared to untreated rats (Table 2); 
however, without reaching the level of statistical significance. Taken together, heparinoids 
had no effect on renal function and RO-heparin had a tendency to reduce proteinuria; 
regular heparin and R-O-heparin prevented the rise of plasma triglycerides 
 
(Non-)anticoagulant heparin(oids) are not effective in 
reducing CTD associated tissue remodeling 
Glomerulosclerosis - FGS was determined by the PAS staining and is abundantly present 
in all the groups. Whereas non-transplanted rats have a FGS score close to zero (not 
shown), animals that are treated with unfractionated heparin and N-Acetyl heparin showed 
FGS score comparable to the vehicle treated group. These groups approximately scored 
median value of 3, indicating FGS in three out of four glomerular quadrants. The RO-
heparin group however showed a lower FGS, scoring median value of 2.5; however, 
without reaching the level of statistical significance (Figure 1A).  
Tubulo-interstitial changes: pre-fibrotic lesions (α-SMA) and lymphangiogenesis - In 
the tubulo-interstitial areas of the cortex, heparin and non-anticoagulant heparins treated 
groups did not show any statistical difference in α-SMA positive cell density compared to 
the vehicle treated group as shown in the figure 1B, suggesting comparable degree of 
interstitial fibrosis. 
In the tubulo-interstitium of the transplanted rats, lymphangiogenesis occurred to ~5 lymph 
vessels/high power field. In vehicle treated rats this ranged from 3 to 8 and neither of the 
heparinoids changed the lymphangiogenic response, although lymph vessel density 
appeared to be a bit lower in the regular heparin group, however without reaching the level 
of statistical significance (Figure 1C).  
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Table 2. Clinical variables from recipients at baseline (pre-Tx) and at 4 and 8 weeks after transplantation. Data shown as 











Heparin (n=4) RO-Heparin (n=7) 
N-acetyl Heparin 
(n=5) 
Body weight (g) 
Baseline 290(285-296) 283(274-291) 270(263-284) 271(270-276) 
4 weeks after Tx 293(281-313) 299(292-302) 284(281-302) 285(276-290) 
8 weeks after Tx 323(298-347) 311(300-320) 298(280-326) 303(299-313) 
Food intake (g/24h) 
Baseline 9(5-11) 5(5-7) 5(4-7) 5(4-7) 
4 weeks after Tx 5(4-8) 7(6-9) 2(1-5) 5(5-11) 
8 weeks after Tx 3(3-6) 1,5(1-4) 4(1-7) 2(1-6) 
Water intake (ml/24h) 
Baseline 17(17-20) 14(12-17) 13(10-16) 12(8-15) 
4 weeks after Tx 25(21-27) 29(19-37) 18(16-24) 19(17-23) 
8 weeks after Tx 27(24-30) 28(24-31) 22(17-46) 18(9-33) 
Urinary output(ml/24h) 
Baseline 14(13-17) 15(15-15) 12(11-14) 11(11-12) 
4 weeks after Tx 26(18-30) 24(20-28) 15(13-28) 19(19-20) 
8 weeks after Tx 33(29-34) 32(28-35) 31(18-44) 30(21-30) 
Plasma creatinine 
(µmol/L) 
Baseline 19(18-21) 19(19-21) 15(14-17) 15(15-19) 
4 weeks after Tx 73(59-120) 64(52-73) 65(54-168) 81(53-84) 
8 weeks after Tx 96(73-139) 72(58-99) 136(70-207) 73(58-122) 
Creatinine Clearance 
(ml/min) 
Baseline 3,0(2,8-3,8) 2,6(2,5-3,0) 3,5(2,7-3,7) 3,0(2,3-3,0) 
4 weeks after Tx 0,7(0,4-1,1) 1,0(1,0-1,3) 1,0(0,5-1,2) 0,7(0,1-0,8) 
8 weeks after Tx 0,6(0,3-1,0) 0,8(0,5-1,2) 0,4(0,2-0,9) 0,9(0,4-1,0) 
Plasma urea (mmol/L) 
Baseline 6(5-7) 6(5-7) 6(5-6) 6(5-6) 
4 weeks after Tx 20(18,3-36) 18(16-20) 20(14-39) 19(15-24) 
8 weeks after Tx 28(21-51) 22(18-37) 43(21-64) 27(24-40) 
Total urinary protein 
(mg/24h) 
Baseline 10(8-11) 7(6-8) 9(7-10) 9(6-9) 
4 weeks after Tx 8(7-12) 8(7-11) 9(7-13) 8(7-10) 
8 weeks after Tx 56(34-93) 61(57-74) 33(23-43) 94(90-184) 
Plasma triglycerides 
(mmol/L) 
Baseline 0,6(0,5-0,6) 0,7(0,6-0,7) 0,6(0,5-0,6) 0,6(0,4-0,7) 
4 weeks after Tx 0,6(0,5-0,7) 0,5(0,5-0,5) 0,7(0,5-0,8) 0,6(0,5-0,6) 
8 weeks after Tx 0,8(0,8-1,0) 0,3(0,3-0,4)* 0,4(0,2-0,5)* 1,0(1,0-1,0) 
Mean arterial pressure 
(mmHg) 
Baseline 118(111-121) 118(111-121) 118(111-121) 118(111-121) 
4 weeks after Tx 110(104-123) 118(106-132) 141(121-148) 146(135-148) 
8 weeks after Tx 138(131-165) 143(138-150) 149(135-154) 166(153-171) 
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Figure 1. Heparin(oid) treatment did not affect glomerular and interstitial tissue remodeling, and lymphangiogenesis. A. 
glomerulosclerosis score was non-significantly reduced in the RO-heparin group. B. Mean area of interstitial myofibroblasts 
(positive for α-SMA showing pre-fibrotic lesions) in cortical regions. C. Mean number of podoplanin positive lymph vessels per 
microscopic cortical field (200x). Graphs represent mean±SE at 9 weeks.  
 
Development of transplant vasculopathy (TV) - All the treated groups showed the 
formation of occlusive neointima in arteries, indicative of TV. In the arteries with a 
diameter <200 µm a significant increase in lumen occlusion was found in unfractionated 
heparin treated group compared to the other groups (p<0.02; Figure 2A-C). In the arteries 
with diameter ≥200 µm, no differences among the groups was observed in arterial 
occlusion due to neointima formation (not shown). In conclusion (non-anticoagulant) 
heparin(oids) are not very effective in reducing CTD-associated tissue remodeling, at least 
not in this fully HLA-mismatched model with severe renal damage 
 
Figure 2. A. Heparin treatment showed significant increase in the arterial occlusion compared to the other treated groups. Graphs 
represent mean±SE at 9 weeks in arteries ≤ 200 µm diameter. B-C. Photomicrograph showing less neointima formation in renal 
arteries of vehicle treated animals compared to heparin treated animals (400x magnification). 
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RO-heparin is effective in reducing CTD associated 
inflammation 
Cortical CD45 staining revealed that the leukocyte influx was significantly decreased by 
~50% in RO-heparin group compared to the vehicle treated group (p=0.0175; Figure 3A-C 
). In order to investigate the subtypes of the leukocytes that are reduced in RO-heparin 
group, we analyzed the macrophage and T-cell influx by morphometric analysis. 
Glomerular and tubulo-interstitial monocyte/macrophage density (ED1 positive) were 
analyzed separately. In the vehicle treated group, the glomerular macrophage influx was 
substantially lower than in the tubulo-interstitial compartment. Overall, both in glomeruli 
and in the interstitial areas, there were no major differences among the groups regarding the 
ED-1 influx(not shown). We next analyzed T-cell infiltration by CD3 staining and 
quantification. The data suggest a lower T-cell infiltration in the RO-heparin group 
compared to the other groups, however, no statistical significance was reached. We 
conclude that RO-heparin reduced the influx of inflammatory cells into the transplanted 




Figure 3. RO-heparin treatment significantly reduced leukocyte influx. A. Graph represents leukocyte quantification (CD45 
positive area, mean±SE ) at 9 weeks. B-C. Photomicrographs showing less leukocyte (CD45) influx in renal tissue of RO-heparin 





Figure 4. RO-heparin treatment non-significantly reduced the T-cell (CD3) influx. Graphs represent mean±SE at 9 weeks 
 
Discussion 
In this study we show that a non-anticoagulant heparinoid (RO-heparin) reduced renal 
inflammation, and plasma triglycerides and exerted modest reducing effects on proteinuria. 
However, this heparinoid is not effective in reducing kidney function, graft survival and 
renal scarring in experimental renal transplantation. One of the most striking findings of our 
study was the fact that the non-anticoagulant RO-heparin was the most active compound 
with respect to proteinuria, inflammation and triglycerides, even more active than regular 
heparin. This might be related to the opening of the ring structure of non-sulfated 
glucuronic acid units in heparin, which results in more flexibility of the polysaccharide 
chain and consequently a more efficient interaction with most heparin-binding proteins(15). 
This is an interesting finding, since RO-heparin lacks anti-thrombotic activity, however, is 
more effective in reducing proteinuria and inflammation. N-acetyl heparin on the contrary, 
lost one of the sulfate groups by the N-desulfation procedure, and thereby most likely 
reduces its binding properties to a number of heparin-binding proteins, and consequently 
did not display any beneficial effects in our study.  
Although our study does not explain how the heparinoids exerted their effects, we propose 
the following mechanisms to be involved. The role of HSPGs in inflammatory leukocyte 
recruitment is well established (7,8) and is in particular due to the binding of HSPGs to L- 
and P-selectins on leukocytes and endothelial cells and the presentation and gradient 
formation of chemokines. Intervention by heparinoids thus will reduce endothelium – 
leukocyte interactions (selectin block), and reduces activation and migration of leukocytes 
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by disturbing chemokines. This finding is in line with a number of other studies showing 
the anti-inflammatory effects of heparin–related compounds(23,31). Our data furthermore 
suggest that T-cell recruitment is inhibited to a larger extent than monocyte influx. At 
present we do not have an explanation for this finding, which however might be related to 
interruption of certain chemokines such as RANTES (CCL5), that specifically attracts T-
cells. The reduction of plasma triglycerides by regular heparin and RO-heparin is most 
likely explained by the release of lipoprotein lipase, which cleaves plasma triglycerides. 
This is a well-known and described effect of heparin (32). Due to a lower degree of 
sulfation, N-acetyl heparin seems not able to release lipoprotein lipase. The apparent 
attenuation of proteinuria development by RO-heparin coincides with the small reduction in 
FGS by RO-heparin. We speculate RO-heparin to interrupt glomerular growth factor 
signaling, resulting in less FGS and improved glomerular filtration function. We finally 
found that regular heparin increased neointima formation in the smaller arteries, which 
however was not found in both non-anticoagulant heparinoids. This suggests neointima 
formation in this model to be associated with reduced coagulation and/or platelet function, 
which however is not clear yet and requires further studies.  
Our study had a number of limitations that should be taken into consideration. First of all, 
from histopathology (e.g. influx of T-cells) it became evident that our model in fact is a 
combination of CTD with transplant rejection and not a pure CTD model. Secondly, 
because of the full HLA mismatch between the donor and recipient there was severe 
damage to the transplanted kidney, resulting in a high number of dropouts in all the groups 
independent of treatment which seriously hampered the power of our study to find 
differences between the groups. We neither can exclude a certain selection bias in the 
surviving animals. 
 It remains a question why the heparin(oids) turned out to be ineffective with regard to renal 
function, graft survival and tissue remodeling. In other experimental models, treatment with 
non-anticoagulant LMWH showed prolonged skin, cardiac and renal allograft survival with 
beneficial outcomes (19,33-35). In addition, LMWH decreases mesangial proliferation and 
matrix expansion (36,37). Moreover RO-heparin have been described to inhibit FGF2 and 
VEGF mediated pathways and to reduce tumor growth(14). We suggest that the full HLA-
mismatch of our DA to Wistar Furth model, without any immunosuppression after day 10 
might explain this. The progressive tissue remodeling in our model might be simply too 
strong to show (partial) down modulation by heparinoids. It also could be that a number of 
non-heparin binding growth factors such as insulin-like growth factors, plasminogen 
activator inhibitor-1, and angiotensin II are involved that cannot be regulated via 
heparinoids. Besides to that, it is known that the half-life of unfractionated heparin(oids) as 
used in our study, is shorter compared to LMW heparinoids. Based on these consideration 
we propose a future experiment using LMW-heparinoids (including LMW-RO-heparin), in 
combination with the immunosuppressive agent cyclosporine A.  
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In conclusion, based on our data we speculate that heparin-like glycomimetics might be 
promising add- on therapeutic modalities next to immunosuppressants, and blood-pressure 
and lipid lowering medication. Future studies in experimental models and in human renal 
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Smooth muscle cells (SMCs) play a key role in the pathogenesis of occlusive vascular 
diseases, including transplant vasculopathy. Neointimal SMCs in experimental renal 
transplant vasculopathy are graft-derived. We propose that neointimal SMCs in renal 
allografts are derived from the vascular media resulting from a transplantation-induced 
phenotypic switch. We examined the molecular changes in the medial microenvironment 
that lead to phenotypic modulation of SMCs in rat renal allograft arteries with neointimal 
lesions.  
 
Dark Agouti donor kidneys were transplanted into Wistar Furth recipients and harvested at 
day 65. Neointimal and medial layers were isolated using laser-microdissection. Gene 
expression was analyzed using low-density arrays and confirmed by immunostaining. In 
allografts, neointimal SMCs expressed increased levels of Tgfβ1 and Pdgfb. In medial 
allograft SMCs, gene expression of Ctgf, Tgfβ1 and Pdgfrb was upregulated. Gene 
expression of Klf4 was upregulated as well, while expression of Sm22α was downregulated. 
Finally, PDGF-BB-stimulated phenotypically modulated SMCs as evidenced by reduced 
contractile function in vitro which was accompanied by increased Klf4 and Col1α1, and 
reduced α-Sma and Sm22α expression. 
In transplant vasculopathy, neointimal PDGF-BB induces phenotypic modulation of medial 
SMCs, through upregulation of KLF4 in the media to contribute to (further) expansion of 
the neointima. 
 




CTD   Chronic transplant dysfunction  
DA   Dark Agouti  
ECM   Extracellular matrix  
IEL   Internal elastic lamina  
IF/TA   Interstitial fibrosis and tubular atrophy  
SMA   Smooth muscle cells  
MYH11   Smooth muscle myosin heavy chain 11 (MYH11) 
TV   Transplant vasculopathy  





Vascular remodeling comprises of structural changes of the arterial wall in response to 
various stimuli including shear stress, hypoxia, and immunological or mechanical injury. 
The structural changes of the arterial wall lead to changes in vessel size and luminal width 
(1). Vascular remodeling has various clinical and pathological manifestations, including 
transplant vasculopathy (TV), (in-stent) restenosis and spontaneous (native) atherosclerosis. 
Hallmark of these obliterative vascular pathologies is neointima formation resulting from 
both an increase in the number of cells in the subendothelial intima as well as deposition 
extracellular matrix (ECM) (2). Narrowing, thickening and stiffening of the vessel wall by 
neointima formation results in reduced blood flow and subsequent ischemia in downstream 
tissues. 
TV in renal allografts is a histopathologic feature observed in addition to transplant 
glomerulopathy, interstitial fibrosis and tubular atrophy (IF/TA) in patients with chronic 
renal transplant dysfunction (CTD). Development of CTD is a major cause of renal 
allograft loss, only second to patient death with a functioning graft (3). Development of TV 
in transplanted kidneys presumably contributes to graft deterioration. In support of this, we 
recently demonstrated that TV severity is indeed associated with premature graft loss in a 
renal transplant model in rats (4). As yet, no adequate preventive or curative therapies for 
TV are available. 
Neointima formation in TV is the accumulation of α-smooth muscle actin (α-SMA)-
positive smooth muscle cells (SMCs) between the endothelial lining and the internal elastic 
lamina (IEL), forming an occlusive neointima (5). Neointimal SMCs secrete ECM leading 
to arterial stiffness, luminal stenosis and, eventually, ischemic graft failure. The overall 
concept of neointima formation in general and in TV in particular, is that local 
inflammatory responses of the vessel wall trigger SMC migration and proliferation (6). 
Until a decade ago, the general dogma was that neointimal SMCs in TV are graft-derived as 
proposed in the response-to-injury hypothesis for atherosclerosis (7). However, this 
response-to-injury hypothesis has been challenged as various research groups, including our 
own, showed recipient-origin of neointimal SMCs in TV in predominantly experimental 
arterial-segment and cardiac transplant models in rodents (5,8,9). Until recently the 
anatomical origin of neointimal SMCs in TV in renal allografts was largely unknown. 
Knowing the anatomical origin of neointimal SMCs is key to the development of new 
therapeutic modalities to attenuate TV development that should lead to prolonged graft 
survival. We therefore determined host vs. graft origin of neointimal SMCs in both an 
experimental renal transplant model in rats as well as in human renal allografts with TV. In 
both experimental renal transplantation in rats as well as in human renal transplantectomy 
samples neointimal SMCs turned out to be of graft origin with only a relatively small 
proportion of host-derived SMCs being detected in human renal allografts (4),(10). Graft 
origin of neointimal SMCs fits with the response-to-injury hypothesis which states that 
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medial SMCs migrate across the internal elastic lamina in response to arterial injury (7). 
However, formal proof for medial origin (rather than recruitment of adventitial or 
interstitial (myo)fibroblasts or SMC precursor cells) still needs to be delivered. Based on 
our previous results on graft origin of neointimal SMCs in renal allografts we hypothesize 
that these cells are indeed derived from the vascular media. Due to the lack of markers 
specific for medial-derived SMCs, it is however not possible to track medial SMCs during 
neointima development using lineage tracing. 
Medial SMCs can only contribute to neointima formation after undergoing a phenotypic 
switch from a contractile to a synthetic state (11). Synthetic SMCs have migratory and 
proliferative capacities and secrete ECM molecules. We hypothesize that the combination 
of ischemia/reperfusion injury and ongoing alloreactivity towards the allograft induces 
medial SMCs to switch to synthetic SMCs. Synthetic SMCs can migrate to the 
subendothelial space which will eventually lead to neointima formation. To test this 
hypothesis, we investigated the spatiotemporal expression of factors in the neointimal and 
medial microenvironment known to influence phenotypic modulation of SMCs. 
Furthermore, we investigated genes indicative of phenotypic modulation of medial SMCs 
in rat renal allografts with TV as well as in isografts and non-transplanted control kidneys 
without TV. To not disturb the location nor the status of the cellular content, neointimal and 
medial layers were isolated using laser dissection microscopy after which gene expression 
was analyzed in these different compartments with a low density array. Results were 




Kidney Transplantation and Experimental Groups 
Animals were handled in compliance with the Principles of Laboratory Animal Care (NIH 
Publication No. 86-23, revised 1985), the University of Groningen guidelines for animal 
husbandry (University of Groningen, the Netherlands), and the Dutch Law on Experimental 
Animal Care.  
Female Dark Agouti (DA) kidneys were orthotopically transplanted into male DA or Wistar 
Furth (WF) recipients as described previously (4). The following experimental groups were 
included: control (non-transplanted) DA kidneys (n = 5), DA-to-DA isografts (n = 5), and 
DA-to-WF allografts (n = 5). Isograft recipients were sacrificed at day 81 (range 70–84 







Laser Dissection Microscopy and Gene Expression Analysis 
The neointima and media were separately laser microdissected from nine serial kidney 
sections per animal. Per renal allograft, an average of 75 (range 25 – 117) arteries was 
dissected (Supplemental Table 1). An average of 46 (range 37 – 52) arteries was dissected 
from renal isografts and an average of 69 (range 47 – 100) was dissected from arteries of 
non-transplanted kidneys (Supplemental Table 1). 
Total RNA was isolated from microdissected vascular structures and gene expression of 
genes known to influence fibrosis and SMC phenotype were analyzed with a custom made 
micro fluidic card-based low density array (Supplemental Table 2). Relative mRNA levels 
were calculated as 2−∆CT, in which ∆CT is CTgene of interest – CTβ-actin. CT values that were 
below detection level were set at 50. 
For gene expression analysis of cultured rat aortic SMCs, total RNA was isolated after 24 
hours of stimulation with PDGF-BB or TGF-β1 (PreproTech EC LTD. London, UK). 
Relative mRNA levels were normalized against β-actin expression as described above. 
 
Immunohistochemistry 
Sections were stained for Masson's trichrome, Verhoeff-van Gieson, TGF-β1, CTGF, 
PDGF-B and smooth muscle myosin heavy chain 11 (MYH11). The degree TV (i.e., 
obliteration in arteries) was measured in all arteries with a clearly visible IEL (Verhoeff-
van Gieson staining) within a section.  
 
Collagen gel contraction assay 
Gel contraction assay of 3D collagen gels were performed using a solution of rat tail 
collagen I (BD Bioscience, Breda, the Netherlands). Aliquots of 50 µL (containing 50,000 
rat aortic SMCs and 0.25 mg Collagen type I) were added to a 96 wells plate that had been 
preincubated with 0.1% BSA. After solidification, collagen gels were further cultured with 
or without additional PDGF-BB or TGF-β1 (PreproTech EC LTD. London, UK). Collagen 
gels were imaged using a common flatbed-scanner (ScanJet 5370C; HP, CA, USA) and gel 
contraction was measured after 24 hours (12). 
 
Statistics 
Data are expressed as mean ± standard error of the mean (SEM). Differences between 
contralateral kidneys, isografts and allografts were analyzed using a one-way ANOVA with 
Tukey’s posthoc test. Differences between unstimulated SMCs and TGF-β1- or PDGF-BB-
stimulated SMCs were analyzed using a one-way ANOVA with Dunnett’s posthoc test. p< 
0.05 was considered statistically significant. Statistical analysis were performed using SPSS 
(version 16.0.2; IBM Nederland B.V., Nieuwegein, the Netherlands). 
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Detailed methods can be found as online Supporting information.  
 
Results 
Chronic transplant dysfunction after experimental renal 
transplantation 
We first confirmed the development of CTD in allograft recipients by renal function 
analysis and histological evaluation of the graft.  
 
 
Figure 1. CTD development after renal allograft transplantation. (A) Creatinine clearance in allografts (n=3) and isografts 
(n=5) before and 8 weeks after transplantation. (B) Protein excretion in allografts (n=3) and isografts (n=5) before and 8 weeks 
after transplantation. (C) Renal allografts developed IF, glomerulosclerosis and TV (Masson’s trichrome staining [collagen: blue]). 
Scale bar represents 50 µm. (D) Gene expression analysis of fibrosis-related genes Tgfβ1 and Col1α1 in total kidney samples from 
renal allografts, isografts and non-transplanted control kidneys (n=5). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. 
Abbreviation: TX; transplantation 
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Creatinine clearance was similar in allograft and isograft recipients before transplantation 
(2.7 mL/min [2.1–3.1 mL/min] (mean [range]) vs. 2.7 mL/min [2.3–2.8 mL/min], 
respectively) (Figure 1A). Eight weeks after transplantation, creatinine clearance in isograft 
recipients did not differ from pre-transplantation levels (2.1 mL/min [1.4-2.8 mL/min]), 
whereas allograft recipients had significantly lower creatinine clearance rates compared 
with pre-transplantation levels and isograft recipients 8 weeks after transplantation (1.1 
mL/min [0.9-1.6 mL/min]) (Figure 1A). In addition, allograft but not isograft recipients 
developed proteinuria as determined 8 weeks after transplantation (150 mg/day [90–237 
mg/day] vs. 18 mg/day [9–26 mg/day], respectively) (Figure 1B). 
 
Functional deterioration observed in allografts was accompanied by histopathological 
changes indicative of CTD, including interstitial fibrosis, glomerulosclerosis and TV 
(Figure 1C). Isografts developed some interstitial fibrosis as well, however, to a 
significantly lesser extent than allografts (Figure 1C), corroborating our previous 
observations (4). These histological changes were associated with significantly upregulated 
mRNA expression levels of fibrosis-related genes Tgfβ1 and Col1α1 in renal allografts 
compared to isografts and non-transplanted contralateral kidneys (Figure 1D). 
 
Neointimal Tgf-β1, Ctgf and Pdgfb mRNA expression 
TV in rat renal allografts developed neointima formation (Figure 2A). Luminal occlusion of 
measured arteries in renal allografts was 37% [range 7-88%], whereas luminal occlusion in 
isografts and non-transplanted kidneys was 15% [1-28%]) and 6% [0-11%], respectively. 
Luminal occlusion detected in non-transplanted control kidneys was comprised of 
endothelial cells covering the IEL and was considered as the basal surface intima (not 
shown). The neointima consisted predominantly of SMCs, as shown by expression of 
smooth muscle myosin heavy chain (MYH11, (13)) (Figure 2C). Staining for CD45 
revealed only a few infiltrating leukocytes in the neointima (data not shown).  
Since we previously showed donor origin of neointimal SMCs in this model we 
hypothesized that neointimal SMCs are derived from the media by migration and 
proliferation. To test whether the microenvironment within the arterial neointima and media 
in allografts support this hypothesis, we determined gene expression levels in the vascular 
media and neointima using a low density array. Genes included in this array were 
associated with SMC phenotype, growth factors and their receptors and ECM molecules as 
summarized in Supplemental table 2. Medial and neointimal tissues were isolated using 
laser microdissection (Figure 2D) and processed for gene expression analysis. Per allograft, 
a mean of 74 (range 25-117) neointimae were microdissected (Table 1). Medial tissue from 
a non-transplanted kidney (i.e., control medial tissue) contained fully differentiated 
contractile SMCs and was used for comparison. When compared with control medial tissue, 
SMCs in the allograft neointima displayed increased Tgf-β1 (~7 fold) and Ctgf (~2 fold) 
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gene expression levels (Figure 2E). Both genes are known for their profibrotic actions 
(reviewed in (14)) which would stimulate SMC accumulation in the neointima.  
 
 
Figure 2. Characteristics of transplant vasculopathy in renal allografts. (A) Artery with neointima in a renal allograft 
(Verhoeff staining [elastin: black; collagen: red]). Scale bar represents 50 µm. (B) Luminal obliteration due to neointima formation 
in renal allografts, isografts and non-transplanted control kidneys. (C) Smooth muscle cells (Myh11, red staining) in the neointima 
of renal allografts. Scale bar represents 20 µm. (D) Laser microdissected neointima (upper photo) and medial (lower photo) layers. 
(E) Gene expression of Tgfβ1, Ctgf and Pdgfb in laser microdissected neointimal tissue normalized to their expression in medial 
tissue of non-transplanted control kidneys. Detection of (F) Tgf-β1, (G) CTGF and (H) PDGF-B protein in the neointima. Scale bar 
represents 20 µm. IEL = internal elastic lamina; M = media; NI = neointima. Dotted line indicates the IEL. Data are presented as 
mean ± SEM (n=5). ***p < 0.001 
 
Furthermore, expression of Pdgfb was ~27 fold upregulated in the neointima compared 
with control medial tissue (Figure 2E), suggesting that the neointimal microenvironment is 
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capable of attracting SMCs to the neointima. PDGF-BB is known to act as a mitogen and 
chemoattractant for SMCs in intimal thickening (15). Due to a relatively high variation in 
neointimal gene expression levels between the different allografts, differences in gene 
expression levels between the neointima and control media were not statistically significant 
although marked differences were observed. Presence of Tgfβ1, Ctgf and Pdgfb mRNA 
transcripts in the neointima was confirmed at the protein level by immunohistochemistry 
(Figure 2F, 2G and 2H). TGF-β1 protein was mainly associated with neointimal SMCs 
close to the internal elastica lamina (Figure 2F), whereas CTGF and PDGF-B protein was 
distributed across the entire neointima (Figure 2G and 2H).  
 
Increased medial Tgf-β1, Ctgf and Pdgfrb mRNA 
expression 
In a healthy artery, medial SMCs are fully differentiated and have a contractile phenotype. 
In contrast, synthetic SMCs have a decreased expression of contractile proteins and show a 
high degree of proliferation and the ability to migrate, which can potentially lead to 
neointima formation (11). Since we found increased expression of profibrotic growth 
factors in the neointima (Figure 2E-G), we subsequently investigated whether the medial 
microenvironment is characterized by increased expression of profibrotic growth factors 
and growth factors known to induce phenotypic modulation of SMCs. 
To this end we analyzed gene expression of Tgfβ1, Ctgf and Pdgfb in laser-microdissected 
medial tissue from iso- and allografts. Gene expression of Tgfβ1 and Ctgf was increased in 
medial SMCs in allografts compared to isografts and non-transplanted control kidneys (~7 
fold (p<0.01) and ~8 fold (p<0.05), respectively) (Figure 3A and 3B). No differential 
expression of Pdgfb was observed in medial tissue from all groups (Figure 3C). However, 
gene expression of Pdgfrb was ~4 fold (p<0.05) increased in the media of allografts when 
compared to isografts and non-transplanted control kidneys (Figure 3D). The increased 
mRNA expression of Tgfβ1 and Ctgf in the media of allografts was confirmed at the protein 
level (Figure 3E and 3F, respectively). TGF-β1 and CTGF protein expression were not 
detected in the media of non-transplanted kidneys and isografts (upper and middle panels, 
respectively in Figure 3E and 3F). In allografts, TGF-β1 expression was associated with 
SMCs at sites in the media adjacent to neointima formation. Protein expression of PDGF-B 







Figure 3. Microenvironment of laser microdissected medial tissues. The medial microenvironment was assessed by low-density 
arrays in laser microdissected media from allografts, isografts and non-transplanted control kidneys. (A-D) Gene expression of (A) 
Tgfβ1, (B) Ctgf, (C) Pdgfb and (D) Pdgfrb in laser-dissected medial tissue of allografts and isografts normalized to non-
transplanted control medial tissue. (E-G) Protein expression of (E) TGF-β1, (F) CTGF and (G) PDGF B in arteries from a non-
transplanted control kidney, an isograft and an allograft. Scale bar represents 100 µm. IEL = internal elastic lamina; M = media; NI 




Allograft medial SMCs are phenotypically modulated 
Next, we investigated whether medial SMCs indeed switch to a synthetic phenotype after 
allogeneic transplantation. In non-transplanted donor-type (DA) kidneys, medial SMCs had 
a relatively high gene expression of Sm22α (Figure 4A). Since the expression of Sm22α is 
required for modulation of vessel contractility (16), this marker is indicative of a contractile 
SMC phenotype. In medial SMCs from isografts, Sm22α gene expression was reduced 
(~1.5 fold) but not significantly different compared with medial tissue from non-
transplanted control kidneys (Figure 4A). When compared to medial SMCs from non-
transplanted control kidneys, expression of Sm22α was significantly reduced in allograft 
medial SMCs (~3 fold, p<0.001) (Figure 4A). In line with the downregulation of Sm22α 
expression in the allograft media, Klf4, which is a transcription factor known to 
downregulate mRNA transcription of SMC genes such as SM22α (17), was significantly 
increased (~8 fold, p<0.05) in allograft medial SMCs compared to medial SMCs from 
isografts and non-transplanted kidneys (Figure 4B). We also investigated the expression of 
myocardin, a transcriptional co-activator for serum response factor (SRF), and SRF which 
regulate the expression of SMC differentiation genes (18). Gene expression of Srf and 
Myocardin was not altered in allograft medial SMCs compared to medial SMCs in isografts 
and non-transplanted control kidneys (Figure 4C and 4D). A hallmark of synthetic SMCs is 
the production of extracellular matrix components. In allograft medial SMCs the expression 
of the ECM molecules Col1α1 and Col4α1 was significantly increased (~8 fold and ~18 
fold, respectively, both p<0.05) compared with medial SMCs in isografts and non-
transplanted control kidneys (Figure 4E and 4F). The question remains what the source is of 
PDGF-BB when there is no neointima formed yet. Therefore, a staining was performed for 
PDGF-B on isografts and allografts harvested 16 days after transplantation. PDGF-B 
protein was found in the arterial media of allografts whereas the arterial media of isografts 
only showed relatively low expression of PDGF-B protein (Supplemental Figure S1). 
 
PDGF-BB-induced synthetic rat aortic SMCs display 
reduced contractility in vitro  
To investigate whether synthetic SMCs display less contractility in vitro, we performed a 
collagen type 1 gel contraction assay. To induce phenotypic modulation, SMCs were 
stimulated with PDGF-BB and TGF-β1, growth factors of which the expression was 
increased within the neointima (Figure 3E). Rat aortic SMCs were prestimulated with 
PDGF-BB (20 ng/mL or 60 ng/mL) or TGF-β1 (5 ng/mL or 15 ng/mL) for 24 hours to 
induce phenotypic modulation followed by subsequent culture in a collagen gel allowing 





Figure 4. Allograft medial SMCs are phenotypically modulated. Medial SMCs were characterized by low-density arrays in 
laser-dissected medial tissue from allografts, isografts and non-transplanted control kidneys. (A-F) Gene expression of (A) Sm22α, 
(B) Klf4, (C) Srf, (D) Myocardin, (E) Col1α1 and (F) Col4α1 in laser-dissected media of allografts and isografts normalized to 
laser-dissected non-transplanted control kidneys. Data are presented as mean ± SEM (n=5). *p < 0.05, **p < 0.01 
 
After one hour of stimulation with PDGF-BB (both 20 and 60 ng/mL), expression of Klf4 
was increased ~2-3 fold (p<0.001) compared with unstimulated and TGF-β1-stimulated 
SMCs (Figure 5A). Stimulation of SMCs with TGF-β1 did not upregulate gene expression 
of Klf4 (Figure 5A). Stimulation of SMCs for 1 hour with either PDGF-BB or TGF-β1 did 
not affect gene expression levels of Srf and Myocardin (Figure 5B and 5C). After 24 hours 
of stimulation with PDGF-BB, a significant decrease in gene expression of α-Sma and 
Sm22α was detected compared with unstimulated and TGF-β1-stimulated SMCs (Figure 
5D and 5E). Stimulation with 60 ng/mL PDGF-BB resulted in a ~2 fold (p<0.001) decrease 
in α-Sma gene expression compared with unstimulated and TGF-β1-stimulated SMCs. 
Stimulation with 20 ng/mL PDGF-BB resulted in a ~1.5 fold decrease (p<0.01) in Sm22α 
gene expression, which was further reduced (~2 fold (p<0.001) following stimulation with 
60 ng/mL PDGF-BB. Gene expression of α-Sma and Sm22α after stimulation with TGF-β1 




Figure 5. PDGF-BB-induced phenotypically modulated rat aortic SMCs display reduced contractility in vitro. Rat aortic 
SMCs were stimulated with TGFβ1 and PDGF-BB. Unstimulated SMCs were used as control. (A-C) Gene expression of (A) Klf4, 
(B) Srf and (C) Myocardin after stimulation for 1 hour with TGF-β1 (5 ng/mL or 15 ng/mL) or PDGF-BB (20 ng/mL or 60 
ng/mL), normalized to unstimulated SMCs. (D-F) Gene expression of (D) α-Sma, (E) Sm22α and (F) Col1α1 after stimulation for 
24 hours with TGF-β1 (5 ng/mL or 15 ng/mL) or PDGF-BB (20 ng/mL or 60 ng/mL), normalized to unstimulated SMCs. To 
investigate functional consequences of phenotypic modulation of SMCs, rat aortic SMCs were stimulated with PDGF-BB (20 
ng/mL) after which SMCs and collagen I gels were admixed. (G) Collagen I gel contraction assay with unstimulated SMCs or 
SMCs prestimulated with PDGF-BB (20 ng/ml) or TFG-β1 (5 ng/mL). SMCs were allowed to contract for 24 hours in the presence 
of TGF-β1 or PDGF-BB. Data are presented as mean ± SEM (n=3). *p < 0.05, **p < 0.01, ***p < 0.001 
 
SMCs with PDGF-BB (both concentrations) led to increased gene expression of Col1α1 
(~2 fold, p<0.001), whereas stimulation with TGF-β1 did not have an effect (Figure 5F). 
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After stimulation for 24 hours, SMCs and collagen type 1 gels were admixed and cultured 
for an additional 24 hours in the presence of PDGF-BB (20 ng/mL) or TGF-β1 (5 ng/mL). 
Reduction of collagen gel size by contraction of unstimulated SMCs was 38±4% (Figure 
5G). Contraction of collagen gels by SMCs prestimulated with PDGF-BB was 30±2%, 
which was significantly less compared to unstimulated SMCs (p<0.05) (Figure 5G). SMCs 
prestimulated with TGF-β1 were able to contract the collagen gels by 53±1% (Figure 5G), 




Neointima formation plays an important role in the pathogenesis of TV, restenosis and 
atherosclerosis. Neointima formation is the luminal narrowing of arteries by SMC 
accumulation which leads to downstream ischemic injury. For the development of new 
treatment modalities to attenuate TV, it is important to know the anatomical origin of 
neointimal SMCs and the molecular mechanisms that lead to the formation of TV. We 
recently showed in a rat kidney transplantation model that all neointimal SMCs were of 
graft origin (4). The results of the present study indicate that medial SMCs are 
phenotypically modulated during neointima formation after rat renal transplantation, and 
are the most likely source for neointimal SMCs in TV. 
According to the response-to-injury hypothesis (7), medial SMCs migrate to the 
subendothelial intimal space in response to transplantation-induced vascular injury, 
culminating in the formation of an occlusive neointima. Due to the lack of markers specific 
for differentiated medial SMCs, it is not (yet) feasible to investigate if medial SMCs are 
truly the anatomical origin of neointimal cells using lineage tracing. Medial SMCs can only 
contribute to neointima formation after a phenotypic switch from a contractile to a synthetic 
phenotype which is induced by growth factors and cytokines produced in response to 
vascular injury (11). To investigate the neointimal microenvironment and presence of 
factors indicative of medial phenotypic modulation of SMCs after allogeneic kidney 
transplantation, we analyzed the gene expression profile in laser microdissected neointimal 
and medial tissue. Within the allograft neointima we observed enhanced gene expression of 
Pdgfb when compared with the normal (non-transplanted) vascular media. Enhanced 
expression of Pdgfb in the neointima was accompanied by increased expression of Pdgfrb 
in the allograft media. This raises the question what the source is of PDGF-BB when a 
neointima has not yet been formed. Protein expression analysis of PDGF-B in arteries 
without a neointima 16 days after transplantation showed the presence of PDGF-B in the 
media of allografts. This suggests that injury to medial SMCs shortly after transplantation 
induces the expression of endogenous PDGF-B which might contribute to initiation of 
SMC phenotypic modulation. PDGF-BB is well documented to act as a potent mitogen and 
chemoattractant for SMCs, leading to intimal thickening (19,20). PDGF-BB is also a 
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known mediator of SMC phenotypic modulation (21). Our observations support a role of 
PDGF-BB in phenotype switching of medial SMCs after allogeneic transplantation 
resulting in subsequent chemoattraction to the developing neointima. 
Phenotypically modulated SMCs are characterized by a decreased expression of SMC-
specific proteins and show a high degree of proliferation and the ability to migrate. We 
found reduced expression of the SMC-specific gene Sm22α and increased expression of 
ECM molecules in medial SMCs from arteries with a neointima. Consistent with the 
downregulation of Sm22α, Klf4, a transcription factor known to downregulate mRNA 
transcription of SMC genes, was increased in allograft medial SMCs. To study whether this 
in vivo observation might be PDGF-BB driven, as PDGF-BB was highly expressed in the 
developing neointima, in vitro experiments using rat SMCs were performed. PDGF-BB 
indeed reduced the expression of Sm22α and α-Sma which was accompanied by increased 
Klf4 and Col1α1 expression indicating phenotypic modulation of SMCs. Stimulation with 
TGF-β1 did not induce phenotypic modulation of SMCs. KLF4 can repress myocardin-
induced activation of SMC genes by selectively decreasing binding of SRF to DNA within 
intact chromatin (22). It is well established that virtually all SMC differentiation genes 
characterized to date are SRF/myocardin-dependent (23). Our observations are in line with 
data reported by Yu et al (24) who showed that stimulation of SMCs with PDGF-BB 
resulted in a downregulation of Sm22α expression which was mediated via KLF4. Also 
KLF5 has been suggested to have a role in phenotype modulation of SMCs. However, we 
did not find any differences in Klf5 expression between the different experimental groups 
analyzed (data not shown). We thus demonstrate for the first time a potential role for KLF4 
in phenotype switching of medial SMCs after transplantation-related injury. 
To further study whether PDGF-BB induced phenotypic modulation of SMCs resulted in 
reduced contractile function, in vitro collagen 1 contraction assays with rat aortic SMCs 
were performed. SMCs stimulated with PDGF-BB showed indeed impaired contractile 
function when compared with unstimulated SMCs, whereas stimulation with TGF-β1 
enhanced contractile function. The stimulating effect of TGF-β1 on SMC contractility is 
probably unrelated to SMC phenotype as TGF-β1 is shown to induce activation of Rho-
GTPase and subsequent contraction of SMCs without interfering with the phenotype of 
SMCs (25,26). 
This is the first study showing an upregulation of Klf4 and a downregulation of Sm22α in 
medial SMCs after renal transplantation thereby indicating phenotypic modulation of 
medial SMCs during neointima formation. One of the questions that can be raised is at what 
time-point after allogeneic transplantation phenotypic modulation SMC is initiated. This 
knowledge will provide valuable information required for the design of interventional 
strategies to attenuate neointima formation using phenotypic modulation of SMC as a 
target. In addition, we need to know whether phenotypic modulation of medial SMCs in 
vivo is associated with the enhanced proliferation rather than migration or vice versa. To 




Figure 6. Scheme illustrating the molecular mechanisms of NI formation after renal transplantation. (A) One of the 
histopathologic features of CTD after renal transplantation is the development of TV. (B) Luminal narrowing of TV by neointima 
formation is the result of SMC accumulation between the endothelial cells and the IEL. Profibrotic growth factors CTGF and TGF-
β1 stimulate matrix production and are found in the neointima and media of arteries with TV. PDGF-BB is present in the 
neointima and may act as a chemoattractant for medial SMCs that express PDGFrβ. (C) Medial SMCs modulate their phenotype 
after transplantation-related injury and switch from a contractile to a synthetic phenotype, characterized by a lower expression of 
SMC genes. (D) In synthetic SMCs, KLF4 abrogates myocardin-induced expression of SMC genes such as Sm22α. 
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neointimal and medial SMCs 12 weeks after transplantation (data not shown). Neointima 
formation after transplantation-related injury seems to be more dependent on migration than 
enhanced proliferation of synthetic SMCs. The pathways involved in increasing Klf4 
expression in our model needs to be determined but we propose an important role for 
PDGF-BB-induced signaling on medial SMCs. miRNAs might be involved as well as it has 
been shown that specific miRNAs (in particular miR-145) influence SMC phenotype by 
targeting KLF4 (27),(28). Local perfusion with miR-145 was indeed shown to reduce 
neointima formation after balloon injury (29). The potential role of miR-145 in the 
development of TV needs to be determined. 
Based on the data described in this study we propose the following cascade of events 
leading to the development of TV in renal allografts (illustrated in Figure 6). Medial SMCs 
in renal allografts have increased expression of growth factors leading to ECM deposition 
and subsequently fibrosis. Furthermore, medial SMCs modulate their phenotype after 
transplantation-related injury and switch from a contractile to a synthetic phenotype, which 
is characterized by a reduced Sm22α and increased KLF4 and ECM expression. PDGF-BB, 
which is expressed in the developing neointima, may act as a chemoattractant for medial 
SMCs that express PDGFrβ. Phenotypically modulated medial SMCs will migrate into the 
subendothelial intimal space followed by proliferation, culminating in the formation of an 
occlusive neointima. 
 
In conclusion, our results indicate that in a rat model for CTD after renal transplantation, 
medial SMCs phenotypically modulated and are the most likely source for neointimal cells. 
Prevention of phenotypic modulation of medial SMCs may provide a novel strategy to 
reduce occlusive neointima formation, including transplant vasculopathy. 
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Inbred female (175–210 gram) and male (200–225 gram) Dark Agouti (DA) rats were 
obtained from Harlan (Horst, the Netherlands) and inbred male Wistar Furth (WF) rats 
(240–295 gram) from Charles River Laboratories Inc. (l'Arbresle, Cedex, France). Animals 
were handled in compliance with the Principles of Laboratory Animal Care (NIH 
Publication No. 86-23, revised 1985), the University of Groningen guidelines for animal 




Female DA kidneys were orthotopically transplanted into male DA or WF recipients (1). 
Donor rats were anesthetized with isoflurane/O2, and left kidneys were flushed in situ with 
saline and removed. The donor rats were then killed by exsanguination, warm ischemia 
time varied between 0 to 15 min. Kidneys were preserved in ice-cold saline (range 16-38 
min) and then transplanted into the recipient from which the left kidney was removed under 
isoflurane/O2 anesthesia. The graft renal vein, artery, and ureter were anastomosed end-to-
end to the recipients’ left renal vein, artery, and ureter, respectively, using 10-0 prolene 
sutures. Vascular clamps were released after a warm ischemia time of 25 to 30 min. Both 
adrenal glands of the recipient remained in situ. All transplanted rats were given 
buprenorphine (Temgesic; 0.01 mg/kg) subcutaneously directly after transplantation and for 
8–10 h and 24 h after transplantation for pain relief. Recipients received cyclosporine A (5 
mg/kg bodyweight) (Sandimmune, Novartis, the Netherlands) subcutaneously during the 
first 10 days after transplantation. The recipients’ contralateral kidney was removed 8 to 14 
days after transplantation. Total follow-up was time 12 weeks unless animals had to be 
sacrificed earlier due to graft failure.  
 
Laser Dissection Microscopy and Gene Expression Analysis 
Frozen kidneys were sectioned at 9 µm and mounted on UV-pretreated slides (PALM 
Micro Laser Technology, Bernried, Germany). Sections were fixed in acetone and air-dried. 
Sections were subsequently stained with Mayer’s hemalum (Merck, Darmstadt, Germany) 
and rinsed in diethyl pyrocarbonate (DEPC)-treated tap water. Slides were then used for 
laser dissection microscopy using a Leica Microdissection System (Leica Microsystems). 
The neointima and media were separately dissected from nine serial sections per kidney.  
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Total RNA was isolated from microdissected vascular structures using the RNeasy Micro 
Kit (Qiagen, Hilden, Germany). Reverse transcription was carried out using Superscript III 
reverse transcriptase (Invitrogen, Breda, the Netherlands) and random hexamer primers 
(Promega, Leiden, the Netherlands). Gene expression was analyzed with a custom made 
microfluidic card-based low density array (Table 2, full manuscript) using the ABI Prism 
7900HT Sequence Detection System (Applied Biosystems, Nieuwerkerk a/d IJssel, the 
Netherlands). Micro fluidic cards consists of 384 wells pre-loaded with oligos including 3 
endogenous controls, for high-throughput, low reaction volume, real-time PCR. For each 
micro fluidic card, 10µl cDNA was diluted in 40µl of double distilled water and mixed with 
50µl of Taqman PCR master mix (Applied Biosystems). Standard recommended PCR 
protocols were performed (50°C for 2 minutes, 94.5°C for 10 min, 97°C for 30 s, 59.7°C 
for 1 min, with steps 3 and 4 repeated for 50 cycles). Relative mRNA levels were 
calculated as 2−∆CT, in which ∆CT is CTgene of interest – CTβ-actin. CT values that were 
below detection level were set at 50. 
For gene expression analysis of cultured rat aortic SMCs, total RNA was isolated after 24 
hours of stimulation with PDGF-BB or TGF-β1 (PreproTech EC LTD. London, UK) using 
the RNeasy Micro Kit (Qiagen Inc., CA, USA). Subsequently, 1µg of total RNA was 
reverse transcribed using the FirstStrand cDNA synthesis kit (Fermentas UAB, Lithuania). 
Real time RT-PCR analysis was performed in a final reaction volume of 10µL, consisting 
of 4.5µL SYBR Green Supermix (Bio-Rad, Veenendaal, The Netherlands), 0.5µL primer-
mix (Table 3, 0.5mmol/L), and 5µL cDNA (1ng/µL) using the ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems, the Netherlands). Reactions were 
performed at 95°C for 15s, 60°C for 30s, and 72°C for 30s, for 40 cycles. Relative mRNA 
levels were normalized against β-actin expression as described above. 
 
Immunohistochemistry 
Immunohistochemistry was performed on 2 µm paraffin sections. Sections were stained for 
Masson's trichrome, Verhoeff-van Gieson, Tgf-β1, Ctgf, Pdfgb and Myh11. Sections were 
dewaxed and antigen retrieval was performed for Tgf-β1 and Pdgfb staining by incubation 
in 0.1 mol/L citric acid buffer for 8 minutes in a microwave. Endogenous peroxidase was 
blocked with 0.1% H2O2 for 10 min at room temperature. Sections were incubated for 1 h 
with primary antibodies i.e. rabbit anti Tgf-β1 (Santa Cruz, Heidelberg, Germany), rabbit 
anti Ctgf (Santa Cruz, Germany), rabbit anti Pdgfb (Abcam, Cambridge, UK) or rat anti 
Myh11 (Abnova, Heidelberg, Germany). Goat anti rabbit-horseradish peroxidase (HRP), 
rabbit anti goat-HRP, Goat anti rabbit-biotin, rabbit anti goat-biotin and rabbit anti rat-HRP 
conjugates were used as secondary antibodies. Detection of biotinylated antibody complex 
was done by incubation with a streptavidin-HRP conjugate. Color development was 
performed with 3-amino-9-ethylcarbazole substrate dissolved in N,N-dimethylformamide 
and 0.5 mol/L acetate buffer (pH 4.9) or with 3,3′-diaminobenzidine tetrachloride. Sections 
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were counterstained with Mayer’s hemalum (Merck) and mounted in Kaiser’s glycerol 
gelatin (Merck). 
The degree TV (i.e. obliteration in arteries) was measured in all arteries within a section 
with a clearly visible internal elastic lamina (IEL) in the Verhoeff-van Gieson stained 
sections. The total surface area lying at the luminal side of the IEL (lumen + neointima), 
was measured and set at 100%. Subsequently, the luminal area was subtracted from this 
total area, to obtain the neointimal area. Luminal occlusion was expressed as mean 
percentage ± SEM. Arteries cut diagonally, i.e. arteries with a compressed lumen, were 
excluded from this measurement. 
 
Collagen gel contraction assay 
Gel contraction assay of 3D collagen gels were performed using a solution of rat tail 
collagen I (BD Bioscience, Breda, the Netherlands). Rat aortic SMCs (prestimulated for 24 
hours with PDGF-BB or TGF-β1, passage 3) (Lonza Benelux BV, Breda, The Netherlands) 
were resuspended in a mixture of collagen I, 10X DMEM, 1.5 mg/mL NaHCO3 and 25 
mmol/L HEPES at a concentration of 3.0 × 106 cells/mL. Aliquots of 50 µL (containing 
50,000 cells and 0.25 mg collagen type I) were added to a 96 wells plate, that had been 
preincubated with 0.1% BSA, and allowed to solidify at 37°C in a humidified incubator 
with 5% CO2 for 1 hour. After solidification, collagen gels were further cultured in 
DMEM/F12 (Lonza) containing 2% FCS with or without additionally added PDGF-BB or 
TGF-β1 (PreproTech EC LTD. London, UK). Collagen gels were imaged using a common 
flatbed-scanner (ScanJet 5370C; HP, CA, USA) and gel contraction was measured after 24 
hours. The degree of gel contraction was determined by dividing the total gel area before 
contraction (i.e. surface area of a 96 well) by the gel area after 24 hours of contraction. 
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Table 2. Composition of low-density array 
 
Gene name General name Gene symbol Assay ID 
 
Smooth muscle phenotype 
 
  
calponin 1, basic, smooth muscle Calponin 1 Cnn1 Rn00582058_m1 
krüppel-like factor 4 KLF4 Klf4 Rn00821506_g1 
krüppel-like factor 5 KLF5 Klf5 Rn00821442_g1 
myocardin Myocardin Mycd Rn01786178_m1 
serum response factor Srf Srf Rn01757240_m1 
transgelin SM22α Tagln Rn00580659_m1 
 
Growth factors and receptors 
 
  
connective tissue growth factor CTGF Ctgf Rn00573960_g1 
platelet-derived growth factor beta polypeptide PDGFB Pdgfb Rn01502596_m1 
platelet derived growth factor receptor, beta polypeptide PDGFRb Pdgfrb Rn00709573_m1 
transforming growth factor, beta 1 Tgf-b1 Tgfb1 Rn01475963_m1 
 
   
 
Number of arteries 
collected per animal 
(n=5) 
NI surface area (µm2) mean 
[range] 
Media surface area (µm2) mean 
[range] 





Isograft kidneys 46 [37-52] NP 
596,368  
[338,924-913,221] 






collagen, type I, alpha 1 Collagen I Col1a1 Rn01463848_m1 





ß-actin Beta-actin Actb Rn00667869_m1 
ß2-microglobulin B2m B2m Rn00560865_m1 
Eukaryotic 18S rRNA 18S 18s Hs99999901_s1 
cadherin 5 VE-cadherin Cdh5 Rn01536708_m1 
 
 
Table 3. Primer sequences used for real-time RT-PCR 
 
Gene Forward (5´-3´) Reverse (5´-3´) 
Col1α1 catgttcagctttgtggacct gcagctgacttcagggatgt 
KLF4 ccgtccttctccacgttc gagttcctctcgccaacg 
Myocardin ccgtgaaagaggctataaaagg ctgtcatcttcaaaggcaaatg 
Sm22α agtgtggccctgatgtgg tcaccaacttgctcagaatca 
α-Sma tgccatgtatgtggctattca accagttgtacgtccagaagc 
Srf gcacagacctcacgcaga atgtggccacccacagtt 




Supplemental Figure Legends 
 
 
Supplemental Figure 1: Expression of PDGF B in the media of isografts and allografts 16 days after transplantation. 
Protein expression of PDGF-B was assessed in the media from allografts and isografts 16 days after transplantation. Polyclonal 
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Syndecan-1, a heparan sulfate proteoglycan, plays an important role in wound healing by 
binding several growth factors and cytokines. As these processes are also crucial in damage 
and repair after renal transplantation, we examined syndecan-1 expression in human control 
kidneys, renal allograft protocol biopsies, and renal allograft biopsies taken at indication 
and non-transplant interstitial fibrosis. Syndecan-1 expression was increased on tubular 
epithelial cells in renal allograft biopsies compared to control kidneys. Increased epithelial 
syndecan-1 in allografts correlates with low proteinuria and serum creatinine, less 
interstitial inflammation, less tubular atrophy, and prolonged allograft survival. Knockdown 
of syndecan-1 on tubular epithelial cells in vitro reduces cell proliferation. Selective 
binding of growth factors suggests that syndecan-1 may promote epithelial restoration. 
Bilateral renal ischemia/reperfusion in syndecan-1 deficient mice resulted in increased 
initial (day 1) renal failure and tubular injury compared to wildtype mice. Macrophage and 
myofibroblast numbers, tubular damage and plasma ureum levels were increased, and 
tubular proliferation reduced in syndecan-1 deficient over wildtype kidneys at day 14. Our 
results indicate that syndecan-1 promotes tubular survival and repair upon renal allograft 
transplantation and ischemia/reperfusion injury. As far as we know syndecan-1 is the first 





Renal allograft transplantation is the treatment of choice for chronic kidney failure. 
Although significant advances have been made in the limiting (hyper) acute renal allograft 
rejection, chronic transplant dysfunction poses a serious risk of renal allograft loss at 
months to years after transplantation. Many factors are known to affect graft function and 
survival. For example, peri-operative ischemia/reperfusion injury (IRI) causes severe 
damage to the tubular epithelial cells (TECs) of the donor organ, and tubular injury due to 
ischemia can persist into the chronic phase as a result of vascular changes (1-4). The 
number and severity of immune-mediated acute allograft rejection episodes, and especially 
chronic transplant dysfunction, characterized by tubular atrophy, interstitial fibrosis and 
transplant glomerulopathy, can result in graft loss. Clearly, repair of tubular damage is a 
crucial step in restoration of renal function upon transplantation, and the balance between 
functional repair of tubular epithelium versus chronic inflammation and non-functional 
scarring, i.e. fibrosis, is a dominant factor determining renal allograft function in the long 
run(5). 
In previous studies, we showed that renal inflammatory responses can be affected by 
changes in heparan sulfate proteoglycans (HSPGs), as observed in experimental renal IRI 
as well as in primary human kidney diseases(6;7). HSPGs are glycoconjugates which 
consist of a core protein to which a number of linear carbohydrate side chains 
(glycosaminoglycans; GAGs) are linked(8;9). HS-GAG chains are typically very 
heterogeneous due to the coordinated action of various enzymes, which modify the 
alternating glucuronic acid and N-acetylglucosamine residues, resulting in varying degrees 
of sulfation and epimerization. HSPGs are involved in diverse biologically processes, 
including angiogenesis, wound healing, development and inflammation(10-12). HSPGs 
exert their functions predominantly by binding and presenting growth factors, chemokines 
and cytokines, and facilitating adhesion of inflammatory cells via binding to the leukocyte 
adhesion molecule L-selectin(6;8;13). Binding of these factors to HSPGs is mediated by the 
HS-GAG chains, and is dependent on the chemical fine-structure of the GAGs(8;14). We 
previously showed that within 24h after renal IRI, HSPGs expressed at the abluminal side 
of peritubular capillaries are induced to bind L-selectin and the monocyte chemoattractant 
protein-1, and that these HSPGs facilitate monocyte extravasation(6). Similar changes were 
observed in human primary kidney diseases associated with interstitial inflammation(7). In 
addition, we noted an increased expression of the cell surface HSPG syndecan-1 on TECs 
in biopsies of proteinuric patients(7). Syndecan-1 is a transmembrane HSPG involved in re-
epithelialization during wound healing and inflammation(10;15;16). Earlier studies have 
implicated syndecan-1 in epithelial differentiation(17;18). These processes are also very 
relevant in the context of renal allograft transplantation, i.e. inflammation as a result of IRI 
and donor-acceptor antigenic mismatching, and tubular re-epithelialization and 
differentiation to restore the damaged tubular epithelium after IRI. Indeed, a recent review 
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by Venkatachalam et al. posed the hypothesis that failure of tubular epithelial 
differentiation and therefore impaired tubular repair upon larger or smaller acute kidney 
injury episodes may play a significant role in the progression of kidney disease(19). 
Based on this background, we hypothesized that syndecan-1 is involved in tubular survival 
and repair upon renal transplantation. We examined expression of syndecan-1 in human 
renal allograft biopsies, including protocol biopsies and biopsies taken at indication, and 
correlated syndecan-1 expression to allograft function and binding of relevant growth 
factors. To directly study the functional role of syndecan-1, we studied the effect of 
syndecan-1 knockdown (in vitro) on TEC proliferation. In addition, we performed bilateral 
renal IRI in syndecan-1 versus wildtype mice and studied functional and histological 
outcome. Based on our data, we propose that syndecan-1 is involved in determining the 
balance between non-functional scarring and functional repair, and could be a novel marker 
indicating prolonged renal allograft survival.  
 
Methods 
Patient characteristics and histopathology 
Renal allograft biopsies used in this study included protocol biopsies taken at one year after 
transplantation (n=9), or taken upon indication, diagnosed according to BANFF criteria 
(39-42), representing minor histological alterations (Tx-MHA, n=27; borderline interstitial 
inflammation and/or borderline tubular atrophy and/or borderline intersitital fibrosis, no 
tubulitis or vasculopathy), acute allograft rejection (AR, n=23), transplants with interstitial 
fibrosis and/or tubular atrophy (Tx-IFTA, n=38; includes chronic allograft rejection (n=6)) 
and non-transplant interstitial fibrosis (non-Tx IF, n=20). Control kidney tissue included 
histologically normal tissue from kidneys removed because of renal carcinoma (n=12) and 
donor kidneys unused because of anatomical issues (n=2). Patient characteristics are 
summarized in Table 1. All patients with a renal allograft used standard 
immunosuppressive regimens according to institutional guidelines. All procedures and use 
of anonymized tissue were performed according to national ethical guidelines. Diagnosis 
and scoring was performed by an experienced nephropathologist according to Banff 
classification of renal allograft pathology, in which the cell-mediated component of AR is 
classified based on significant interstitial infiltration with foci of tubulitis (Type IA/B), 
signs of intimal arteritis (Type IIA/B), or transmural arteritis potentially accompanied by 
fibrinoid changes and medial smooth muscle cell necrosis (Type III), and the severity of 
Tx-IFTA is graded based on the amount of interstitial fibrosis and tubular atrophy (Grade I; 
mild, Grade II; moderate, Grade III, severe). Data on interstitial inflammation, tubulitis, 
tubular atrophy, acute tubular necrosis, epithelial vacuolization, interstitial fibrosis, 
vasculopathy, global glomerulosclerosis and C4d staining (anti-human polyclonal, 




Table 1: Patient characteristics 














Control 14 67 (29-84) 9/3B     
Tx-Protocol 9 51 (32-66) 7/2 50 (45-53)* 104 (93-129) 102 (47-115) 0.2 (0-0.7) 
Tx-MHA 25 48 (18-70) 19/6 3 (1-288) 101 (74-120) 222 (105-
1229)** 
0.3 (0-1.7)*** 
Tx-AR 28 45 (25-66) 16/12 2 (0.4-1248) 99 (62-137) 252 (127-
1021)** 
0.4 (0-11.3)*** 
Tx-IFTA 33 43 (11-69) 20/13 337 (12-
1092)* 
106 (80-153) 276 (125-730)** 1.6 (0-9.4)**** 
NonTx-IFTA 20 57 (20-79) 10/10  104 (84-133) 394 (80-632)** 1.1 (0.3-
11.6)**** 
Values are expressed as median and range 
Adetermined at time of biopsy; MAP= mean arterial pressure 
Bno data were available from two donor kidneys 
*p<0.05 Tx-protocol compared to Tx-AR p<0.05 Tx-IFTA compared to Tx-MHA and Tx-AR 
**p<0.005 compared to Tx-protocol 
***p<0.05 compared to Tx-IFTA and Non-Tx-IFTA 
****p<0.001 compared to Tx-protocol 
Kruskal-Wallis test with pairwise multiple comparisons (adjusted p-values) 
 
Renal biopsy immunofluorescence and scoring 
Formalin-fixed, paraffin-embedded archival renal tissue was used. Staining for syndecan-1 
(CD138; Serotec) and anti-HS mAbs JM-403 (43), JM-13 (44), 10E4 (45; Seikagaku)) and 
HK249 (46; Seikagaku) was performed after microwave-citrate antigen retrieval by 
incubating appropriate dilutions of primary antibodies for 1hr at room temperature (RT; 
20˚C), followed by incubation of AlexaFluor-labelled anti-mouse IgG and anti-rabbit IgG 
secondary antibodies (Molecular Probes, Invitrogen) for 45 min at RT. Binding 
experiments were performed by incubating excess amounts of recombinant human FGF-2 
(2.5µg/ml; Peprotech) or HB-EGF (2.5µg/ml; R&D Systems) on tissue sections for 2hr at 
RT, followed by anti-human basic FGF (Sigma-Aldrich) or anti-human HB-EGF (R&D 
Systems) for 1 hr, and AlexaFluor-labelled anti-mouse IgG secondary antibodies for 45 min 
at RT. Isotype matched non-relevant antibodies served as background controls and proved 
to be negative. In some experiments, tissue sections were pre-treated with heparitinase I 
(0.05 U/ml; EC4.2.2.8; Seikagaku Corp.) in acetate buffer (50mM C2H3O2Na, 5mM 
CaCl2•2H2O, 5mM MgCl2•6H2O, pH 7.0) for 1h at 37ºC. Sections were examined using a 
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Nikon Eclipse E800 fluorescence microscope with digital camera using identical 
microscopy conditions and exposure time for different samples. Stainings were scored as % 
of TECs involved in cortical regions of biopsies (typically 5-10 visual fields per biopsy), or 
non-biopsy tissues (15 visual fields)(200x magnification) without knowledge of diagnosis. 
 
Cell culture 
The human TEC cell line HK-2(47) was kindly provided by Dr. C. van Kooten, Leiden 
Universtity Medical Center, Leiden, the Netherlands. Cells were cultured in Dulbecco's 
modified Eagle's medium (DMEM)/F-12 (Gibco/Invitrogen) supplemented with 5µg/ml 
insulin, 5µg/ml transferrin, 5ng/ml selenium, 36ng/ml hydrocortisone, 10ng/ml epidermal 
growth factor (Sigma-Aldrich), 50U/ml penicillin, 50µg/ml streptomycin and 2mM L-
glutamine (Cambrex). 
 
shRNA silencing  
shRNAs targeting syndecan-1 (synd1-shRNA; target sequence 3’-
GGTGCTTTGCAAGATATCA-5’) and renilla luciferase (control vector; target sequence 
3’-AAACATGCAGAAAATGCTG-5’) were cloned into the pTER expression vector 
(kindly provided by Prof. H. Clevers, Hubrecht Laboratory, Centre for Biomedical 
Genetics, Utrecht, the Netherlands). HK-2 cells were transfected with synd1-shRNA vector 
or control vector using Lipofectamine (Invitrogen) according to manufacturer’s protocol 
and selected based on zeocine resistance(7). Knockdown of syndecan-1 expression was 
determined by flow cytometry. Cells were detached using EDTA-mix (10mM EDTA, 
150mM NaCl, 6mM KCl, 1.2mM KH2PO4, 20mM Hepes, 5mM glucose, 0.5% BSA; pH 
7.4), washed with PBS/0.5%BSA (PBA) and incubated with anti-syndecan-1 (CD138) 
antibody in PBA (30min on ice). After washing, cells were incubated with FITC-labeled 
anti-mouse IgG (30 min on ice), washed and analysed (FACSCalibur, Becton Dickinson). 
Non-relevant mouse IgG served as isotype control. 
 
Standardized scratch assay 
Control vector or synd1-shRNA HK-2 cells were grown to confluency in a 24-well plate. A 
standardized scratch was made in all wells, and digital images were taken at indicated time-
points using a time-lapse microscopy stage (37˚C; 5% CO2). Scratch area was calculated 
using AnalySIS (SIS Pro) software. 
 
MTT assay 
Control vector or synd1-shRNA HK-2 cells were seeded in a 96-well plate at 6000 
cells/well. Cell proliferation was determined at indicated time-points by adding 10µl MTT 
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(5mg/ml; 3-[4,5-dimethylthiazol-2-yl]-2,4 diphelnyltetrazolium bromide) per well and 
incubating for 2h at 37˚C. Supernatant was removed, 100µl/well DMSO/glycine (7:1 v/v) 
was added to dissolve the formed formazan crystals, and absorbance at 540nm was 
measured. Data are expressed as % MTT activity, with input at t=0 set at 100%. 
 
ELISA-based growth factor binding assay 
Nunc maxisorp ELISA plates were coated overnight with 2.5µg/ml heparin-albumin 
(Sigma) in PBS. After blocking (PBS/5%BSA; 2hr RT), wells were incubated for 2hr at RT 
with indicated concentrations of FGF-2 or HB-EGF in blocking buffer. Wells were washed 
(PBS/0.05%Tween-20) and incubated with anti-human basic FGF or anti-human HB-EGF 
diluted in blocking buffer. After washing, wells were incubated with biotinylated anti-
mouse IgG (1hr RT) and streptavidin-peroxidase (30min RT) in blocking buffer. Wells 
were extensively washed and substrate solution (TMB) was incubated for 15 min at RT, 
after which the reaction was stopped using 10% H2SO4. Absorbance was read at 450nm.  
 
Bilateral renal IRI 
Syndecan-1 deficient mice(16;26) and wildtype mice (both C57BL/6 background, 
syndecan-1 deficient mice backcrossed >6 generations) were bred in VU University 
Medical Center facilities, the Netherlands. Age and sex-matched mice were used in all 
experiments. The animal ethics committee of the VU University Medical Center approved 
all experiments. Briefly, renal pedicles were clamped for 25 min using microaneurysm 
clamps through a midline abdominal incision under anesthesia (0.07 ml/10 g mouse of 
fentanyl citrate fluanisone midazolam mixture containing 1.25 mg/ml midazolam [Roche 
Diagnostics Corp.], 0.08 mg/ml fentanyl citrate, and 2.5 mg/ml fluanisone [Janssen 
Pharmaceutica]). After 25 min of ischemia, clamps were removed and kidneys were 
inspected for restoration of blood flow. The abdomen was closed in 2 layers, mice received 
s.c. analgesic (50 µg/kg buprenorphin [Temgesic; Schering-Plough]) and were allowed to 
recover from surgery under a warm lamp. Sham-operated mice underwent the same 
procedure without clamping and were sacrificed 1 day after surgery. IRI mice were 
sacrificed at indicated time points and blood was taken by cardiac puncture. Kidneys were 
removed, and one half was snap-frozen, one half was formalin-fixed, paraffin-embedded 
for (immuno)histology.  
 
Renal IRI histology and scoring  
Formalin-fixed kidney sections (4 µm) were stained with periodic acid Schiff's (PAS) 
reagent and hematoxylin according to routine protocol to determine tubular damage. For 
specific detection of monocytes/macrophages, acetone-fixed (10 min RT) tissue sections 
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were rehydrated in PBS, blocked with PBS+5% normal goat serum (10 min RT), incubated 
with anti-monocyte/macrophage F4/80 (1h RT), and subsequently with anti-rat Alexa 488-
labeled secondary antibody. For specific detection of myofibroblasts, α-SMA staining was 
performed by incubating the sections with mouse anti-smooth muscle actin (1h RT), and 
subsequently with Goat anti-Mouse IgG2a peroxidase labeled secondary antibody, followed 
by the TSATM tetramethylrhodamine system (PerkinElmer LAS Inc., Waltham, MA, 
USA). Immunofluorescence stainings were scanned by using TissueFAXS (TissueGnostics 
GmbH, Vienna, Austria) and 15 digital photographs were made (magnification 200x) from 
renal cortex and outer medulla per kidney (30 photos for left and right kidney together), 
using n=7 mice per group per time-point. The total area stained was quantified using 
ImageJ 1.41 (Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, 
Maryland, USA) which was downloaded from http://rsb.info.nih.gov/ij/download.html). 
Ki67 (Ab 15580, Abcam) staining was done on 4% formaldehyde fixed cryosections. 
Endogenous peroxidase activity was blocked by 0.01% H2O2 in PBS, followed by blocking 
with 10% normal mouse serum. Primary antibody was incubated overnight at 4ºC, followed 
by peroxidase-labeled goat anti-rabbit IgG, and peroxidase-labeled rabbit anti-goat IgG, 
and 3-Amino-9-Ethyl-Carbozol. Quantification was done on 10 cortical fields/kidney at 20x 
magnification. Indicated is the mean number of Ki67 positive tubular nuclei/high power 
field per mice (left and right kidney together).  
 
Statistical analysis 
Data were analysed using Kruskal-Wallis test with pairwise comparisons (p-values adjusted 
for multiple comparisons), Spearman’s rank correlation test, Student’s t-test or survival 
analysis by log-rank test as indicated (PASW 18 statistics software). For Kaplan-Meyer 
analysis with log rank test, groups of normal (as in control kidneys; <30%) versus increased 
(30-100%) TEC syndecan-1 were compared. Loss of graft was defined by graft failure 
requiring dialysis treatment or explantation of renal allograft. p-values of <0.05 were 
considered to be statistically significant. 
 
Results 
Increased syndecan-1 expression on TECs in a subset of 
renal allograft biopsies 
In 13 out of 14 control kidneys, weak staining for syndecan-1 protein was detected in a 
limited percentage of TECs (Fig.1A,B). In contrast, very prominent TEC syndecan-1 
staining was observed in all Tx-protocol biopsies (taken according to protocol at one year 
after transplantation), and a large subset of Tx-MHA (minor histological alterations; 
borderline interstitial inflammation and/or borderline tubular atrophy and/or borderline 
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intersitital fibrosis, no tubulitis or vasculopathy), acute allograft rejection biopsies (Tx-AR), 
and Tx-IFTA biopsies (interstitial inflammation/tubular atrophy)(Fig.1B). This increased 
syndecan-1 staining showed distinct localization to the basolateral side of TECs (Fig.1A). 
Syndecan-1 staining was not observed in glomeruli or interstitial vasculature in any of the 
biopsies examined.  
Within the Tx-AR and Tx-IFTA group, the percentage of syndecan-1 positive TECs was 
heterogeneous throughout the different pathological types/grades (Fig.1B-D), and there was 
a trend towards a lower percentage of syndecan-1 positive TECs in the more severe Tx-
IFTA grades, which was however not statistically different. To further characterize the 
pathological status of transplant biopsies included in this study, we scored for interstitial 
inflammation, tubulitis, tubular atrophy, C4d status, glomerulosclerosis, vasculopathy, 
acute tubular necrosis, epithelial vacuolization and interstitial fibrosis according to BANFF 
criteria (as indicated in Suppl. Table 1). Correlation analysis across the whole panel of 
biopsies revealed that increased TEC syndecan-1 is associated with lower scores for 
interstitial fibrosis (Spearman’s rho=-0.356, p<0.001), interstitial inflammation 
(Spearman’s rho=-0.305, p<0.005) and tubular atrophy (Spearman’s rho=-0.262, p<0.01). 
 
Increased TEC syndecan-1 is associated with better graft 
function and prolonged allograft survival 
We next examined whether the percentage of syndecan-1 positive TECs was associated 
with clinical parameters, including time between transplantation and biopsy (time Tx to 
biopsy), markers for renal function (proteinuria, serum creatinine) and graft survival. A 
negative correlation was found between the percentage of syndecan-1 positive TECs and 
time Tx to biopsy (Spearman’s rho=-0.254, p=0.016; analysed over Tx-protocol, Tx-MHA, 
Tx-AR and Tx-IFTA groups together), indicating that a longer time between transplantation 
and biopsy is associated with lower percentage syndecan-1 positive TECs. However, in 
subgroups of Tx-MHA and Tx-IFTA which were matched according to similar time Tx to 
biopsy (Fig.2A; time Tx to biopsy between 32 to 288 weeks; Tx-MHA n=6, median 216 
weeks, range 32-288 vs. Tx-IFTA n=12, median 188 weeks, range 40-265), the percentage 
of syndecan-1 positive TECs was significantly higher in the Tx-MHA subgroup compared 
to Tx-IFTA subgroup (Fig.2B; p=0.032). Within the Tx-MHA or Tx-IFTA groups no 
statistical correlation was observed between time Tx to biopsy and the percentage 
syndecan-1 positive TECs (Spearman’s rho=0.150, p=0.495 for Tx-MHA; Spearman’s 
rho=0.193, p=0.315 for Tx-IFTA). These data suggest that TEC syndecan-1 expression is 
initially increased upon transplantation and decreases over time, although expression 









Figure 1. Increased syndecan-1 expression on TECs in a subset of renal allograft biopsies. (A) Immunostaining of human 
control kidney and Tx-MHA biopsy for syndecan-1 protein expression. G=glomerulus, bar=50µm. (B) Scoring for syndecan-1 
positive TECs in control kidney, Tx-protocol, Tx-MHA, Tx-AR, Tx-IFTA and nonTx-IFTA biopsies. *Kruskal-Wallis test 
p<0.001; p<0.05 control vs. Tx-protocol, Tx-MHA, Tx-AR and Tx-IFTA, p<0.05 nonTx-IFTA vs. Tx-IFTA (p-values adjusted for 
multiple comparison using Bonferroni) (C) Scoring for the percentage of syndecan-1 positive TEC in biopsies with different 
types/grades AR according to Banff-classification; not statistically different (Kruskal-Wallis). (D) Scoring for the percentage of 
syndecan-1 positive TEC in biopsies diagnosed as Tx-IFTA grade I, II and III according to Banff-classification; not statistically 
different (Kruskal-Wallis). 
  
We next investigated whether TEC syndecan-1 expression in the allografts was related to 
clinical markers indicative of allograft function (determined at time of biopsy). A 
statistically significant negative correlation was found between the percentage of syndecan-
1 positive TECs and proteinuria (as indicated in Fig.2C; Spearman’s rho=-0.315, p<0.005) 
and serum creatinine (as indicated in Fig.2D; Spearman’s rho=-0.334, p<0.001; both 
analysed across Tx-protocol, Tx-MHA, Tx-AR and Tx-IFTA groups). These data 
demonstrate that increased TEC syndecan-1 expression is associated with improved renal 
allograft function.  
In control kidneys, 13 out of 14 biopsies showed syndecan-1 expression in 30% or less of 
TECs, which we therefore regarded as a relevant cut-off for survival analysis. There was a 
statistically significant correlation between an increased percentage of syndecan-1 positive 
TECs and renal allograft survival (Fig.2E; <30% TEC syndecan-1 mean survival= 405 
weeks, >30% TEC syndecan-1 mean survival=862 weeks; log-rank test p<0.001). As 
expected, increased proteinuria was associated with decreased graft survival (log-rank test 
p=0.039). 
Together, these data show that TEC syndecan-1 is differentially expressed in renal 
allografts, and increased TEC syndecan-1 is associated with better renal allograft function 
and prolonged graft survival. 
 
Silencing of syndecan-1 in TEC cell line results in reduced 
proliferation 
We next examined the effect of shRNA mediated silencing of syndecan-1 in the human 
TEC cell line HK-2 on short-term in vitro re-epithelialization and more long-term 
proliferation. As shown in Fig.3A, shRNA mediated silencing of syndecan-1 (synd1-
shRNA) reduced cell-surface syndecan-1 expression to background levels, whereas 
transfection with a control vector did not affect syndecan-1 expression. In the standardized 
scratch assay, no difference was observed between control vector and synd1-shRNA TECs 
in short-term re-epithelialisation (Fig.3B,C). However, the more long-term proliferation of 
synd1-shRNA TECs was significantly reduced compared to control vector TECs (Fig.3D). 
Together, these data show that although knockdown of syndecan-1 in TECs does not affect 
short-term (likely predominantly migration-induced) in vitro re-epithelialization, syndecan-





Figure 2 Increased TEC syndecan-1 expression is associated with time Tx to biopsy, renal allograft function and survival. 
(A) Subgroups of Tx-MHA and Tx-IFTA were matched based on similar time Tx to biopsy. (B) Scoring for the percentage of 
syndecan-1 positive TEC in Tx-MHA and Tx-IFTA subgroups; *p=0.032 (Mann-Whitney test). (C&D) Graphic representation of 
the association between TEC syndecan-1 and proteinuria (C) and serum creatinine (D). (E) Kaplan-Meier curve showing the 
association between TEC syndecan-1 and allograft survival. <30%TEC syndecan-1 n=22 with 13 events, >30% TEC syndecan-1 





Figure 3 Silencing of syndecan-1 reduces TEC proliferation in vitro. (A) Knockdown of cell-surface syndecan-1 expression on 
the human TEC cell line HK-2 transfected with syndecan-1 specific shRNA (synd1-shRNA) compared to control vector as shown 
by flow cytometry. (B&C) Knockdown of syndecan-1 does not affect short-term re-epithelialisation of HK-2 cells in a 
standardized scratch assay. Representative photographs (B), mean and SD of 5 separate experiments (C). (D) Reduced proliferation 




Increased TEC syndecan-1 shows specific binding with HB-
EGF and anti-HS mAb 10E4, but not FGF-2 and the anti-
HS mAbs JM-403, JM-13 and HK249 
Knowing that HSPGs, including syndecan-1, can be modified to present growth factors 
depending on cellular activation status, we explored whether the association between 
syndecan-1 and TEC proliferation could be attributed to growth factor binding. We chose to 
use FGF-2 (basic FGF) and HB-EGF, which are both known to bind HSPGs(20-22), 
although possibly with differences in GAG-chain requirements(20-23). In an ELISA-type 
binding assay, we were able to detect dose-dependent binding of FGF-2 and HB-EGF to a 
heparin-albumin coating, which is used as a model molecule for HSPGs (heparin is a highly 
sulfated HS-GAG chain)(Fig.4A). As shown in Fig.4B and Table 2, no basolateral FGF-2 
binding was observed in Tx-MHA biopsies despite high syndecan-1 expression. Limited 
basolateral TEC binding of FGF-2 was observed in one Tx-IFTA biopsy (Table 2), and 
binding of FGF-2 to interstitially infiltrated cells was observed in a number of biopsies 
(predominantly Tx-IFTA and non Tx-IF; likely representing binding to heparin-containing 
mast cells; not shown). When incubation of FGF-2 was omitted no staining was observed, 
indicating that binding of the exogenously added FGF-2 was detected rather than 
endogenously present FGF-2 (not shown). Although FGF-2 is a prototypic HSPG binding 
growth factor, it is also a pro-fibrotic growth factor, and therefore increased binding and 
expression in the renal allograft could be harmful/ disadvantageous. We therefore also 
examined binding of HB-EGF, an epithelial survival factor, which is associated with renal 
epithelial repair and is expressed in the regeneration phase upon renal injury(24;25). As 
shown in Fig.4B and Table 2, prominent binding of HB-EGF to the basolateral side of 
TECs was observed most dominantly in the Tx-MHA group, although it was also observed 
to different extents in control tissue, Tx-IFTA and non Tx-IF. Pre-treatment of Tx-MHA 
tissue sections with heparitinase I, an enzyme that specifically degrades HS-GAG chains, 
completely diminished HB-EGF binding to TECs, showing that HB-EGF binds to 
basolateral TEC HSPGs (Fig.4C). To explore the structural characteristics of tubular 
epithelial HS in more detail, we also evaluated four different anti-HS mAbs, namely JM-
403, JM-13, 10E4 and HK249. The various epitope requirements of these anti-HS mAbs 
have been detailed elsewhere (see Materials and Methods section). All four anti-HS mAbs 
stained subsets of renal basement membranes, however 10E4 in addition stained tubular 
epithelial cells in a baso-lateral fashion in a number of biopsies. Sub-group analysis 
revealed a close colocalization of anti-HS mAb 10E4 and syndecan-1 (Table 2 and Fig.5). 
Together, our data show increased binding of HB-EGF, but not FGF-2, to basolateral TEC 
HSPGs, colocalizing with syndecan-1 and 10E4 HS expression, in a subset of renal 
allograft biopsies. Syndecan-1 positive tubules however failed to bind with FGF-2, and 
anti-HS mAbs JM-403, JM-13 and HK249. These data highlight two levels of regulation by 
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which the cells modulate growth factor affinity, namely syndecan-1 protein expression and 
the formation of specific sulfation motifs in the HS polysaccharide side chains. 
 
Table 2: Scoring for TEC syndecan-1 protein expression and binding of FGF-2, HB-EGF, and anti-HS mAb 10E4 in a 
subset of renal biopsies. 
 
Case Diagnosis Syndecan-1A FGF-2 bindingA HB-EGF bindingA 
Anti-HS mAb 
10E4A 
1 Control 5 0 5 ndB 
2 Control 20 0 30 nd 

























8 Tx-MHA 80 0 70 nd 
9 Tx-MHA 60 0 70 72 
10 Tx-MHA 90 0 80 nd 













14 Tx-IFTA 60 0 30 53 
15 Tx-IFTA 30 0 0 1 
16 Tx-IFTA 20 10 10 13 
17 Tx-IFTA 0 0 0 nd 
18 Non-Tx IFTA 10 0 0 2 















 percentage of TECs positive for expression/binding 
B







Figure 4. Specific binding of HB-EGF, but not FGF-2, to basolateral TEC HSPGs in Tx-MHA biopsies. (A) Dose-dependent 
binding of HB-EGF and FGF-2 to heparin-albumin in vitro. (B) Binding of FGF-2 (left) or HB-EGF (right) to control kidney 
(upper panels) and Tx-MHA biopsies (lower panels). (C) Basolateral TEC binding of HB-EGF in Tx-MHA binding is lost after 




Figure 5. Specific binding of anti-HS mAb 10E4 in syndecan-1 positive biopsies. Staining of syndecan-1 (left) and HS 10E4 
epitope (right) in control kidney (upper panel) and Tx-MHA biopsy (lower panel). Note the absence of syndecan-1 and 10E4 HS 
staining in control tissue, whereas 10E4 HS positivity co-localizes with baso-lateral syndecan-1 in representative Tx-MHA biopsy. 
Bar = 50 µm. 
 
Syndecan-1 deficient mice are more susceptible to renal 
IRI and show repair skewed to fibrosis  
To determine the in vivo importance of syndecan-1 in renal IRI, we next performed bilateral 
warm IRI in syndecan-1 deficient mice (16;26). Anticipating a more severe phenotype in 
syndecan-1-/-, we used a relatively mild IRI model (25 min bilateral warm ischemia, 
followed by bilateral reperfusion). Induction of syndecan-1 in the WT mice was evidenced 
from day 1 onwards, which by definition was not observed in the syndecan-1 KO mice (Fig 
6A-E). Compared to wildtype mice, syndecan-1-/- proved to be more susceptible to IRI-






Figure 6. Impaired renal function upon bilateral IRI in syndecan-1-/- compared to wildtype mice. Renal IRI was performed 
by bilateral clamping of renal pedicles for 25 min (warm ischemia), followed by bilateral reperfusion. (A) Syndecan-1 expression 
is nearly absent in sham-operated wildtype animals, whereas tubular syndecan-1 is clearly induced in cortical regions upon I/R 
from (B) day 1, (C) day 3, (D) day 7 to (E) day 14. Plasma creatinine (F) and ureum (G) were determined at indicated timepoints, 
and were increased compared to wildtype at day 1 and 14 (for plasma ureum). *p<0.05 (Mann-Whitney test) 
 
At day 1 after IRI, plasma creatinine and ureum levels were significantly increased in 
syndecan-1-/- compared to wildtype mice (Fig.6F and G). Histologically, clearly more 
tubular damage was observed in syndecan-1-/- kidneys at day 1 after IRI (Fig.7A,C). 
Interestingly, tubular damage appeared to remain constant over time in syndecan-1-/- 




Figure 7. Increased tubular damage, reduced proliferation, and increased amounts of macrophages and myofibroblasts in 
syndecan-1-/- kidneys upon bilateral IRI. Renal IRI was performed by bilateral clamping of renal pedicles for 25 min (warm 
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ischemia), followed by bilateral reperfusion. (A) Increased tubular damage was observed at day 1 and 14 after IRI, whereas (B) 
reduced tubular proliferation (Ki67 positive tubular cells) was observed at day 14 in the syndecan-1 KO mice. (C) Representative 
photographs of PAS-stained kidney sections of wildtype and syndecan-1-/- at day 1 and 14 after IRI. (D) Monocytes/macrophages 
(F4/80 staining) appear to accumulate over time upon IRI in syndecan-1-/- compared to wildtype, with significantly more 
monocyte/macrophages in syndecan-1-/- kidneys at day 14. (E) Myofibroblasts (αSMA staining) are increased in syndecan-1-/- 
kidneys compared to wildtype at day 14 after IRI. *p<0.05 (Mann-Whitney test) 
 
 (Fig.7A,C). By Ki67 staining we evaluated the proliferative response of the tubular 
epithelium both in wildtype and syndecan-1 KO mice. Although there is quite some 
proliferation at day 3 after I/R (not different between both groups), at day 7 and 14 of the 
regeneration phase the syndecan-1 KO mice revealed lower proliferation rates compared to 
the WT (day 14: p=0.0411; Fig.7B).  
 
Both macrophages and myofibroblasts are known to play an important role in renal IRI 
damage/repair responses. We therefore quantified the amounts of these cells by staining for 
F4/80 (monocytes/macrophages) and α-SMA (myofibroblasts). As shown in Fig.7D, 
monocytes/macrophages steadily accumulated in syndecan-1-/- compared to wildtype 
kidneys. Interestingly, also the amount of myofibroblasts was increased in syndecan-1-/- 
compared to wildtype kidneys at day 14 after IRI (Fig.7E).  
Together, these data show that syndecan-1-/- mice have impaired renal function and 
increased tubular damage upon renal IRI compared to wildtype mice. In addition, our data 
indicate that tubular damage is restored less efficiently in syndecan-1-/- mice, and repair 
mechanisms may be skewed towards fibrosis rather than restoration of tubular epithelium.  
 
Discussion 
In this study, we show that syndecan-1 protein expression is increased on the basolateral 
side of TECs after renal transplantation and that the percentage of syndecan-1 positive 
TECs is significantly associated with better allograft function and survival. We provide 
evidence that syndecan-1 is involved in TEC proliferation, and that binding of the growth 
factor HB-EGF to TEC HSPGs is increased on the basolateral side of TECs that also 
express syndecan-1. Finally, we show that syndecan-1 deficient mice show more impaired 
renal function, increased tubular damage associated with reduced tubular repair in an 
experimental IRI model. Based on our data, the role of syndecan-1 in the renal epithelium 
may be similar to its role in dermal wound healing(10;16). Indeed, we show that shRNA 
mediated knockdown of syndecan-1 expression in a TEC cell line significantly reduces cell 
proliferation, affirming a role of syndecan-1 in tubular re-epithelialization and repair. The 
involvement of HB-EGF in TEC proliferation and renal epithelial repair has been proposed 
earlier(24;25). Moreover, in a murine I/R experiment we show that syndecan-1 promotes 
survival (day 1) and proliferation/repair (day 14) of injured epithelial cells, probably by 
acting as co-receptors for survival/growth factors such as hepatocyte growth factor, stromal 
derived factor and HB-EGF. 
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Tubular induction of syndecan-1 likely reflects a certain degree of de-differentiation of the 
tubular cells in order to be responsive after transplantation and permanent immunological 
attack. Thus, renal tubular syndecan-1 expression probably reflects a meaningful early 
epithelial mesenchymal transition response and mirrors syndecan-1 expression of the 
developing kidney (18). The presence of syndecan-1 on epithelial cells brings the cells in a 
mobilized condition, now able to respond effectively to growth factors such as HB-EGF. 
We speculate that the loss of syndecan-1 in a number of transplantation biopsies is due to 
further de-differentiation and/or more advanced epithelial mesenchymal transition. These 
fully de-differentiated epithelial cells are not able to respond to survival/growth factors 
anymore and will contribute to chronic inflammation and IFTA. In our opinion, this 
interpretation nicely corresponds to the concept of Venkatachalam et al. (19), that 
prolonged deep de-differentiation of tubular cells contribute to progression in chronic 
kidney disease. Our data are also in line with the findings of Halloran et al. (5), who 
showed that impaired renal function in transplantation biopsies is correlated with increased 
expression of tissue injury gene sets and decreased expression of kidney transcripts, 
indicating de-differentiation of renal epithelial cells. We thus conclude that the tubular 
induction of syndecan-1 reflects a physiological response of the epithelium in order to 
maintain/restore tubular integrity and regeneration/repair.  
The mechanism behind increased expression of syndecan-1 protein was not specifically 
addressed in this study. There are indications that syndecan-1 transcription can be regulated 
by the pro-inflammatory transcription factor NF-κB, as well as by an FGF-inducible 
response element located upstream of the syndecan-1 promotor(27-29). Both pathways are 
relevant in the context of renal transplantation(30;31). Furthermore, both TGF-β and EGF 
have been shown to induce syndecan-1 mRNA expression in vitro, and 
expression/activation of these factors is enhanced upon renal transplantation, although 
especially TGF-β has been associated with fibrosis, and EGF with proliferation(28;32-34). 
Apart from transcriptional regulation, increased staining for syndecan-1 protein could be a 
result of reduced syndecan-1 shedding from the cell surface.  
From a clinical point of view, it would be interesting to assess whether syndecan-1 
concentration and binding properties in urine of patients after renal allograft transplantation 
are of diagnostic value to predict allograft status and survival (ongoing, van den Born et 
al.). In addition, since immunosuppressive drugs used in the context of renal transplantation 
are typically anti-proliferative, it would be interesting to investigate their effect on 
syndecan-1 expression and/or growth factor binding.  
As far as we know syndecan-1 is the first tubular marker that is positively associated with 
graft function and survival. Other tubular markers such as KIM-1 (35;36) and NGAL (37) 
or typical tubular EMT markers such as vimentin and S100A4 (38) are negatively 
associated with graft function and graft loss. Therefore, larger studies with protocol 
biopsies have to show whether tubular syndecan-1 might be a novel independent, 




In conclusion, our data provide evidence for a role of syndecan-1 in tubular epithelial 
survival and repair in the renal allograft. We propose that syndecan-1 can help shift the 
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Control 14 0 0 0 0 0 0 0 1 0 
Tx-Protocol 9 0 0 0 0 0 0 0 0 0 
Tx-MHA 25 2 0 0 1 4 0 4 7 4 
Tx-AR 28 6 1 14 5 12 24 26 20 9 
Tx-IFTA 33 1 0 0 2 27 2 27 24 20 
Non-Tx IFTA 20 0 0 0 0 17 0 17 15 13 










In this thesis, studies were designed and performed to increase our knowledge on the role of 
proteoglycans in tissue remodeling associated with chronic renal transplant dysfunction 
(CTD). CTD is characterized by decline in kidney function over time and is histologically 
characterized by focal glomerulosclerosis (FGS), interstitial fibrosis and tubular atrophy 
(IF/TA), and transplant vasculopathy.  
To better understand the pathogenesis of CTD and identify targets of intervention, we 
investigated the expression and involvement of various proteoglycans in a rat CTD model. 
Numerous studies have shown that proteoglycans, especially HSPGs, are able to bind a 
myriad of proteins that include growth factors, cytokines and adhesion molecules and act as 
co-receptors and thereby involved in various cell functions. The role of HSPGs in 
remodeling of the various functional compartments of the kidney after transplantation is 
discussed below.  
 
Involvement of HSPGs in glomerulosclerosis 
After renal transplantation, glomerulosclerosis is one of the histopathological hallmarks 
which is associated with development of proteinuria. The data presented in chapters 2 and 
3, showed glomerular upregulation of the HSPG perlecan in renal allografts at both mRNA 
and protein levels. Similarly, the pro-fibrotic heparin binding growth factor FGF2 
accumulated in the glomeruli of the allografted kidneys. Data presented in chapters 2 and 3 
furthermore showed a massive increase in matrix HSPG-mediated binding capacity for 
FGF2. Enhanced binding capacity for this growth factor was the result of increased HSPG 
(like perlecan) expression, and modified HS sulfation [most likely increased 2-O sulfation 
leading to loss of JM-403 staining (1) and increased FGF2 binding (2)]. This finding 
suggests that upon allo-transplantation the kidney mobilizes matrix HSPGs to become 
docking molecules for heparin-binding growth factors such as FGF2. This was also 
reported by Morita et al. (3) showing increased FGF2 binding in fibrotic areas in native 
kidney diseases. In vitro studies reported in chapter 3 support that the FGF2-driven 
proliferation of mesangial cells crucially depends on the sulfation of mesangial HSPGs, 
indicating that the observed differential expression of perlecan and FGF2 in the renal 
allografts most likely also have functional consequences. 
 
Involvement of HSPGs in neo-intima formation 
Neo-intima formation is a central event in the pathogenesis of transplant vasculopathy. 
Neo-intimal tissue consists of migrated smooth muscle cells (SMCs), infiltrated immune 
cells and extracellular matrix components. In chapter 5 we focused on the molecular 
pathways in the arterial media which facilitate neointima formation. Enhanced expression 
of Pdgfb in the neointima was accompanied by increased expression of Pdgfrb in the 
allograft media. PDGF-BB is well documented to act as a potent mitogen and 
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chemoattractant for SMCs, leading to intimal thickening (4,5). PDGF-BB is also a known 
mediator of SMC phenotypic modulation (6). Our observations support a role of PDGF-BB 
in phenotype switching of medial SMCs after allogeneic transplantation resulting in 
subsequent chemoattraction towards the developing neointima. PDGF-BB is known to be a 
heparin-binding growth factor. It has been shown in vascular development that PDGF-BB-
dependent pericyte recruitment and migration is critically dependent on HSPGs (7). 
Recently it has been shown that neointima formation is attenuated in syndecan-4 KO mice, 
and that PDGF-BB- and FGF2-induced proliferation of vascular SMCs is impaired in 
syndecan-4 KO cells (8). 
In chapter 2 we showed abundant expression of basement membrane (BM) HSPGs collagen 
type XVIII and perlecan and interstitial chondroitin/dermatan sulfate (CS/DS) PGs versican 
in the neo-intimas of CTD kidneys. Upregulated Collagen type XVIII expression in 
neointima has not been reported before and the potential role of this proteoglycan is as yet 
unknown. Previously it has been shown that perlecan expression in arteries is associated 
with inhibition of SMC proliferation and reduced intimal hyperplasia (9-12) which favors 
for a role of perlecan in neointima stabilization. However, data reported by others indicate 
that arterial HSPGs can actually activate SMC proliferation by modulating the function of 
basic fibroblast growth factor (FGF2) (13). Based on these results from chapters 2 and 5 we 
speculate arterial HSPGs to be involved in PDGF-BB- and possibly FGF2-mediated 
proliferation and migration of the VSMCs and thereby contribute to neointima formation. 
Future experiments targeting PDGF-B and/or FGF2 pathways in HS mutated versus wild 
type animals might reveal the impact of our findings. 
 
Involvement of HSPGs in inflammation and tubulo-
interstitial fibrosis 
As shown in chapter 2 there is an increase of perlecan in the endothelial BM of peritubular 
capillaries in rat renal allografts when compared to the non-transplanted controls and 
isografts. The upregulated expression upon transplantation suggests that these molecules 
are involved in inflammatory leukocyte influx, since our group previously showed perlecan 
and collagen XVIII to be involved in leukocyte recruitment upon renal 
ischemia/reperfusion (14). Recently, we extended these studies in mice deficient for 
collagen XV, collagen XVIII and the compound double mutant mice. These yet 
unpublished results indeed confirm the crucial role of subendothelial BM HSPGs in 
leukocyte recruitment. Related to this finding, in chapter 5 we documented a reduced influx 
of CD45+ leukocytes in allograft kidneys upon treatment with RO-heparin. This indicates 
that heparin-like polysaccharides, most likely heparan sulfates, are indeed involved in 
leukocyte recruitment. 
The increased Collagen XVIII and perlecan in the tubular BM of allograft kidneys could 
play a role in the EMT process by binding of chemokines and growth factors resulting in a 
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concentration gradient over the tubular BM (15). This gradient might then direct migration 
of tubular epithelial cells into the interstitium during EMT. Recently it has been 
demonstrated that heparanase is crucially involved in induction of EMT by FGF-2 in 
proximal tubular epithelial cells (16). In addition to tubular atrophy and EMT, proteoglycan 
expression in the tubular BM could be involved in binding of L-selectin and chemokines 
such as MCP-1, thereby facilitating inflammatory responses in tubules (14,17). We also 
showed expression of versican in interstitial fibrosis (IF) (chapter 2), which is likely 
involved in leukocyte recruitment and infiltration by its L-selectin-binding capacity (14,18). 
The abundant versican expression in IF supports our previous finding that L-selectin in the 
interstitium binds to CS/DS side chains and not HS side chains (19). Moreover, the high L-
selectin-binding capacity of CS/DSPGs in IF fits well with our observation that most 
leukocyte infiltration was observed in interstitial regions and to a far lesser extent in 
neointimal lesions and within the glomeruli, suggesting that these interstitial GAGs form a 
retention motif for infiltrated leukocytes.  
 
Involvement of HSPGs in lymphangiogenesis 
In chapter 2 we showed a marked increase of lymph angiogenesis in allografts, which was 
accompanied by the expression of perlecan at the abluminal side of lymphatic endothelium. 
This expression of perlecan in close proximity of lymphatic endothelial cells suggests a 
functional role for perlecan in lymph angiogenesis. This is supported by results from 
studies performed in a mouse model for regenerating skin which suggest that perlecan is 
involved in lymphatic endothelial cell migration, lymphatic organization and maturation 
(20). In addition, also versican, which was abundantly present in the interstitium of CTD 
kidneys, might play a role in lymph angiogenesis (21). Recently it has been shown that 
lymphatic endothelial heparan sulfate is required for the lymphatic endothelial cell growth 
and sprouting by binding to key lymphangiogenic growth factor VEGF-C (22). Indeed, 
preliminary data in our heparinoids intervention study (chapter 5) suggest a reduction in 
lymph vessel density upon treatment with heparin. In our study in chapter 2, increased 
lymph angiogenesis correlated with reduced graft function. The existence of a causal 
relation between lymph angiogenesis and loss of graft function, however, needs to be 
established in future studies. 
 
Involvement of HSPGs in epithelial survival and repair 
Syndecan-1, a transmembrane cell surface proteoglycan, is known to be involved in 
epithelial regeneration and repair upon wound healing (23-25). In chapter 6 we show that 
syndecan-1 protein expression increased in tubular epithelial cells at the basolateral side 
after human renal transplantation, which is significantly associated with better allograft 
function and survival. We confirmed a fundamental role of syndecan-1 in tubular cell 
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survival and repair by in vitro studies and by in vivo experiments in syndecan-1 KO mice. 
These data highlight the importance of the epithelial compartment for renal function. Our 
data suggest that promoting epithelial syndecan-1 might be a promising way to improve 
renal function in transplanted kidneys and possibly in native renal diseases as well. The 
mechanism behind increased expression of syndecan-1 protein was not specifically 
addressed in this study. There are indications that syndecan-1 transcription can be regulated 
by the pro-inflammatory transcription factor NF-κB, as well as by an FGF-inducible 
response element located upstream of the syndecan-1 promoter (26-28). Both pathways are 
relevant in the context of renal transplantation (29,30). Furthermore, both TGF-β and EGF 
have been shown to induce syndecan-1 mRNA expression in vitro, and 
expression/activation of these factors is enhanced upon renal transplantation, although 
especially TGF-β has been associated with fibrosis, and EGF with proliferation (27,31-33). 
Apart from transcriptional regulation, increased staining for syndecan-1 protein could be a 
result of reduced syndecan-1 shedding from the cell surface. Down-modulation of 
syndecan-1 shedding might be an interesting therapeutic target point. Syndecan-1 
ectodomain can be shedded by a number of MMPs and other proteolytic enzymes (34,35), 
most promising candidate being ADAM17/TACE (36). We recently described a role for 
ADAM17 in renal transplant dysfunction (37), not known however is whether preserved 
syndecan-1 accounted for the results.  
From a clinical point of view, it would be interesting to assess whether syndecan-1 
concentration and binding properties in urine of patients after renal allograft transplantation 
are of diagnostic value to predict allograft status and survival (ongoing, van den Born et 
al.). As far as we know syndecan-1 is the first tubular marker that is positively associated 
with graft function and survival. Other tubular markers such as KIM-1(38,39) and NGAL 
(40) or typical tubular EMT markers such as vimentin and S100A4 (41) are negatively 
associated with graft function and graft loss. Prospective studies with protocol biopsies 
could have the potential to show whether tubular syndecan-1 might be a novel independent, 
player in tubular repair processes. Accordingly, it would be interesting to investigate 
whether urinary syndecan-1 excretion could be a non-invasive marker of renal tubular 
repair, and whether it has independent prognostic power for renal outcome.  
 
HSPGs as therapeutic target 
Although the advances in immunosuppressive treatment resulted in a sharp decline in the 
incidence of acute rejection, the long term graft survival rates have hardly or not improved 
over the last decade. Over time the graft develops CTD associated with massive tissue 
remodeling. In addition to the immunosuppressive regimen, current treatment in the renal 
transplant recipients targets common risk factors for renal function loss and cardiovascular 
complications, such as proteinuria, hypertension and hyperlipidemia but until now there is 
no therapy available to retard tissue remodeling in CTD. Accordingly, novel therapeutic 
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modalities to retard tissue remodeling in the process of CTD, that includes inflammation, 
unlimited proliferation and fibrosis, might provide novel perspectives to improve outcome. 
Based on previous research on the involvement of HSPGs in inflammation, proliferation 
and fibrosis, these glycoconjugates could be interesting target molecules to retard CTD. 
Especially in the field of oncology, HSPGs are considered as therapeutic molecules or 
targets (42). Exogenously administered heparin-like glycomimetica interfere with the 
growth factor signaling and inflammation (43-45). This would be especially relevant in 
developing CTD. As long term heparin administration will chronically inhibit the 
coagulation system, this might result in severe complications (46). This led to the invention 
of various heparin derivatives that include non-anti-coagulant heparins, low molecular 
weight heparins (LMWH), HS mimetics, chemically prepared oligosaccharides and 
synthetic heparins(43,44,47-49). LMWH has been shown to be effective in binding 
inflammatory cytokines and down regulating expression of MHC (class I and class II) and 
ICAM-1, independently of anticoagulant capacity (50). In experimental models, treatment 
with non-anticoagulant LMWH showed prolonged skin, cardiac and renal allograft survival 
with beneficial outcomes (48,51-53). In addition, LMWH decreases mesangial proliferation 
and matrix expansion (54,55). Human data after renal transplantation suggest that LMWH 
may possess renoprotective properties in human renal transplantation as well (56). In 
chapter 4, it has been shown that treatment with non-anticoagulant heparin, RO-heparin, 
reduces the clinical parameters such as urinary protein, serum triglycerides and in addition 
ameliorates renal inflammation. Recently it has been demonstrated that intervention with a 
LMWH, sulodexide, was not renoprotective in patients with type 2 diabetes, renal 
impairment, and macroalbuminuria (57). Although sulodexide has similar structure as 
unfractionated heparin, it has a lower degree of sulfation and shorter polysaccharide length 
compared to normal unfractionated heparin and RO-heparin (58). Altogether, these data 
provide a rationale for clinical studies in renal transplant recipients using a non-
anticoagulant heparinoid as add on drug next to standard immunosuppressive medication, 
eventually with graft survival as hard endpoint, and GFR loss over time and proteinuria 
development as intermediate endpoints. 
Alternative approaches to use HSPGs as targets could be the use of antibodies that 
recognize and thereby block specific HS-motifs/domains. It was demonstrated by in vitro 
experiments that 6-O-sulfate specific anti-HS antibodies produced in a phage-display 
library can inhibit leukocyte rolling and firm adhesion to glomerular endothelial cells (59). 
In addition, generation of non-GAG binding chemokines can interfere with chemokine 
receptor signaling (60). Recently, a novel approach was presented using biologically 
inactive CXCL8 with however significantly increased binding affinity for GAGs, thereby 
competing of endogenous CXCL8 from endothelial GAGs resulting signaling down 
modulation of the corresponding chemokine receptor (61). Together, there are many 
options for the use of HSPGs in therapeutic strategies, although many need further 




The data presented in this thesis show the involvement of PGs in CTD tissue remodeling. 
We showed an upregulation of the HSPGs, collagen type XVIII and perlecan and CSPG 
versican in rat renal allografts. The binding properties of the upregulated PGs has increased 
upon renal allo transplantation. Perlecan and FGF2 were found to be upregulated in renal 
allografts. The functional and mechanistical role of these HSPGs were studied in vitro 
using rat mesangial cells. The results showed that HSPGs mediated FGF2-dependent 
proliferation of mesangial cells. Treatment with non-anti-coagulant heparin (RO-heparin) 
showed beneficial effects after rat renal transplantation. Considering the molecular 
mechanisms behind neointima formation, we showed that in response to allogeneic 
transplantation there will be medial dedifferentiation, probably mediated by PDGF-B. 
Lastly we showed that syndecan-1, a trans-membrane cell surface proteoglycan, is involved 
in tubular regeneration and repair after renal transplantation and ischemia/reperfusion 
which correlated with better graft function and survival. Overall PGs are crucially involved 
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Written in English by Kirankumar Katta 




Niertransplantatie is de beste behandeling voor patiënten met eindstadium nierfalen met 
betrekking tot kwaliteit van leven en levensverwachting. Door verschillende oorzaken, 
waaronder toenemende leeftijd en incidentie van vetzucht en diabetes, neemt het aantal 
patiënten met nierfalen wereldwijd toe. Als gevolg daarvan is er ook een grotere behoefte 
aan donornieren. In 2010 werden in Nederland meer dan 800 niertransplantaties uitgevoerd, 
waarvan de helft met nieren van levende donoren. Daarnaast staan er in Nederland meer 
dan 900 patiënten op de wachtlijst voor een niertransplantatie; de gemiddelde wachttijd 
voor een donornier afkomstig van een overleden donor is inmiddels langer dan 4 jaar. Door 
het gebruik van nieuwe afweeronderdrukkende medicijnen is de incidentie van acute 
afstoting van getransplanteerde nieren de laatste jaren sterk afgenomen. De 
langetermijnoverleving van getransplanteerde nieren is echter nauwelijks verbeterd in de 
afgelopen 30 jaar. Dit heeft vooral te maken met de ontwikkeling van chronisch 
transplantaatfalen van de getransplanteerde nier. Chronisch transplantaatfalen is 
geassocieerd met achteruitgang van nierfunctie en toenemende verbindweefseling van de 
getransplanteerde nier. De oorzaken hiervan zijn multifactorieel en deels immunologisch, 
en deels niet-immunologisch van aard. De verbindweefseling wordt vooral gezien in de 
filterorgaantjes, de glomeruli (ontwikkeling glomerulosclerose), aan de binnenzijde van de 
grote bloedvaten (ontwikkeling transplantatie arteriopathie of neointimavorming) en in het 
bindweefsel tussen de nierbuisjes (ontwikkeling interstitiële fibrose). Algemeen gesproken 
speelt een groot aantal mediatoren een rol bij deze verbindweefseling. Veel van deze 
mediatoren zijn uitsluitend werkzaam in de aanwezigheid van proteoglycanen. 
Proteoglycanen vormen een diverse groep complexe eiwit-suiker verbindingen die als co-
receptoren een rol spelen bij de weefsel remodellering. Dit is al langer bekend bij 
weefselveranderingen zoals die worden gezien bij embryonale ontwikkeling, wondgenezing 
en tumorgroei, maar of vergelijkbare mechanismen ook optreden bij chronisch 
transplantaatfalen na niertransplantatie is niet bekend. De meeste biologische effecten van 
proteoglycanen worden bepaald door de binding van de mediatoren betrokken bij 
weefselveranderingen. Daarom lijkt het voor de hand liggend om uit te zoeken of 
therapeutisch ingrijpen in de proteoglycaan – mediatoren interactie bescherming kan bieden 
tegen chronisch transplantaatfalen. Dit onderzochten we in een serie experimenten in een 
rattenmodel voor chronisch transplantaatfalen, en in nierbiopsieën uit getransplanteerde 
nieren bij de mens. 
In hoofdstuk 2 tonen wij in dit model aan dat er bij chronisch transplantaatfalen een 
ophoping van de proteoglycanen perlecan en collageen XVIII plaatsvindt in de glomeruli 
en neointima’s van getransplanteerde nieren. In het bindweefsel tussen de tubuli wordt het 
proteoglycaan versican verhoogd aangetroffen, alsmede een sterk verhoogd aantal 
lymfevaten. Het aantal lymfevaten correleert met de mate van interstitiële 
verbindweefseling en verminderde nierfunctie. 
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In hoofdstuk 3 isoleren we met behulp van laserdissectiemicroscopie glomeruli en 
neointima’s uit nierweefsel van getransplanteerde ratten. In dit weefsel worden een aantal 
mRNA transcripten gekwantificeerd. We ontdekken dat er naast de ophoping van perlecan 
ook een groeifactor is die op deze locaties verhoogd wordt aangemaakt. Het gaat hier om 
basic fibroblast growth factor (FGF2). In celkweekexperimenten laten we vervolgens zien 
dat FGF2 heparansulfaatproteoglycanen nodig heeft om niercellen te laten groeien, maar 
ook dat therapeutische interventie met aan heparansulfaat gerelateerde polysachariden deze 
proliferatieve respons afremt.  
De bevindingen in hoofdstuk 3 gaven ons aanleiding om een interventiestudie met 
heparinoïden uit te voeren in het chronisch niertransplantatiemodel in de rat. Dit onderzoek 
staat beschreven in hoofdstuk 4. Naast interventie met gewone heparine (een polysacharide 
die nauw verwant is aan heparansulfaten) werd geïntervenieerd met twee verschillende non-
anticoagulante heparinoïden. Alhoewel de heparinoïdeninterventie geen effecten had op 
transplantaatoverleving of nierfunctie, werd toch een aantal opmerkelijke bevindingen 
gedaan. Behandeling met RO-heparine, een van de twee non-anticoagulante heparines, 
verminderde de instroom van ontstekingscellen in de nier en verbeterde de plasma 
triglyceridewaarden, die verhoogd waren in de onbehandelde transplantatiegroep. 
Bovendien was er een tendens tot verminderde eiwitlekkage in de urine en vermindering 
van glomerulosclerose bij behandeling met ditzelfde RO-heparine. Verder onderzoek dient 
uit te wijzen of het gebruik van laag moleculair gewicht heparinoïden of een verhoging van 
de dosering tot betere resultaten zal leiden.  
In hoofdstuk 5 proberen we te ontrafelen welke moleculaire processen leiden tot 
neointimavorming in de nierarteriën na niertransplantatie. Daarom werden in het ratten-
niertransplantatiemodel met behulp van laserdissectiemicroscopie de media en neointima 
geïsoleerd en de transcripten van een groot aantal mediatoren gekwantificeerd. In 
vergelijking met controlevaten vertonen de mediale gladde spiercellen minder contractiele 
kenmerken, en meer synthetische en migratoire kenmerken. Zeer waarschijnlijk spelen de 
groeifactoren platelet derived growth factor B en transforming growth factor beta hierbij 
een cruciale rol door inductie van de migratie van deze gladde spiercellen van de media 
naar de neointima, en dragen ze zo bij aan de transplantatie-arteriopathie. 
In hoofdstuk 6 tenslotte, wordt de brug geslagen naar niertransplantatie bij de mens. Na 
een evaluatie van verschillende proteoglycanen in humane transplantatiebiopten wordt een 
uitvoerige studie gedaan naar de expressie van syndecan-1, een epitheliaal 
celoppervlakgebonden heparansulfaatproteoglycaan. Het blijkt dat in de biopten afkomstig 
van getransplanteerde patiënten de expressie van syndecan-1 in tubulusepitheelcellen 
correleert met betere transplantaatoverleving, verbeterde nierfunctie en minder 
histologische afwijkingen in de biopten. Experimenten met gekweekte niercellen tonen aan 
dat syndecan-1 belangrijk is voor de regeneratie van tubulusepitheel. Dit laatste konden we 
vervolgens ook overtuigend aantonen in een muismodel, waarin expressie van syndecan-1 
met behulp van genetische manipulatie werd voorkomen.  
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Vervolgonderzoek moet duidelijk maken of non-anticoagulante heparinoïden een rol 
kunnen spelen bij de bescherming van de getransplanteerde nier, naast de gebruikelijke 
medicatie die wordt gegeven om chronisch transplantaatfalen te voorkomen of af te 
remmen. Daarnaast moet vervolgonderzoek duidelijk maken of de expressie van syndecan-
1 in protocolaire nierbiopten en/of de uitscheiding van syndecan-1 in de urine van 
niertransplantatie patiënten een voorspellende waarde hebben voor het functioneren van de 
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